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ABSTRACT 
 
MEHMET KARACA:  Regulation of Androgen Receptor Function by Tyrosine 
Phosphorylation (Under the direction of Dr. Young E. Whang) 
 
 Androgen receptor (AR) re-activation under low androgen environment is the 
hallmark of castration resistant or hormone refractory prostate cancer (HRPC).  Non-receptor 
tyrosine kinases phosphorylate AR in an androgen independent manner, and are thereby 
involved in HRPC.  Herein, we investigated the role of Ack1 target phosphorylation sites 
(Tyr-267 and Tyr-363) on growth factor-regulated AR phosphorylation as well as AR 
transcriptional and functional activity.  Both Tyr-267 and Tyr-363 have a critical role for 
ligand-dependent and –independent control of activity of AR.  Treatment of LNCaP cells 
overexpressing full length or truncated AR (missing the ligand binding domain (LBD) with 
epidermal growth factor (EGF), heregulin, or Gas6 (ligand binding to Mer receptor tyrosine 
kinase and activating Ack1 downstream) induced AR phosphorylation at Tyr-267 and that 
phosphorylation was lost in the AR-Y267F mutant protein.  The full length (FL) AR 
overexpressing cells proliferated strongly without androgen treatment and they reached 
optimal growth at a lower dose of DHT treatment (0.1 nM DHT).  However, cells expressing 
full- or -truncated AR-Y267F mutant did not show androgen-independent proliferation and 
did not respond to androgen treatment.  Overexpression of the Y267F mutant within full 
length- or truncated-AR showed significant reduction in soft agar colony formation, 
compared to the AR-WT.  The extent of reduction in colony formation of 
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Y363F AR expressing cells was moderate, but not as much as Y267F.  The analysis of AR 
subcellular localization by both immunoblotting and immunofluoresence assays suggested 
that mutating the Tyr-267 site impaired both androgen-dependent and –independent nuclear 
translocation, compared to the AR-WT.  Global gene expression profiling analysis 
demonstrated that there were no common genes regulated by both full length AR and AR-
Y267F, suggesting that mutating Tyr-267 has a significant impact on not only AR dependent 
target gene expression but also global gene expression of LNCaP cells.  Taken together, the 
results of our study demonstrate that tyrosine kinase target phosphorylation sites are 
important for both ligand-dependent and ligand-independent activity of AR protein.  
Targeting upstream tyrosine kinases and the N terminal domain of AR in truncated AR 
missing LBD may expand the repertoire of therapeutics for combating prostate cancer. 
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1.1 Prostate Cancer Epidemiology 
 Prostate cancer (PCa) is the most commonly diagnosed cancer (192,280 new cases 
per year) and second leading cause of death (27,360 deaths annually) among US men (Jemal 
et al., 2009).  What causes prostate cancer is not completely known, but age, a family history, 
and African ancestry are strongly linked or associated with prostate cancer development 
(Gronberg, 2003; Schaid, 2004).  The rate of prostate cancer is the highest among the African 
American men (AAM) in the United States (Brawley and Barnes, 2001) and mortality due to 
PCa in this group was higher than that of European American men (EAM) (American Cancer 
Society, 2007).  The other ethnic groups such as Asian American men, American Indian and 
Alaskan Native men (AI/AN) and Hispanic men all have a lower prostate cancer and 
mortality rate compared to the EAM (American Cancer Society, 2007).  
 It is estimated that genetic predisposition to PCa accounts 9% of the PCa (Steinberg 
et al., 1990).  Having a number of relatives that had PCa increases the risk of PCa.  The 
estimated risk of getting PCa for a man with one first-degree relative, two relatives, and three 
relatives affected with PCa were 2.5, 5, and 11-fold, respectively.  The recent research 
suggested that instead of one or two genes with a large effect determining a risk of getting 
prostate cancer, there may be many genes that may interact with environmental factors 
(Gronberg, 2003; Powell, 2007; Schaid, 2004).  The results of linkage mapping studies 
indicated that there are a number of loci associated with the susceptibility to PCa.  These loci 
are on chromosome 1, 8, 10, 16, 17, 20, and X (Schaid, 2004).  The possible susceptibility to 
PCa candidate genes were HPC1 on chromosome 1q23-25, PCAP on chromosome 1q42-43, 
and CAPB on chromosome 1p36 (Schaid, 2004).  In addition to these candidate genes, there 
are trinucleotide repeats encoding polyglutamine (CAG)n and polyglycine (GGN)n of 
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androgen receptor, whose polymorphism is associated with risk of PCa (Zeegers et al., 2004).  
In general, there is an association between shorter (CAG)n repeats and having more 
aggressive PCa, an earlier age of onset, and a longer time to recurrence, yet these effects 
appear to be population specific (Bratt et al., 1999; Giovannucci, 2002; Soronen et al., 2004)  
Although the rate of  (CAG)n repeats were higher in AAM compared to EAM and Asians, 
that did not associate with an increased PCa risk (Gilligan et al., 2004; Powell et al., 2005).      
 In addition to genetic linkage studies, the clinically more relevant genetic 
polymorphism studies have identified that a polymorphism in CYP17 might be associated 
with susceptibility to prostate cancer in AAM, but not in men of European descent (Ntais et 
al., 2003).  In another study, the proportion of G allele of CYP3A4 was found to be higher in 
AAM compared to EAM (Powell et al., 2004) and later in a case-control study, a strong 
association between the variant G allele and aggressive PCa in AAM were reported (Bangsi 
et al., 2006; Rebbeck et al., 1998).  
 There is mounting evidence that dietary (environmental) and life style factors play a 
critical role in the pathogenesis of PCa.  There is a striking difference in distribution of PCa 
incidence and mortality rates in different geographical parts of the world (American Cancer 
Society, 2007).  Countries like Japan and China have historical lower rates of PCa and 
mortality compared to that of the United States and Caribbean nations (Liu et al., 2001; 
Schaid, 2004).  The high intake of saturated fat, red meat, and dairy products was found to be 
associated with the pathogenesis of PCa (Gronberg, 2003; Schaid, 2004).  The rate of animal 
protein in total protein consumed was higher in the US than in Asian countries.  This may 
account for over 20-fold increase in PCa rate in the US (Griffiths et al., 1999; Wang et al., 
2005).  Although conclusive evidence for the association of obesity and the development of 
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prostate cancer has not been found yet, there are reports that suggest the risk of getting 
aggressive cancer increases with obesity (Buschemeyer and Freedland, 2007).   
1.2 Natural History of Prostate Cancer 
 Prostate cancer is a gland specific cancer that affects the prostate gland.  However, 
other glands in the urogenital tract such as cowper gland have no known cancer.  
Anatomically, the prostate gland is composed of three regions, peripheral, central and 
transition zone.  Unlike benign prostate hyperplasia (BHP), prostate cancer occurs in 
peripheral zone (McNeal et al., 1988).  There are two types of cells that make up the epithelia 
of prostate, basal and luminal epithelial cells.  Basal cells, not expressing AR, contain stem 
cells and trans-amplifying (TA) cells that have limited proliferative capacity and 
differentiated from basal cells.  The terminally differentiated secretory luminal cells 
expressing AR result from cell division, differentiation, and migration of TA from the basal 
to luminal layer (Litvinov et al., 2003).  The surrounding stromal cells that are AR positive 
are the source of growth and survival factors in the paracrine regulation of the glandular 
epithelium.  In the normal prostate, in response to stromal cell signaling, the ligand bound 
AR shows a growth-suppressing effect and mediates the secretory protein (PSA and HK2) 
production.  The anti-proliferative effect of AR was in response to the paracrine signaling of 
stromal cells, yet in prostate cancer, this paracrine signaling evolved into autocrine signaling 
with self sufficiency (Gao et al., 2001). 
 From initiation to development of prostate cancer, there are several steps.  Like any 
other cancer, mutation in normal prostate epithelium and accumulation of other somatic 
mutations underlines the morphological changes that occur with tumor development.  The 
natural history of prostate cancer begins with normal prostate exposed to proliferative 
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inflammatory atrophy (PIA), followed by prostatic intraepithelial neoplasia (PIN) that is a 
precursor for invasive adenocarcinoma, and eventually to prostatic adenocarcinoma (Nelson 
et al., 2003b) (Nelson et al., 2003; Shen-Abate and Shen 2000).  After cancer develops, it 
may eventually metastasize into secondary distant sites such as bone and lymph node (Abate-
Shen and Shen, 2000; Litvinov et al., 2003; Nelson et al., 2003b).  There are several lines of 
evidence that suggest that AR expression is sustained at every stage of prostate cancer 
(primary and metastatic), as well as hormone refractory prostate cancer (HRPC) (Taplin, 
2008).  AR knockdown results in inhibition of growth and induction of apoptosis in both 
prostate cancer cells and tumor xenografts (Taplin and Balk, 2004).  There is additional 
evidence that the AR signaling pathway exhibits sustained activity during prostate cancer 
initiation, development and progression to the hormone refractory disease.  (1) The AR gene 
amplification and AR protein expression (Taplin et al., 1999).  (2)The AR overexpression 
was the only detectable change occurring in castration recurrent isogenic cell lines derived 
from the xenograft tumors that are resistant to the androgen deprivation therapy (Chen et al., 
2004). (3)  The AR protein was active and stabilized in the CWR22R prostate cancer cell line 
derived from the castration recurrent prostate cancer that render CWR22R to be induced by 
lower levels of androgen (Gregory et al., 2001).  (4)  Even in castration recurrent prostate 
cancer cells, knocking down of AR abrogated cell proliferation and induced apoptosis 
suggesting that AR has a critical role in the castration recurrent stage of disease.           
1.3 Prostate Cancer Therapy 
 Androgen receptor is not only involved in normal prostate development, but also in 
prostate cancer development and progression.  In 1941, Huggins and Hodges’s discovery of 
the dependence of prostate cancer to androgens led to androgen deprivation therapy (ADT) 
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as the first line of treatment against metastatic prostate cancer (Huggins and Hodges, 2002).  
ADT is carried out by using surgical or medical castration.  ADT does not lead to complete 
androgen depletion, since the adrenal cortex produces approximately 5-10% of total 
androgen produced in the body.  The majority of the patients respond to ADT positively with 
tumor shrinkage.  This is temporary as they progress with tumor growth and relapse even 
under the low androgen environment with a median duration of 18-24 months in patients 
with metastasis.  Cancer in this stage called hormone refractory (HRPC) or castration 
resistant prostate cancer (CRPC).  The median survival of men with HRPC is about 1.5 years 
and chemotherapy is the mainstay of therapy in this stage of disease (Smaletz et al., 2002).     
 The multifocal and heterogeneous nature of PCa makes its diagnosis and management 
of PCa a very complex process.  Within one tumor, it is not uncommon to detect 
simultaneously multiple clones of tumor foci.  These heterogeneous foci might have different 
degrees of genetic alterations and thereby progress with different degrees of aggressiveness.  
The presence of multifocal prostate cancer at diagnosis ranged from 60-90% (Andreoiu and 
Cheng, 2010).  Although the biological basis of multifocal and histological heterogeneity of 
prostate cancer has not been explained completely, there are two main theories that attempt 
to explain this phenomenon: (1) multiclonality of the initial diseases, and (2) clone evolution 
from the initial disease.  Although the multifocal and histologically heterogeneous nature of 
prostate cancer has complicated the treatment choices, recently there have been numerous 
attempts to devise novel approaches to reduce the complications of radical resection of 
prostate cancer as well as complete eradication of local lesions with good survival outcome 
(Barqawi and Crawford, 2005; Koch et al., 2007; Polascik and Mouraviev, 2009). 
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 Anatomically, prostate cancers have originated most commonly at peripheral zone 
(PZ) and transition zone (TZ) (McNeal, 1968, 1969, 1981a, b, 1984, 1988; McNeal et al., 
1988; McNeal et al., 1986).  These initial studies demonstrated that 70% of tumors take place 
in the PZ, while 25% originated in TZ.  The tumors rising in PZ can commonly be detectable 
with transrectal palpation and biopsy.  However, tumors in TZ cannot be easily detectable 
with biopsy and are mostly discovered with TURP specimens (Augustin et al., 2003).  
Patients with TZ tumors had an 81% 5-year cure rate compared to 53% seen in PZ tumors 
(Stamey et al., 1998).  TMPRSS2-ERG gene fusion was commonly detected in PZ cancers 
and not in TZ cancers (Guo et al., 2009).   
 Cryosurgery, brachtherapy, high intensity focused ultrasound, external beam radiation 
therapy (EBRT), high-intensity focused ultrasound radio frequency, interstitial ablation, and 
others have been used to treat locally grown prostate cancer.  The limitations in preoperative 
mapping of all tumor lesions that intrinsically multifocal and histological heterogeneous have 
a significant impact on selecting patients for focal treatment as well as overall determination 
of optimal surgical management.  The selection of treatment plans is made with taking into 
account both tumor related factors (i.e. clinical stage, PSA, and Gleason score) and patient 
related factors (i.e. age, other illness, and patient preference).  Radical prostatectomy (RP) is 
a treatment of choice when the patient is young (<70 years old) with organ confined disease 
(Bill-Axelson et al., 2005; Gettman and Blute, 2010).  The success of RP depends on 
complete removal of tumor.  Preoperative staging and tumor characteristics are instrumental 
in identifying the region that contains tumor.  The patients in the low risk group defined as 
clinical T1 and T2 disease, PSA≤ 10 ng/ml and Gleason score ≤ 6 have a lower probability of 
cancer recurrence compared to the patients in the high risk groups.  External beam radiation 
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therapy (EBRT) is an advancement of three-dimensional conformal radiotherapy (3D-CRT) 
with the use of high energy photon field in precisely defined locations in the prostate by 
using computer generated tomographic images of patient’s anatomy (Ling et al., 1996; Perez 
et al., 2000; Potters et al., 2000).  Depending on the extent of tumor involvement, prostate 
and part of seminal vesicles are irradiated.  The typical treatment of EBRT takes 5 days a 
week with 1.8-2 Gy daily in a 10-20 minutes per session to a total dose of 70-78 Gy (Horwitz 
et al., 2001).  In brachytherapy (seed implant therapy), the radioactive sources by itself are 
placed into tumors (D'Amico and Coleman, 1996).  Depending on the characteristics of 
cancer and patient, low-dose rate or high-dose rate (HRT) is recommended.  There are 3 
energy sources used for this therapy: iodine-125, palladium-103 for LDR and iridium-192 for 
HDR (Stock and Stone, 2010). 
 The current standard of care for metastatic HRPC is docetaxel treatment.  The current 
rate of survival in HRPC patient in response to standard treatment modalities shows that 
there is a space for improvement in novel therapeutic approaches.  These approaches includes 
angiogenesis inhibitors, small molecule inhibitors, novel cytotoxic therapeutics, anti-sense 
oligonucleotide based targeted therapeutics (Richard et al., 2006).    
 Metastasis to bone is a common event in advanced prostate cancer and can be a cause 
of great pain and skeletal complications.  Furthermore, long-term ADT will enhance the loss 
of bone mineral density in patients (Toni et al., 2010).  Bisphosphonates are used to reverse 
the aforementioned osteoclastic bone destruction.  In addition to its affect on bone 
destruction, bisphosphonates may be effective to inhibit bone metastasis by modulating 
matrix metalloproteinases (MMPs), cell adhesion, and cancer cell growth (Lee et al., 2001).  
Because of its beneficial affect on skeletal complications, FDA approved zoledronic acid for 
 9 
use in patients with HRPC who have not respond to at least one regimen of hormonal therapy 
(Saad et al., 2004).   
 Prostate cancer generally has a long natural history with slow progression.  Therefore, 
this long time span may enable induction and activation of T-cell mediated antitumor activity 
(Florian et al., 2007).  Second, prostate is a target of chronic inflammation that can be 
associated with autoimmunity or pathogenic infection (Bardia et al., 2009; Florian et al., 
2007).  Since these patients have the capacity to enhance their response to these non-
malignant pathologic conditions, it is expected that these patients may mount cell-mediated 
immune response that may suppress the prostate tumor progression.  Unlike other vital 
organs, prostate is a dispensable organ and autoimmunity due to immune therapy will have a 
very limited consequence to the patient.  There has been intensive work to develop vaccine 
by using dendritic cells, APC8015 (Provenge, Dendreon, Seattle, WA) or GVAX (whole cell 
vaccine) and Prostvac-VF (viral vaccines) (Stavridi et al., 2010).  APC8015 is an autologous 
vaccine developed by harvesting CD54+ dendritic cells and combined with the recombinant 
fusion protein PAP (prostate acid phosphatase) and the cytokine GM-CSF.  GVAX (Cell 
Genesys, San Fransisco, CA) is composed of a combination of two prostate carcinoma cell 
lines (PC3 and LNCaP) that have been genetically modified to secrete GM-CSF.   
 The enhanced understanding of the molecular basis of cancer progression and 
therapeutic resistance has generated therapeutic targets that cannot be inhibited by small 
molecule or antibody inhibition.  Therefore, antisense oligonucleotide (ASO) may be a 
perfect tool to prevent cancer progression.  For example, the anti-apoptotic Bcl-2 gene was 
overexpressed in therapy resistant prostate cancer and targeting this gene may improve the 
chemotherapy induced apoptosis (Gleave et al., 2005).  Because of its role in therapy 
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resistance, ASO targeting first six codon of Bcl-2 has been developed (G3139).  There have 
been a number of clinical trials in HPRC combining cytotoxic chemotherapy with G3139.  
The results of phase I trials using G3139 and either mitoxantrone or docetaxel (Chi et al., 
2001; Tolcher et al., 2004) showed that addition of G3139 to standard chemotherapy 
regimens did not increase toxicity.  
 Another successful use of a second generation antisense inhibitor was reported to 
inhibit the clusterin gene, also known as testosterone repressed message-2 (TRPM-2).  It has 
a chaperon function to stabilize the protein conformation in cells under stress by preventing 
protein aggregation and prevention.  In prostate cancer, the clusterin level has been correlated 
with the pathological grade (Steinberg et al., 1997).  Furthermore, the clusterin level was 
significantly elevated in response to neoadjuvant hormone therapy (July et al., 2002).  
Preclinical studies indicated that clusterin prevented apoptotic cell death due to androgen 
withdrawal, chemotherapy, and radiation (Miyake et al., 2000a; Miyake et al., 2000b; 
Zellweger et al., 2001).  The results from preclinical models of prostate cancer indicate that 
OGX-11, the clusterin antisense inhibitor enhanced the efficacy of androgen withdrawal, 
chemotherapy, and radiation by reducing the expression of clusterin and concomitantly 
enhancing the apoptotic response (Miyake et al., 2000a; Miyake et al., 2000b; Zellweger et 
al., 2002; Zellweger et al., 2001)  
 The multiple roles of endothelin and its receptor ET-A on cellular physiology and 
paracrine signaling in prostate cancer made it a therapeutic target.  Endothelin by interacting 
with the MAPK pathway influences the cell growth and regulates apoptosis through its 
interaction with Bcl-2 and PI3K/Akt pathways (Nelson et al., 2003a).  Atrasentan (Xinlay, 
Abbott Labs, Abbott Park, IL) is a potent ET-A receptor antagonist developed and used in 
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clinical trials.  Although the result of the phase III trial is not satisfactory (in time to 
progression), its role in combination therapy remains to be determined.   
 Angiogenesis is an important part of cell growth, invasion and metastatic potentials of 
solid tumors (Ferrara and Kerbel, 2005).  Therefore, agents targeting angiogenesis may have 
a potential impact to delay progression or to induce regression of tumors if used in 
combination with other treatment modalities (Kluetz et al., 2010).  Bevacizumab is a 
humanized murine monoclonal antibody that neutralizes vascular endothelial growth factor 
(VEGF) activity and has shown potential in HRPC (Aragon-Ching and Dahut, 2008).  The 
sustainable tumor growth requires angiogenesis, the development of new blood vessels from 
the pre-existing vascular bed. The critical balance between endogenous angiogenesis 
inducers (fibroblast growth factor, VEGF) and inhibitors (endostatin and angiostatin) of 
endothelial cells is important for cell proliferation and invasion.  Likewise, thalidomide 
inhibits b-FGF induced angiogenesis.  In phase II trials, treatment of HRPC patients with 
thalidomide resulted in 18% patients having a PSA decline of  ≥ 50 and 27% of patients 
having a PSA decline of ≥40% (Figg et al. 2001).  Another phase II clinical trial used 
thalidomide in combination with docetaxel reported greater PSA decline (51% versus 37% 
demonstrating >50% PSA decline) as well as median progression free survival (5.9 months 
versus 3.7 months) and improved survival (29.8 moths in the combination group compared 
with 14.7 months in the docetaxel only group).   
1.4 Androgen Receptor Genomic Structure  
 Androgens are important for male sexual differentiation and development as well as 
development of prostate cancer.  Androgens exert their effects through androgen receptor.  
Testosterone and dihydrotestosterone (DHT) are the physiological ligands for the AR.  DHT 
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is synthesized from testosterone by 5α-reductase enzymes.  The human AR gene, located on 
chromosome Xq11-12, consists of 8 known exons which encode ~110 kDa protein.  The AR 
protein shows typical modular functional units of the steroid hormone receptor family of 
transcription factors (Bain D. L., 2006).  The AR shows homology to the genetic structure of 
other steroid hormone receptor such as the estrogen, progesterone, glucocorticoid, retinoid, 
mineralocorticoid and thyroid hormone receptors (Matias et al., 2000; Rozanov et al., 2004; 
Shaffer et al., 2007).   Like other steroid receptors, AR has three functional domains: an 
amino terminal domain, a central DNA-binding domain, and a carboxy ligand binding 
domain.  A large part of AR protein, almost 60%, is encoded by exon 1 and designated as the 
NH2-terminal domain (NTD) which contains a ligand-independent AF1 transcriptional 
regulatory domain (Figure 1.1).  AR has two transcriptional activation function domains (AF-
1 and AF-2).  Unlike AF-1, AF-2 is a ligand-dependent coactivator binding domain which 
shows great homology among steroid receptors.  Transcriptional activity of the C-terminal 
domain (CTD) of AR was very weak compared to the other steroid hormones.  AR NTD has 
no sequence homology to the other receptors and show strong transcriptional activity (Dehm 
and Tindall, 2006b, 2007; Rozanov et al., 2004).  The exon 2 and 3 encode the central DNA 
binding domain (DBD) with two zinc finger motifs (Figure 1.2).  The rest of the exons (4 to 
8) encode ligand binding domain (LBD) where the ligand-dependent AF-2 activity resides.   
 The subcellular dynamics of AR is orchestrated by ligand binding.  AR without a 
ligand is sequestered in the cytoplasm by the heat shock protein family of chaperons. 
Androgen binding to the LBD of AR induces conformational changes and stabilizes AR.  
This leads to its dissociation from heat shock proteins and translocation into the nucleus.  
Within the nucleus, AR, an activated transcription factor, binds to the sequence motif called 
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androgen response elements (AREs, CGTACAnnnTGTTCT) in the promoter and enhancer 
regions of the genes.  Once AR bounds to AREs, it coordinates the recruitment of cofactors 
as well as chromosomal remodeling proteins that are essential for the transcriptional 
activation (Alimirah et al., 2006; Shang et al., 2002).  In addition to its function as a 
transcription factor, AR involved in non-genomic androgen effects, intracellular calcium flux 
and kinase activation (Heinlein and Chang, 2002). 
1.5  Role of Androgen Receptor in Hormone Refractory Prostate Cancer 
 
  Androgens are essential for normal development of sexual characteristics as well as 
normal prostate growth and development.  The androgen dependency of normal prostate 
extents into the initial stages of prostate cancer.  However, PCa eventually becomes 
“androgen independent” or castration resistant under the selective pressure of androgen 
deprivation therapy (ADT), which is the mainstay of treatment of advanced prostate cancer 
devised by Huggins and Hodges in 1941.  Although PCa becomes castration resistant, AR 
and its downstream signaling pathways are found to be active in the hormone refractory stage 
of PCa.  There are several explanations of how AR becomes reactivated under the low 
androgen microenvironment (Borchert et al., 2007; Koivisto, 1997; Koivisto et al., 1995; 
Koivisto et al., 1996; Litvinov et al., 2003; Liu et al., 2005; Pienta and Smith, 2005; Williams 
et al., 1996).  These include AR gene amplification, post-transcriptional modification of AR 
protein, growth factor-regulated activation of AR, mutations in the ligand binding domains, 
and differential expression of AR associated co-regulatory proteins (i.e. enhanced interaction 
of AR with coactivators).  AR gene amplification leads to AR protein overexpression, 
thereby keeping the AR signaling pathway intact even in the absence of the normal level of 
androgens.  AR gene amplification accounts for the one-third of tumors (Koivisto et al., 
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1997; Koivisto et al., 1996; Linja et al., 2001).  The mutations in LBD of AR explain 
approximately 10% of androgen independent prostate cancers (Taplin et al., 2003).  AR post-
transcriptional modifications such as phosphorylation may enhance the AR protein stability.  
Growth factors such as EGF, heregulin may stimulate the phosphorylation and activation of 
AR.  The anti-androgen drugs used in combined androgen deprivation therapy induce 
mutations in the ligand binding domain of AR that broadens the ligand specificity of AR.  
The frequency of AR mutations are higher in metastases than local diseases and these 
mutations may allow  AR to bind with estrogens, glucocorticoids and anti-androgens (Culig 
et al., 2003; Marcelli et al., 2000).  For example; bicalutamide induces mutations in LBD of 
AR that can turn this strong antagonist into an agonist of AR.  There might also be protein 
kinases that can directly phosphorylate and activate AR.  As an alternative to the 
aforementioned mechanisms of aberrant AR activation, the measurement of androgen levels 
in prostate cancer specimens indicated that the tissue androgen levels under androgen 
deprivation therapy are still sufficient to activate AR (Mohler et al., 2004; Titus et al., 2005). 
 The newly found mutations made the AR not only sensitized to lower levels of 
androgens and dehydro epiandrosterone (DHEA) but also broaden the ligand choices such as 
17β-Estradiaol, progesterone, corticosteroids, and anti-androgens (Chen et al., 2005; Monge 
et al., 2006; Shi et al., 2007; Yeh et al., 1998).  There are several reports that showed AR 
nonsense mutation arose and resulted in truncated AR protein which lacks ligand binding 
domain and is constitutively active (Alvarado et al., 2005; Lapouge et al., 2007).  These 
nonsense mutations were detected in metastatic tumors and sometimes coexist with other AR 
mutants such as T877A mutation.  Alvarado et al. (2005) reported that a particular non-sense 
AR mutant Q640X was responsible for the androgen independent transcriptional activity 
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observed with T877A.  The studies with TRAMP model suggested that somatic mutations 
were adaptive responses to ADT since the rate of mutation increases dramatically when 
TRAMP mice switched to ADT (Han et al., 2001).  The mutation analysis of human prostate 
cancer shows parallelism to the mouse model in that somatic mutations were more 
commonly detected in castration recurrent disease (Linja and Visakorpi, 2004).  In summary, 
these gain-of-function somatic mutations may provide prostate cancer a growth advantage 
under the low androgen environment and render AR as a proto-oncogene.  
1.6 Role of N-Terminal Domain of AR in Hormone Refractory Progression 
  The AR NTD domain may play a significant role in mediating prostate cancer therapy 
resistance (Dehm and Tindall, 2006b, 2007).  It has been instrumental to study the structure 
function relationship of NTD to characterize the NTD domain which cannot be defined due 
to the amorphous nature of the NTD domain.  There are co-activators that directly bind and 
activate NTD such as members of p160 family (Alen et al., 1999; Bevan et al., 1999). Steroid 
receptor co-activator 1 (SRC1) binding to AR does not require LxxLL motif in the AF-2 
domain to bind and activate AR (Bevan et al., 1999).  Likewise, the X-chromosome linked 
melanoma antigen gene product, MAGE11, binds to FxxLF motif in NTD and that stabilizes 
AR protein and enhances its transcriptional activity (Figure 1.2) (Bai et al., 2005).  
Furthermore, MAGE-11 binding to FxxFL motif enhances AF-2 accessibility to LxxLL 
containing the p160 coactivator such as TIF-2 (Wilson, 2007).    
 The expansion of the NTD region with increased AF-1 activity relative to AF-2 has 
been evolutionarily observed for AR and other nuclear receptors (Rozanov et al., 2004).  The 
majority of transcriptional activity of AR has been mediated by the NTD AF-1 domain.  The 
AF-1 consists of two functional subunits: transactivation unit 1 (TAU1) and TAU5 (Jenster, 
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1999).  Further deletion studies showed that TAU1 has two transcriptionally distinct motifs 
(AF-1a and AF-1b).  The core motif that mediates transcriptional activity of TAU1 was 
found to be 178LKDIL182  (Figure 1.2) (Sadar, 1999).  The TAU5 motif (435WXXLF439) was 
found to be direct binding sites of SRC1 and protein kinase C related kinase-1 coactivator 
proteins (Callewaert et al., 2006; Metzger et al., 2003).    
 The reports indicated that prostate cancer evades the hormone ablation therapy and 
becomes HRPC due to ligand independent transcriptional activity (Dehm and Tindall, 2006a, 
2007).  Dehm et al. (2008) hypothesized that selective pressure due to hormone ablation 
therapy leads to activation of NTD where AF-1 resides (Dehm et al., 2008). The deletion of 
LBD generates an androgen independent transcriptional activator protein(Jenster, 2000).  
Libertini et al. (2007) showed that calpain mediated AR cleavage created an AR protein 
variant that lacks CTD and is constitutively active (Libertini et al., 2007).  Their in vitro and 
in vivo characterization of the mechanism of calpain mediated AR activation suggested that 
calpain cleavage of AR led to constitutively active AR which was more robust in 
transactivating transcription from the PSA promoter.  Furthermore, they reported elevated 
expression of the truncated AR isoforms in some prostate tumor tissues.  The Rv1 cells used 
in this study has been derived from CWR22 cells and expresses concomitantly both truncated 
AR isoforms and full length wild type AR.  The treatment of Rv1 cells with a calpain 
inhibitor or HIV protease inhibitors in the absence of androgens induced apoptosis by 
preventing the generation of constitutively active truncated AR, suggesting that full length 
wild type AR drives cells into apoptosis in the absence of androgens.  This study underscored 
the importance of a mechanism that led to constitutive activation of AR in the absence of 
androgen; thereby a strategy to prevent calpain mediated activation of AR in the hormone 
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refractory stage of prostate cancer may be an option to add to the repertoire of limited 
therapeutic choices.     
 Recent report underscored the importance of somatic mutations arising under ADT to 
evade the selective pressure of therapy.  Hu et al. (2009) using in silico sequence analysis of 
the AR gene identified 7 cryptic exons (AR variants) that harbor premature stop codons 
downstream of DBD, generating AR-LBD truncated proteins when they have been translated 
(Hu et al., 2009).  From these 7 variants, they further characterized two of them (V1 and V7) 
and developed an antibody that specifically detects AR-V7.  There is a significantly elevated 
expression (~20 fold) of AR-V1 and AR-V7 mRNA in HRPC tumor samples compared to 
the hormone naïve prostate cancer.  The elevated expression of the AR-V7 splicing variant in 
a subset of hormone naïve prostate cancer was predictive for recurrence of prostate cancer 
after surgical treatment (Hu et al., 2009).  AR-V7 was constitutively active and localized in 
the nucleus in the absence of androgens.  Furthermore, androgen stimulation did not change 
the proportion of AR-V7 localized in the nucleus.  Functional assays done by transfecting 
AR-V7 into PC3 cells showed that AR-V7 localized to the nucleus and induced PSA reporter 
activity in an androgen independent manner.  Microarray gene expression analysis of LNCaP 
cells transfected with AR-V7 showed that AR-V7 stimulated the expressions of androgen 
dependent genes KLK3, KLK2, NKX3-1, FKBP5, and TMPRSS2 in the absence of 
androgens.  Mutation induced truncated AR missing LBD has been reported as constitutively 
active (Ceraline et al., 2003).  Ceraline et al. (2003) using a yeast based functional assay 
showed that AR-Q640Stop/T877A mutation isolated from bone marrow metastasis of 
hormone refractory prostate cancer was constitutively active in the absence of androgens.  
They indicated that elevated transcriptional activity observed with the luciferase reporter 
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assay was not affected by the presence of DHT treatment.  This report shows that mutations 
in androgen receptor can be a basis for transition of prostate cancer from hormone dependent 
to independent.  
 The recent studies elucidated the mechanism of alternative splice variants of AR that 
generated a ligand-independent constitutively active AR (Dehm et al., 2008; Dehm and 
Tindall, 2006a).  Dehm et al. (2008) reported that the 22Rv1 cell line, derived from the 
relapsed CWR22 xenograft during androgen ablation therapy, expressed three isoforms of 
AR: a full length version with duplicated exon 3 (ARex3dup), and two truncated versions 
lacking the COOH terminal domain (CTD) (ARex1/2/2b or ARex1/2/3/2b) (Dehm et al., 2008).  
Unlike the reports of Tepper et al. (2002) and Libertini et al. (2007), Dehm et al. showed that 
truncated isoforms (ARex1/2/2b or ARex1/2/3/2b) of AR were not due to proteolytic cleavage of 
AR with exon 3 duplication (ARex3dup) but derived from distinct mRNA species.  AR NTD 
isoforms expressed in 22Rv1 cells are the result of the splicing of a novel exon 2b after AR 
exon 2 (ARex1/2/2b) or exon 3 (ARex1/2/3/2b) (Dehm et al., 2008).  Exon 2 encodes the first zinc 
finger that harbors the recognition helix that directly engages with one hexameric half site 
with an androgen response element (ARE) (Shaffer et al., 2007).  Based on this structural 
information, ARex1/2/2b has only one zinc finger and missing second canonical zinc finger that 
is encoded by exon 3 and mediates dimerization with an AR molecule engaged with the 
neighboring ARE half site (Shaffer et al., 2007).  siRNA functional analysis of these 
isoforms showed that siRNA targeting exon 1 abolished the protein expression of both 
ARex3dup and truncated isoforms (ARex1/2/2b or ARex1/2/3/2b).  However, siRNA targeting exon 7 
specifically abolishes the full length AR protein expression but not the truncated AR protein 
that runs around 75 kDa.  The ARex3dup isoform did not induce androgen dependent gene 
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transcription in AR dependent genes such as PSA, TMPRSS2, and maspin.  However, the 
truncated AR isoforms (ARex1/2/2b or ARex1/2/3/2b) induced constitutive, yet selective ligand 
independent transcription of hK2, TMPRRSS2, PSA, and NKX3.1.  Comparison of ARex3dup 
with the truncated AR isoforms (ARex1/2/2b or ARex1/2/3/2b) showed that the truncated isoforms 
mediated the androgen independent cell proliferation and growth of 22Rv1 cell but not 
apoptosis.  The truncated AR isoforms showed constitutive activity in the absence of 
androgens.  Further, they showed that the truncated AR isoforms (ARex1/2/2b or ARex1/2/3/2b) 
are not specific to 22Rv1, but detectable in other prostate cancer cell lines such as LNCaP, 
VCaP, and LAPC4.  They also tested whether androgen ablation would select for prostate 
cancer cells that express truncated isoform by xenografting LuCaP23.1 and LuCaP35.  They 
showed that both full length and truncated AR isoforms were elevated in the hormone 
refractory tumors of both LuCaP23.1 and LuCaP35. 
 The aforementioned recent reports suggest that the AR NTD plays a role in the 
hormone refractory stage of prostate cancer.  The fact that current androgen deprivation 
therapy eventually fails makes it urgent to search for an alternative means of therapeutic 
interventions to prevent or delay the progression to this highly deadly stage of prostate 
cancer.  Therefore, it is of utmost importance to study the mechanisms of AR NTD 
regulation to discover a novel approach to generate alternative means of therapy.  The fact 
that truncated forms of AR coexist with full length AR under the selective pressure of 
androgen deprivation therapy implies that AR NTD activation may be a driving force in 
transition to the hormone refractory stage.  In this study, we will try to understand the 
mechanism of AR NTD activation through the biological and functional characterization of 
phosphorylation site mutations of truncated AR. 
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1.7 Role of Ack1 in Hormone Refractory Prostate Cancer  
The human Ack1 (activated cdc42-associated tyrosine kinase 1) gene is located on 
chromosome 3q29 which is implicated in adenocortical carcinoma (Dohna et al., 2000) and 
hematologic neoplasia (Slavutsky et al., 1986).  Ack1 mRNA is ubiquitously expressed and 
its protein expression was detected in brain, thymus, spleen, fat, heart, skin, testis, and liver 
tissues (Galisteo et al., 2006).  Ack1, 120-kDa intracellular non-receptor tyrosine kinase, was 
initially identified as a binding partner of the activated GTP-bound Cdc42, a small G protein 
(Manser et al., 1993).  Subsequently, Mott et al.(1999) and Cerione et al. (2004) identified 
the region of Ack1 that interacts with the GTPase Cdc42 as a specific domain of 42 amino 
acids called Cbd (Cdc42 binding domain) (Cerione, 2004; Mott et al., 1999).  Ack1 consists 
of an N-terminal protein tyrosine kinase (PTK) domain, a Src homology 3 (SH3) domain, a 
Cdc42/Rac interactive binding (CRIB) domain, and a C-terminal proline-rich region.  
Amongst the Cdc42 associated proteins, Ack1 specifically interact with activated GTP-bound 
Cdc42 through its CRIB domain, but not Rac (Kiyono et al., 2000).  The other effector 
proteins such as serine-theroine kinase PAK interacts both with activated GTP-bound Cdc42 
and Rac (Morreale et al., 2000).   
Several growth factors activated Ack1, including epidermal growth factor receptor 
(EGFR), M3 muscarinic receptor, integrin, and proteoglycans (Eisenmann et al., 1999a; 
Linseman et al., 2001; Satoh, 1996; Yang and Cerione, 1997; Yang et al., 1999).  In prostate 
cancer cells, Ack1 activity was enhanced by two receptor tyrosine kinases, Mer and HER2 
(Grovdal et al., 2008; Mahajan et al., 2005).  However, the exact mechanisms of upstream 
signaling that activate Ack1 still need to be elucidated. 
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 Ack1 preferentially binds to cdc42 in its GTP bound active form through a unique site 
47 amino acid C-terminal to an SH3  domain and inhibits both the intrinsic and GAP-
stimulated GTPase activity of cdc42.  There are several mechanisms that override the auto 
inhibitory mode of Ack1 tyrosine kinase such as mutations, amplification, and 
overexpression (van der Horst et al., 2005).   The constitutively active form of Ack1 
(caAck1) was made by mutating Leucine-487 to Phenylalanine which abrogates the 
regulatory effect of the intramolecular interaction between the kinase and the cdc42/Rac 
interactive binding domains.  The constitutively active form of Ack1 (caAck1) significantly 
enhanced the androgen independent growth of prostate cancer LNCaP and LAPC-4 xenograft 
tumor growth in mice (Mahajan et al., 2007; Mahajan et al., 2005).    
 There are several reports that suggested a role for Ack1 in cell spreading (Eisenmann 
et al., 1999b), vesicle trafficking (Teo et al., 2001), axonal guidance (Worby et al., 2002), 
dorsal closure in Drosophila melanogaster (Bousema et al., 2000), and metastasis (van der 
Horst et al., 2005).  Ack1 was found to be recruited to the EGFR or PDGFR upon EGF or 
PDGF stimulation (Galisteo et al., 2006) and Grb2 had a role in activation of Ack1 by EGF.   
 Ack1 has a role in regulation of endocytosis and intracellular sorting of the EGFR.  
Starkova et al. reported that overexpression of Ack1 enhanced the degradation of the EGFR, 
and siRNA knock down of Ack1 inhibited EGFR degradation (Starkova et al., 2007).  
Grovdal et al. showed that overexpression of Ack1 inhibited endosomal sorting of activated 
EGFR, thereby EGF induced degradation of EGFR was depend upon the activity of Ack1 
(Grovdal et al., 2008).   
 Elevated expression of Ack1 has been detected in several cancers including protate 
cancer.  Van der Horst et al. (2005) reported that Ack1 gene amplification, determined using 
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comparative genomic hybridization (CGH), led to increased mRNA expression.  However 
the majority of tumors overexpressed Ack1 in the absence of gene amplification (van der 
Horst et al., 2005).  Ovarian and lung tumors exhibit the highest frequency of amplification.  
Ack1 overexpression is frequently associated with metastatic hormone refractory tumors 
(10/13 samples showed 5-100-fold overexpression, yet none of the 64 primary prostate 
tumors had Ack1 gene amplification (van der Horst et al., 2005).  The overexpression of 
Ack1 in breast cancer cell lines led to increased invasiveness and mortality.  The data from 
their in vivo studies suggests that Ack1 has a role in extravasation step of metastasis and 
increased mortality.  They suggested that α3β1 integrin ligations activate Ack1 that led to 
increased Rac activity and cell motility. 
 There are several recent reports that show the role of Ack1 in different aspects of 
carcinogenesis and tumor formation such as cell survival.  MacKeigan et al. reported that 
Ack1 function as an anti-apoptotic gene in an RNAi screen targeting against human kinases 
(MacKeigan et al., 2005).  Mahajan et al. showed that Ack1 enhanced growth of prostate 
cancer xenograft tumors by inducing degradation of tumor suppressor Wwox, hence 
abrogating Wwox’s apoptotic effects (Mahajan et al., 2005).  Ack1 is also implicated in 
survival of v-Ras transformed cells (Nur-E-Kamal et al., 2005). 
 The aberrant protein tyrosine kinase Ack1 activation has been linked to prostate 
cancer (Mahajan et al., 2007; van der Horst et al., 2005).  Initial proteomic screening 
identified Ack1 as a binding partner of MER, a receptor tyrosine kinase highly expressed in 
prostate (Graham et al., 1994; Mahajan and Earp, 2003) .  The constitutively active form of 
Ack1 (caAck), defined by a L487F mutation that relieves autoinhibition of kinase (Kato et 
al., 2000), dramatically increased prostate xenograft tumor growth in castrated mice (Kato et 
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al., 2000; Mahajan et al., 2005).  Furthermore, a survey of primary tumor samples for 
activated Ack1 revealed that androgen independent prostate cancer specimens had a higher 
level of activated Ack1 expression suggesting a role in tumorigenesis.  The activated Ack1 
induced the AR transcriptional activity of AR regulated genes by enhancing AR recruitment 
into the promoter of these genes.  Their in vitro and in vivo data showed that activated Ack1 
bound and phosphorylated AR at tyrosine residues (i.e. Tyr-267, Tyr-363) (Figure 1.3).  
Furthermore, they identified a role of Ack1 in heregulin dependent activation of AR.  
Heregulin treatment of both LNCaP and LAPC4 cells led to phosphorylation of both Ack1 
and AR.  Further, they showed that AR phosphorylation and activation in response to 
heregulin treatment was dependent on Ack1 activity.  The knockdown of endogenous Ack1 
in LNCaP and LAPC4 cells showed that AR recruitment to the enhancer or promoter regions 
of AR regulated genes (i.e. PSA) was dependent on Ack1.  Mass spectrometric analysis of 
putative Ack1 mediated phosphorylation target tyrosine sites revealed that tyrosine 
phosphorylation at Try-267 was a major site of AR phosphorylated by Ack1.  Further 
characterization of Ack1 phosphorylation target tyrosine residues showed that mutating 
tyrosine 267 and 363 to phenylalanine dramatically decreased AR transcriptional activity and 
recruitment to the enhancer regions of AR target genes and Ack1 driven androgen 
independent LNCaP cell xenografts tumor growth. 
 In addition to Ack1, Src kinase phosphorylates AR at Tyr-534 and activates AR under 
the androgen depleted condition (Guo et al., 2006).  The Src mediated AR phosphorylation at 
Tyr-534 resulted in promoting the growth of prostate cancer cells in the low androgen 
environment, recruitment of AR to the promoter regions of AR target genes and nuclear 
localization of AR protein.     
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1.8 Dissertation Research Objectives  
 Continued AR signaling activity throughout prostate cancer development has become 
a common theme.  The mechanisms of AR activation under HRPC are being actively studied 
by many research groups.  Along with results from in vitro and in vivo experiments 
conducted in our laboratory, the elevated levels of phosphorylated Ack1 and AR proteins 
were prominent feature of HRPC samples compared to benign prostate hyperplasia (BPH) 
and androgen dependent prostate cancer (Mahajan et al., 2007).  The previously identified 
Ack1 target phosphorylation sites (Tyr-267 and Tyr-363) need to be functionally 
characterized in order to understand the significance of AR phosphorylation in HRPC.  By 
studying the functional significance of Ack1 target phosphorylation sites of AR, we will be 
able to contribute to the current state of knowledge about the mechanisms of androgen 
independent AR phosphorylation and activation under the androgen deprivation condition.  
The objective of this research were: (1) to understand the role of AR phosphorylation sites 
(Tyr-267 and Tyr-363) in AR transcriptional activity of full length AR as well as truncated 
AR missing ligand binding domain (LBD); (2) to determine the role of AR phosphorylation 
sites on the AR driven cellular phenotypes in cells stably overexpressing AR; (3) to identify 
the global gene expression changes in LNCaP cells overexpressing either full or truncated 
mutated AR expression constructs. 
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Figure 1.1.   Androgen receptor (AR) modular structure and functional domains.  AR is 
consisted of 8 exons encoding four functional domains: N-terminal domain, DNA binding 
domain, hinge region, and ligand binding domain (Adapted from Gelmann, 2002).   
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Figure 1.2.  AR modular structure and coactivator interacting motifs.  AR consists of 
NH2-terminal region (NTD), a DNA binding domain (DBD), a ligand binding domain 
(LBD).  AF1 is a predominant activating function domain located in NTD.  Ligand 
dependent AF-2 interacts with two motifs (FXXLF and WXXLF) motifs in the NTD.  
LKDIL is a core motif that mediates transcriptional activity of TAU1.  The coregulators such 
as SRC/p160 interacts with AF-2 through the LXXLF motifs (Adapted from Wilson, 2007).    
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Figure 1.3.  Full length and truncated AR proteins bearing Y267F and Y363F 
mutations.  Ack1 target phosphorylation sites Y267 and Y363 were mutated into Y267F and 
Y363F. NTD: N-Terminal domain; DBD: DNA binding domain; H:Hinge region, and LBD: 
Ligand binding domain.  
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2.1 Abstract 
     Activation of androgen receptor (AR) may play a role in the development of castration 
resistant prostate cancer.  Two intracellular tyrosine kinases, Ack1 (activated cdc42-
associated kinase) and Src, phosphorylate and enhance AR activity and promote prostate 
xenograft tumor growth in castrated animals.  However, the upstream signals that activate 
these kinases and lead to AR activation are incompletely characterized.  In this study, we 
investigated AR phosphorylation in response to non-androgen ligand stimulation using 
phospho-specific antibodies.  Treatment of LNCaP and LAPC-4 cells with epidermal growth 
factor (EGF), heregulin, Gas6 (ligand binding to Mer receptor tyrosine kinase and activating 
Ack1 downstream), interleukin (IL)-6 or bombesin stimulated cell proliferation in the 
absence of androgen.  Treatment of LNCaP and LAPC-4 cells with EGF, heregulin, or Gas6 
induced AR phosphorylation at Tyr-267; IL-6 or bombesin treatment did not.  AR 
phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or bombesin, but not 
by heregulin or Gas6.  siRNA-mediated knockdown of Ack1 or Src showed that Ack1 
mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation whereas Src mediates 
Tyr-534 phosphorylation induced by EGF, IL-6, and bombesin.  Dasatinib, a Src inhibitor, 
blocked EGF-induced Tyr-534 phosphorylation.  In addition, we show dasatinib also 
inhibited Ack1 kinase.  Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR 
Tyr-267 phosphorylation.  Dasatinib inhibited heregulin-induced AR-dependent reporter 
activity.  Dasatinib also inhibited heregulin-induced expression of endogenous AR target 
genes.  Dasatinib inhibited Ack1-dependent colony formation and prostate xenograft tumor 
growth in castrated mice.  Interestingly, Ack1 or Src knockdown or dasatinib did not inhibit 
EGF-induced AR Tyr-267 phosphorylation or EGF-stimulated AR activity, suggesting the 
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existence of an additional tyrosine kinase that phosphorylates AR at Tyr-267. These data 
suggest that specific tyrosine kinases phosphorylate AR at distinct sites and that dasatinib 
may exert anti-tumor activity in prostate cancer through inhibition of Ack1. 
2.2 Introduction 
 Androgen deprivation therapy through surgical or medical castration is commonly 
used as a systemic therapy of advanced prostate cancer because it is initially effective in 
causing tumor regression and palliating cancer-related symptoms.  However, virtually all 
patients eventually progress and develop hormone refractory prostate cancer or castration 
resistant prostate cancer (CRPC), a terminal disease with poor prognosis.  Substantial 
evidence indicates that androgen receptor (AR) activation in the environment of low 
circulating testosterone plays a critical role in the development of CRPC.  Studies using 
xenograft tumor models demonstrate that prostate xenograft tumors that recur following 
castration express AR-dependent genes (Gregory et al., 1998).  In these cells, the AR protein 
is stabilized and constitutively localized to the nucleus and is hypersensitive to low levels of 
androgen (Gregory et al., 2001).  Overexpression of AR enhanced the ability of androgen-
dependent prostate xenografts to form tumor in castrated animals while knockdown of AR 
inhibited their tumorigenicity (Chen et al., 2004).  Multiple mechanisms have been shown to 
activate AR in CRPC.  These include AR gene amplification, increased AR expression, AR 
point mutations frequently occurring in the ligand binding domain that broaden ligand 
specificity, overexpression of AR coactivators, and intratumoral production of androgen 
(Scher and Sawyers, 2005). 
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 In addition to these mechanisms, AR may be activated by crosstalk with signaling 
pathways initiated by cell surface receptors binding to growth factors, cytokines, and 
neuropeptides.  Intracellular pathways involving mitogen activated protein kinase (MAPK) 
or phosphatidylinositol 3-kinase/Akt have been proposed to mediate activation of AR 
downstream of receptor tyrosine kinases (Gregory et al., 2004; Wang et al., 2007).  For 
example, epidermal growth factor (EGF) receptor enhances AR transcriptional activity 
through increasing the interaction between AR and the steroid receptor coactivator TIF2 
secondary to MAPK-dependent phosphorylation of TIF2 (Gregory et al., 2004).  HER-2 
(ErbB2) activates the AR transcriptional function by increasing protein stability, recruitment 
and DNA binding (Liu et al., 2005; Mellinghoff et al., 2004).  AR protein is phosphorylated 
at multiple serine/threonine residues and phosphorylation at some of these sites has been 
proposed to regulate nuclear localization and export (Gioeli et al., 2006; Gioeli et al., 2002; 
Ponguta et al., 2008).  Recently, several groups reported that tyrosine phosphorylation of AR 
protein by nonreceptor tyrosine kinases Src and Ack1 (activated cdc42-associated kinase) 
may play a role in AR activation in the low androgen environment, thereby promoting the 
development of CRPC (Guo et al., 2006; Kraus et al., 2006; Mahajan et al., 2007).  Src-
mediated phosphorylation of AR at Tyr-534 resulted in activation of AR and nuclear 
translocation and DNA binding in the absence of androgen (Guo et al., 2006; Kraus et al., 
2006).  Our previous work identified Ack1 as a protein activated downstream of Mer 
receptor tyrosine kinase in prostate cancer cells (Mahajan et al., 2005).  Furthermore, we 
demonstrated that expression of activated Ack1 increased prostate xenograft tumor growth in 
castrated animals as well as AR target gene expression and AR recruitment to the enhancers 
of target genes at suboptimal androgen concentrations (Mahajan et al., 2007).  Ack1 
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interacted with and phosphorylated AR protein at Tyr-267 and Ack1 was shown to be 
required for optimal AR target gene expression and AR recruitment.  Tyrosine 
phosphorylated AR protein was expressed in 8 out of 18 primary CRPC tumor samples and 
its expression was correlated with Ack1 activation in the same tumors.  In this report, we 
investigate the upstream signals activating AR phosphorylation and we show that Src and 
Ack1 kinases each contribute to site-specific phosphorylation of AR. 
2.3 Materials and Methods 
 Cells and Reagents.  LAPC-4 cells were provided by Dr. Charles Sawyers (Klein et 
al., 1997).  EGF (R&D Systems, Minneapolis, MN), IL-6 (R&D), Gas6 (R&D), and 
bombesin (Sigma-Aldrich, St. Louis, MO) were purchased.  Heregulin was a gift from 
Genentech (South San Francisco, CA).  Dasatinib was obtained from Bristol-Myers-Squibb 
(Princeton, NJ).  Phospho-specific polyclonal antibody against Tyr-267 of AR was generated 
by a commercial vendor (21st Century Biochemicals, Marlboro, MA).  Rabbits were 
immunized with carrier-conjugated phospho-peptides spanning Tyr-267.  Immunodepletion 
using a nonphospho-peptide column and affinity purification using the phospho-peptide 
column were performed by the vendor.  Phospho-specific antibody against Tyr-534 of AR 
was raised in rabbits using standard methods and affinity purified in a similar fashion; its 
characterization has been reported (DaSilva et al., 2009).  A mouse monoclonal antibody 
against total AR (F39.4.1, Biogenex, San Ramon, CA) was used for immunoblotting.  A 
polyclonal antibody against AR (C-19, Santa Cruz) was used for immunoprecipitation.  The 
antibody against total Ack1 was described previously (Mahajan et al., 2005).  A phospho-
specific antibody against Ack1 p-Tyr-284 (# 09-142) was obtained from Millipore (Billerica, 
 48 
MA).  Antibodies against total Src (#2108) and phospho-specific Src p-Tyr-416 (#2101) 
were obtained from Cell Signaling Technology (Beverly, MA). 
 Transfection and Knock Down.  293T cells and COS7 cells were transfected with 
AR or Ack1 or Src expression vectors using Effectene (Qiagen, Valencia, CA) according to 
the manufacturer’s direction.  siRNA sequences against Ack1 were previously described 
(Mahajan et al., 2007).  For knocking down Src, Validated Stealth RNAi™ siRNA against 
Src (Invitrogen, Carlsbad, CA) was used according to the manufacturer.  LNCaP cells were 
transfected using siPort Lipid (Ambion, Austin, TX) with 100 nM of siRNA or negative 
control scrambled siRNA.  After 24 hrs, cells were treated with ligands as indicated.  All 
experiments were repeated at least three times.      
 Proliferation Assays.  LNCaP cells or LAPC-4 cells were seeded at a density of 104 
cells per well in triplicate in a 96-well plate in serum-free medium (RPMI 1640 for LNCaP 
and IMDM for LAPC-4).  On day 0, cells were treated with DHT (10 nM), EGF (100 ng/ml), 
heregulin (10 ng/ml), Gas6 (100 ng/ml), bombesin (1 nM), or IL-6 (10 ng/ml).  After 3 days 
of incubation, relative cell proliferation was measured using colorimetric dye WST-8 (Cell 
Counting Kit-8, Dojindo, Rockville, MD) according to the manufacturer’s direction. 
 Western Blot Analysis.  Whole-cell lysates were prepared on ice using Mammalian 
Protein Extraction Reagent (M-PER) (Pierce Biotechnology, Rockford, IL) according to 
manufacturer’s instructions.  Cytoplasmic extracts were prepared as previously described 
(Mayo et al., 1997).  Protein extracts were quantified by Bradford assay (Bio-Rad 
Laboratories, Hercules, CA) and analyzed by SDS-PAGE as previously described 
(Steinbrecher et al., 2005).   
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 Reporter Assays and Quantitative RT-PCR.  LNCaP cells (8 X 105 cells per 6-cm 
plate) were transfected with the ARR2-PB-luciferase reporter (500 ng) (Zhang et al., 2000) 
along with the AR expression vector (50 ng), using Effectene, as described (Mahajan et al., 
2007).  After overnight incubation, cells were pre-treated with dasatinib as indicated for 2 
hrs, then EGF (100 ng/ml) or heregulin (10 ng/ml) for 20 hrs.  Luciferase activity was 
determined, as described (Mahajan et al., 2007).  The IC50 concentration of dasatinib 
required for inhibition of heregulin-driven luciferase activity was calculated using the dose-
response variable slope (four parameters) function of the GraphPad Prism 5 software 
(GraphPad, La Jolla, CA).  For measurement of PSA and hK2 mRNA levels, LNCaP or 
LAPC-4 cells were incubated in serum-free medium and were pre-treated with dasatinib (10 
nM) for 2 hrs, then treated with heregulin (10 ng/ml) or EGF (100 ng/ml) for 20 hrs.  Total 
RNA was isolated and the mRNA levels of PSA and hK2 were determined by quantitative 
RT-PCR, as described (Mahajan et al., 2007).  
 Colony Formation in Soft Agar.  LNCaP cells expressing Ack1 or vector control 
(104 cells per well) were suspended in 0.45% Noble agar prepared in growth medium along 
with the indicated concentration of dasatinib and placed above a layer of solidified 0.9% 
Noble agar in 6 well plates in triplicates.  After 3 weeks, colonies were visualized by staining 
with MTT. 
 Xenograft Tumor Growth. LNCaP cells stably expressing activated Ack1 by 
retroviral transduction have been described (Mahajan et al., 2005).  LNCaP-Ack1 cells (2 X 
106) were mixed with an equal volume of Matrigel (BD Biosciences, Franklin Lakes, NJ) and 
implanted subcutaneously in the flank of castrated nude male mice, as described (Mahajan et 
al., 2007; Mahajan et al., 2005).  When tumors became palpable, mice were randomly 
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divided into two groups.  Dasatinib was dissolved in citrate buffer (80 mM, pH 3.1) and 
administered to mice via oral gavage at a dose of 30 mg/kg twice daily.  Tumor size was 
measured with calipers twice per week.  These procedures were approved by the Institutional 
Animal Use and Care Committee. 
 Statistical Methods.  The nonparametric Wilcoxon rank-sum test (using Van der 
Waerden normal scores) was used for the two-group comparisons of tumor volumes of the 
treated group (n=8) to the control group (n=7) at days 25 and 29 of treatment.  Exact nominal 
(unadjusted for multiple comparisons) two-sided p-values were reported.  Statistical analyses 
were performed using SAS statistical software, Version 9.2 (SAS Institute, Inc., Cary, NC). 
2.4 Results 
 Site-specific Phosphorylation of Androgen Receptor by Ack1 and Src Kinases.  
Previous reports demonstrated that AR protein may be phosphorylated at Tyr-534 or Tyr-267 
residues (Guo et al., 2006; Kraus et al., 2006; Mahajan et al., 2007).  To elucidate signaling 
pathways leading to AR tyrosine phosphorylation, phospho-specific antibodies against AR 
protein phosphorylated at these residues were generated.  Their specificity was tested against 
wildtype and phosphorylation-site mutant AR. Wildtype AR, Y267F AR, or Y534F AR 
expression vectors were co-transfected along with the activated Ack1 or activated Src kinase 
expression vector.  The phospho-Y267 specific antibody detected AR only when Ack1 was 
co-expressed and did not detect the AR Y267F mutant protein in cell lysates co-expressing 
Ack1 (Figure 2.1A).  The phospho-Y534 specific antibody detected AR only when Src was 
co-expressed and did not recognize the AR Y534F mutant protein in the presence of Src 
(Figure 2.1B).  Co-expression of Ack1 led to phosphorylation of Tyr-267 but not Tyr-534 of 
AR.  Conversely, co-expression of Src resulted in phosphorylation of Tyr-534 but not Tyr-
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267 of AR.  These data suggest that Ack1- and Src-mediated phosphorylation of AR is site-
specific (i.e. Ack1 targets Tyr-267 but not Tyr-534 and vice versa for Src). 
 Phosphorylation of Androgen Receptor by Ligand Stimulation.  Tyrosine 
phosphorylation of endogenous AR in prostate cancer cells induced by physiologic ligand 
stimulation was characterized using the phospho-specific antibodies.  Extracellular ligands 
that bind to the cell surface receptors and have previously been reported to enhance AR 
activity or may potentially enhance AR activity were tested for their ability to induce AR 
tyrosine phosphorylation.  Gas6 is the ligand for Mer receptor tyrosine kinase, which we 
have previously shown to activate Ack1 in prostate cells (Mahajan et al., 2005).  Heregulin 
binds to HER-3 and activates HER-2 kinase through the formation of the HER-2/HER-3 
heterodimer.  Bombesin (also known as gastrin-releasing peptide) is a neuropeptide produced 
by neuroendocrine cells, which has been reported to support growth of androgen-dependent 
LNCaP cells in an androgen-depleted condition through Src-mediated activation of AR 
(Desai et al., 2006; Gong et al., 2006; Yang et al., 2009).  Interleukin-6 leads to ligand-
independent activation of the AR N-terminal domain that involves MAPK and steroid 
receptor coactivator-1 (Ueda et al., 2002b).  Treatment of LNCaP cells with EGF, heregulin, 
or Gas6 induced phosphorylation of the AR protein at Tyr-267 (Figure 2.1C).  AR 
phosphorylation was transient and peaked at 60-90 min. and returned to the basal level by 4 
hrs (data not shown).  Treatment with IL-6 or bombesin did not induce phosphorylation of 
the AR at Tyr-267.  Phosphorylation of the AR at Tyr-534 was induced by treatment with 
EGF, IL-6 or bombesin, but not with heregulin or Gas6 (Figure 2.1D).  EGF was the only 
ligand tested that induced AR phosphorylation at both Tyr-267 and Tyr-534 sites, in contrast 
to other ligands that produced site-specific AR phosphorylation (i.e. heregulin and Gas6 at 
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Tyr-267 and IL-6 and bombesin at Tyr-534).  LAPC-4 prostate cancer cells that express 
wildtype AR endogenously (Klein et al., 1997) were treated with these ligands and AR 
phosphorylation at Tyr-267 and Tyr-534 sites was analyzed similarly.  LAPC-4 cells 
exhibited the same pattern of AR phosphorylation by these ligands as LNCaP cells (Figure 
2.2). 
 Stimulation of Cell Proliferation by Non-androgen Ligands.  Since cell 
proliferation requires AR activation in androgen-dependent prostate cancer cells, the effect of 
these ligands inducing AR phosphorylation on cell proliferation was determined.  In LNCaP 
cells, treatment with EGF, heregulin, Gas6, bombesin, or IL-6 all stimulated cell proliferation 
to similar levels as the androgen dihydrotestosterone (DHT) (Figure 2.3).  In LAPC-4 cells, 
all ligands stimulated cell proliferation although Gas6 and IL-6 were less effective than DHT 
or other ligands.  These results are in agreement with previous reports of stimulation of 
proliferation in the absence of androgen by heregulin (Gregory et al., 2005), bombesin (Desai 
et al., 2006; Lee et al., 2001), or IL-6 (Ueda et al., 2002a).  These data demonstrate that these 
non-androgen ligands inducing AR phosphorylation promote prostate cancer cell 
proliferation in the absence of androgen. 
 Dasatinib Inhibits Ack1 Kinase Activity but does not Inhibit EGF-induced AR 
Phosphorylation at Tyr-267.  For characterization of signaling pathways and therapeutic 
applications, a small molecule kinase inhibitor of Ack1 would be desirable.  A previous 
report indicated that dasatinib, a potent inhibitor of Src and Abl kinases, interacted with 
several additional tyrosine kinases in a competition binding assay, including Ack1 (Carter et 
al., 2005).  The ability of dasatinib to inhibit Ack1 autophosphorylation as a marker of kinase 
activity was tested in 293T cells transfected to express activated Ack1 (Figure 2.4A).  
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Dasatinib inhibited Ack1 autophosphorylation in a dose dependent manner, with dasatinib 
doses of 10 nM or greater demonstrating nearly complete inhibition of Ack1 
phosphorylation, consistent with the previously reported Kd of 6 nM (Carter et al., 2005).  
Treatment of LNCaP cells with dasatinib inhibited heregulin-induced Ack1 phosphorylation 
almost completely at doses of 10 nM or greater (Figure 2.4B).  Dasatinib treatment inhibited 
heregulin-induced AR phosphorylation at Tyr-267.  The concentration of dasatinib required 
for inhibition of AR phosphorylation at Tyr-267 was similar to that for inhibition of 
heregulin-induced Ack1.  This result is consistent with the notion that heregulin-induced 
activation of Ack1 mediates AR phosphorylation at Tyr-267.  The effect of dasatinib on 
EGF-induced phosphorylation of AR was tested.  EGF-induced AR phosphorylation at Tyr-
534 was inhibited by dasatinib (Figure 2.5A).  Since dasatinib inhibits Src, this finding is 
consistent with the idea that Src activation downstream of EGF receptor leads to AR 
phosphorylation at Tyr-534.  Dasatinib had no effect on EGF-induced AR phosphorylation at 
Tyr-267, even at doses as high as 1000 nM (Figure 2.5B).  However, Src activation after 
EGF treatment was inhibited by dasatinib at a dose as low as 1 nM (Figure 2.5D).  In LNCaP 
cells, Ack1 was not activated after EGF treatment while heregulin-induced Ack1 activation 
was detected (Figure 2.5C).  These results suggest that at least one other tyrosine kinase 
(other than Src and Ack1) mediates AR phosphorylation at Tyr-267 after EGF treatment in 
LNCaP cells and that this kinase (or kinases) is insensitive to dasatinib. 
 Role of Ack1 and Src in Ligand-stimulated AR Phosphorylation.  To investigate 
more directly the role of Ack1 or Src in AR phosphorylation after ligand stimulation, the 
effect of Ack1 or Src knockdown by siRNA was tested (Figure 2.6).  Ack1 knockdown 
inhibited AR phosphorylation at Tyr-267 induced by heregulin or Gas6 treatment.  Src 
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knockdown inhibited AR phosphorylation at Tyr-534 induced by EGF or IL-6 or bombesin 
treatment.  However, EGF-induced AR phosphorylation at Tyr-267 was not inhibited by 
Ack1 knockdown or Src knockdown, despite markedly reduced expression levels of Ack1 or 
Src by siRNA confirmed by immunoblotting.  These data suggest that downstream of cell 
surface receptors, Ack1 mediates AR tyrosine phosphorylation at Tyr-267 and Src mediates 
AR tyrosine phosphorylation at Tyr-534.   However, EGF-induced AR phosphorylation at 
Tyr-267 likely involves an additional kinase(s) that is not inhibited by dasatinib.  
 Effect of Dasatinib on Ack1-Induced AR Activation.  The biological effect of 
dasatinib on prostate cancer cells was investigated.  First, LNCaP cells transfected with the 
AR-dependent reporter ARR2-PB-luciferase were investigated.  Treatment of these cells with 
heregulin or EGF (without androgen) increased luciferase activity.  AR antagonist 
bicalutamide inhibited androgen-induced AR reporter activity but did not inhibit heregulin- 
or EGF-induced AR reporter activity (Figure 2.7).  Therefore, heregulin- or EGF-induced AR 
activation likely reflects ligand-independent activation of AR via receptor tyrosine kinase-
mediated pathways.  Dasatinib treatment inhibited heregulin-induced AR reporter activity 
with the IC50 of 4.9 nM, consistent with the hypothesis that the stimulatory effect of 
heregulin is mediated by downstream Ack1 activation (Figure 2.8A).  However, dasatinib 
treatment had no effect on EGF-induced AR reporter activity, even at doses as high as 1000 
nM, in contrast to its inhibitory effect on heregulin-mediated AR reporter activity (Figure 
2.8B).  The effect of dasatinib on expression of endogenous AR target genes prostate specific 
antigen (PSA) and human kallikrein 2 (hK2) (also known as KLK2) was tested.  Treatment 
of LNCaP cells with EGF or heregulin increased PSA and hK2 mRNA levels by 4-6 fold.  
Dasatinib treatment partially blocked heregulin-induced expression of PSA and hK2 mRNA 
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but not EGF-induced expression of PSA and hK2 mRNA (Figure 2.8 C and D).  Similar 
results were seen in LAPC-4 cells (Figure 2.9).  Since heregulin-induced Tyr-267 
phosphorylation is blocked by dasatinib, but EGF-induced Tyr-267 phosphorylation is not 
blocked by dasatinib, these results suggest that the stimulatory effect of growth factors on 
AR is correlated with induction of Tyr-267 phosphorylation, either by Ack1 or an 
unidentified tyrosine kinase downstream of EGF. 
 Effect of Dasatinib on Ack1-induced Colony Formation and Xenograft Tumor 
Growth.  Activated Ack1 enhances the ability of LNCaP cells to form colonies in soft agar 
and grow as subcutaneous xenograft tumor in castrated mice (Mahajan et al., 2007; Mahajan 
et al., 2005).  The effect of dasatinib on Ack1-induced colony formation was determined.  
Dasatinib treatment decreased the number of soft agar colonies in LNCaP cells expressing 
activated Ack1 in a dose-dependent manner (Figure 2.10A).  Dasatinib also inhibited soft 
agar colony growth of LNCaP vector control cells, likely through inhibition of Src kinase 
expressed in LNCaP (Park et al., 2008).  We investigated the effect of dasatinib treatment in 
vivo on the xenograft tumor growth of LNCaP-Ack1 cells in castrated mice.  Castrated mice 
with xenograft tumors were treated with dasatinib orally or vehicle control and the tumor 
volume was monitored.  Administration of dasatinib resulted in significant inhibition of 
xenograft tumor growth.  At day 25 and 29, the tumor volume of the dasatinib treatment 
group was decreased by approximately 50% compared to the tumor volume of the control 
group (Figure 2.10B).   The phosphorylation status of Ack1 and AR proteins was determined 
by immunoblotting of protein extracts of harvested tumor tissues at the conclusion of the 
experiment.  In tumors harvested from control animals, Ack1 and AR at Tyr-267 were 
constitutively phosphorylated, whereas in tumors from dasatinib treated animals, Ack1 and 
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AR proteins were not phosphorylated (Figure 2.10C).  These data suggest that inhibition of 
Ack1 kinase by dasatinib leads to loss of AR phosphorylation and decreased xenograft tumor 
growth. 
2.5 Discussion 
 In this report, we demonstrate that Ack1 and Src tyrosine kinases target distinct AR 
phosphorylation sites (i.e. Tyr-267 by Ack1 and Tyr-534 by Src) after activation by cell 
surface receptors.  EGF, IL-6, and bombesin-induced AR phosphorylation at Tyr-534 was 
inhibited by Src knockdown and dasatinib, a potent Src inhibitor, suggesting Src involvement 
downstream of these ligands.  Activation of AR by EGF and bombesin through Src had been 
reported previously (Desai et al., 2006; Guo et al., 2006; Kraus et al., 2006).  A recent report 
indicated that the neuroendocrine-derived peptide parathyroid hormone-related protein 
stabilizes AR by reducing interaction with the ubiquitin ligase CHIP through Src-mediated 
phosphorylation of AR at Tyr-534 (DaSilva et al., 2009).  Involvement of Ack1 downstream 
of heregulin and Gas6 in AR phosphorylation at Tyr-267 was confirmed by Ack1 
knockdown as well as dasatinib, which has been shown to be an inhibitor of Ack1 in this 
work.  However, inhibition of Src and Ack1 did not prevent EGF-induced AR tyrosine 
phosphorylation at Tyr-267, suggesting the existence of an additional unidentified tyrosine 
kinase (or kinases) capable of phosphorylating AR at Tyr-267 (Figure 2.11).  Although 
identification and understanding the functional role of this kinase on AR signaling will 
require further work, it is clear that Tyr-267 phosphorylation is involved in some modes of 
AR transactivation no matter which tyrosine kinase is involved.  Inhibition of growth factor-
induced AR activity by dasatinib correlates with loss of AR phosphorylation at Tyr-267, as 
dasatinib inhibits heregulin-induced AR Tyr-267 phosphorylation and AR reporter activity 
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and target gene expression.  In contrast, EGF-induced AR Tyr-267 phosphorylation and AR 
reporter activity and target gene expression are resistant to dasatinib.  This result raises a 
possibility that phosphorylation of Tyr-267 is required for AR activation downstream of 
receptor tyrosine kinases. 
 The functional consequences of AR phosphorylation at Tyr-267 and Tyr-534 appear 
similar in that phosphorylation at both sites has been linked to enhanced AR recruitment and 
expression of AR target genes at suboptimal androgen concentrations (Guo et al., 2006; 
Mahajan et al., 2007).  However, chromatin immunoprecipitation analysis demonstrated that 
Src-induced AR activation involves AR recruitment preferentially to the proximal promoter 
elements of the canonical target gene prostate specific antigen and that there is no increase in 
the binding of AR to the distal enhancer where androgen-induced and Ack1-driven AR 
recruitment takes place (Desai et al., 2006; Mahajan et al., 2007; Yang et al., 2009).  Whether 
this difference in the AR recruitment sites stems from the distinct AR phosphorylation sites 
or possibly due to other components of the transcriptional complex regulated by these 
kinases is unclear.  The differential effect of AR phosphorylation sites on target gene 
expression and binding of coactivators and corepressors and other proteins involved in the 
assembly of the active transcriptional complex requires further elucidation. 
 Dasatinib inhibits a wide spectrum of kinases such as Abl and Src and its ability to 
inhibit Bcr-Abl kinase (unmutated and mutated forms) led its approval for treatment of 
imatinib-resistant chronic myelogenous leukemia (Brave et al., 2008).  In addition to the 
ability of Src to promotes castration resistant progression and AR activation, Src is involved 
in regulating prostate cancer cell migration, invasion, and metastasis and affects bone 
remodeling (Araujo and Logothetis, 2009; Park et al., 2008).  Therefore, dasatinib is 
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currently being studied in treatment of CRPC as a single agent and in combination with 
docetaxel chemotherapy (Araujo et al., 2009; Yu et al., 2009).  Our data show that Ack1 
kinase is inhibited by dasatinib at clinically relevant concentrations, and preclinical xenograft 
studies demonstrate the feasibility of inhibiting Ack1 in vivo as tumors exhibit loss of 
constitutive Ack1 and AR phosphorylation after oral treatment with dasatinib.  This raises a 
possibility that dasatinib may have clinical activity against Ack1-driven malignancies.  Ack1 
binds and is activated by several receptor tyrosine kinases such as EGFR, HER-2, Mer, Axl, 
platelet derived growth factor receptor, LTK (leucocyte receptor tyrosine kinase belonging to 
the insulin receptor family) and ALK (anaplastic lymphoma kinase) (Galisteo et al., 2006; 
Mahajan et al., 2005; Pao-Chun et al., 2009).  A recent study demonstrated that the Ack1 
gene is amplified and overexpressed in several tumor types, including castration resistant 
prostate cancer, and this was correlated with cancer progression and poor prognosis (van der 
Horst et al., 2005).  Additionally, Ack1 may also be activated by oncogenic mutations.  The 
current release (version 42) of the Catalogue of Somatic Mutation in Cancer database 
reported 5 out of 229 tumor samples containing point mutations in Ack1, some of which are 
likely to lead to constitutive activation of kinase (Forbes et al., 2006).  In a subset of primary 
CRPC tumor specimens (8 out of 18), expression of tyrosine-phosphorylated AR and Ack1 
was detected by immunoprecipitation and immunoblotting of tumor lysates (Mahajan et al., 
2007).  Our findings provide additional mechanisms by which dasatinib may exert anti-tumor 
activity in CRPC.  Although both Src and Ack1 phosphorylate AR protein, they target 
distinct sites.  Therefore, phospho-Tyr-267 and phospho-Tyr-534 AR expression in CRPC 
tumors may serve as a predictive biomarker of tyrosine kinase inhibitor therapy.  
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Figure 2.1.  Phospho-specific antibodies demonstrate that AR is phosphorylated at Tyr-
267 and Tyr-534 after ligand stimulation.  (A) 293T cells were transfected with the 
expression vector encoding wildtype AR or Y267F AR or Y534F AR along with 
constitutively active Ack1 or empty vector.  After 24 hours, protein extracts were 
immunoblotted with the antibody specific for phospho-Y267 AR or total AR.  (B) COS7 
cells were transfected with the vector encoding wildtype AR or Y267F AR or Y534F AR 
along with constitutively active Ack1 or activated Src or empty vector, as indicated.  After 24 
hours, protein extracts were immunoprecipitated with the AR antibody, then immunoblotted 
with the antibody specific for phospho-Y267 AR or phospho-Y534 AR or total AR, as 
indicated.  (C) LNCaP cells were treated with EGF (100 ng/ml), heregulin (10 ng/ml), Gas6 
(100 ng/ml), IL-6 (10 ng/ml), or bombesin (1 nM) for 60 min.  Protein extracts were 
immunoblotted with the antibody specific for phospho-Y267 AR or total AR.  (D) LNCaP 
cells were treated as above.  Protein extracts were immunoprecipitated with the AR antibody, 
then immunoblotted with the antibody specific for phospho-Y534 AR.  Blots shown are 
representative of three independent experiments.  
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Figure 2.2.  AR is phosphorylated at Tyr-267 or Tyr-534 after ligand stimulation in 
LAPC-4 cells.  (A, B) LAPC-4 cells were treated with EGF (100 ng/ml), heregulin (10 
ng/ml), Gas6 (100 ng/ml), IL-6 (10 ng/ml), or bombesin (1 nM) for 60 min.  Protein extracts 
were immunoblotted with the antibody specific for phospho-Y267 AR or phospho-Y534 AR 
or total AR, as indicated. 
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Figure 2.3. EGF, heregulin, Gas6, bombesin, and IL-6 stimulate proliferation of 
androgen-dependent prostate cancer cell lines in the absence of androgen.  Cells were 
seeded in serum-free medium in triplicate wells of a 96-well plate and treated with EGF (100 
ng/ml), heregulin (10 ng/ml), Gas6 (100 ng/ml), IL-6 (10 ng/ml), or bombesin (1 nM) for 72 
hours.  Relative cell proliferation was determined by addition of colorimetric dye WST-8 and 
measuring absorbance at 450 nM.  (A) LNCaP cells.  (B) LAPC-4 cells.  Data shown are 
representative of three similar independent experiments. All treatment conditions are 
significantly different from untreated control with p <0.05 by t-test. 
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Figure 2.4.  Dasatinib inhibits Ack1 kinase activity and inhibits heregulin-induced AR 
phosphorylation at Tyr-267.  (A) 293T cells were transfected with empty vector or kinase-
dead Ack1 or constitutively active Ack1.  After 24 hours, cells were treated with increasing 
concentrations of dasatinib for 2 hours.  Protein extracts were immunoblotted with the 
antibody against phospho-Ack1 or total Ack1.  (B) LNCaP cells were pre-treated with 
dasatinib at increasing concentrations for 2 hours, then treated with heregulin (10 ng/ml) for 
60 min.  Protein extracts were immunoblotted with the antibody against phospho-Y267 AR 
or total AR or phospho-Ack1 or total Ack1.  Blots shown are representative of three 
independent experiments. 
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Figure 2.5. Dasatinib inhibits EGF-induced AR phosphorylation at Tyr-534 but not 
Tyr-267.  (A)  LNCaP cells were pre-treated with dasatinib (10 nM) for 2 hours, then treated 
with EGF (100 ng/ml) for 60 or 90 min.  Protein extracts were immunoprecipitated with the 
AR antibody, then immunoblotted with the antibody specific for phospho-Y534 AR or total 
AR.  (B)  LNCaP cells were pre-treated with dasatinib at increasing concentrations for 2 
hours, then treated with EGF (100 ng/ml) for 60 min.  Protein extracts were immunoblotted 
with the antibody against phospho-Y267 AR or total AR.  (C, D)  LNCaP cells were treated 
as above.  Cells were also treated with heregulin (10 ng/ml) for 60 min as a positive control 
of Ack1 activation.  Protein extracts were immunoblotted with the antibody against phospho-
Ack1 or total Ack1 or phospho-Src or total Src.  Blots shown are representative of three 
independent experiments.  
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Figure 2.6.  Knockdown of Src or Ack1 demonstrates the existence of an additional 
kinase that induces AR phosphorylation at Tyr-267 after EGF stimulation.  LNCaP cells 
were transfected with control or Src-specific or Ack1-specific siRNA.  After 24 hours, cells 
were treated with heregulin, Gas6, EGF, IL-6, or bombesin, as indicated, for 60 min.  (A) 
Protein extracts were immunoblotted with the antibody specific for phospho-Y267 AR or 
total AR.  (B) Protein extracts were immunoprecipitated with the AR antibody, then 
immunoblotted with the antibody specific for phospho-Y534 AR.  Protein extracts were also 
immunoblotted with the antibody specific for Src or Ack1.  Blots shown are representative of 
at least three independent experiments.  
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Figure 2.7.  AR antagonist bicalutamide inhibits androgen-induced AR reporter activity 
but not growth factor-induced AR reporter activity.  LNCaP cells were transfected with 
the AR reporter ARR2-PB-luciferase.  After overnight incubation, cells were pre-treated with 
bicalutamide for 2 hrs, then with DHT (10 nM), heregulin (10 ng/ml) or EGF (100 ng/ml) for 
20 hrs.  Cell extracts were assayed for luciferase activity.  The mean and standard deviation 
of triplicate samples of a representative experiment are shown from three independent 
experiments that showed similar results. 
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Figure 2.8.  Dasatinib inhibits heregulin-induced AR activity, but not EGF-induced AR 
activity.  (A, B) LNCaP cells were transfected with the AR reporter ARR2-PB-luciferase.  
After overnight incubation, cells were pre-treated with dasatinib for 2 hrs, then with 
heregulin (10 ng/ml) (A) or EGF (100 ng/ml) (B) for 20 hrs.  Cell extracts were assayed for 
luciferase activity.  The mean and standard deviation of triplicate samples of a representative 
experiment are shown from three independent experiments with similar results. (C, D) 
LNCaP cells were pre-treated with dasatinib (10 nM) for 2 hrs, then with heregulin (10 
ng/ml) or EGF (100 ng/ml) for 20 hrs.  RNA was isolated and quantitative RT-PCR was 
performed to determine the levels of PSA (C) or hK2 (D) mRNA.  Data shown are 
representative of two independent experiments with similar results.  
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Figure 2.9.  Dasatinib inhibits heregulin-induced expression but not EGF-induced 
expression of PSA and hK2 mRNA in LAPC-4 cells. LAPC-4 cells were pre-treated with 
dasatinib (10 nM) for 2 hrs, then with heregulin (10 ng/ml) or EGF (100 ng/ml) for 20 hrs.  
RNA was isolated and quantitative RT-PCR was performed to determine the levels of PSA 
(A) or hK2 (B) mRNA.  Data shown are representative of two similar experiments.  
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Figure 2.10.  Dasatinib inhibits anchorage-independent colony formation and xenograft 
tumor growth of LNCaP-Ack1 cells in castrated mice.  (A) LNCaP-Ack1 cells and vector 
control cells were plated in soft agar with indicated concentrations of dasatinib in the top 
layer and incubated for 21 days.  Colonies were stained and counted.  The mean and standard 
deviation of triplicate wells of a representative experiment are shown from three independent 
experiments with similar results.  (B) Castrated mice were implanted subcutaneously with 
LNCaP-Ack1 cells.  When tumors became palpable, mice were treated with vehicle control 
(n=7) or dasatinib (n=8) via oral gavage at a dose of 30 mg/kg bid and the tumor volume was 
measured twice per week.  (* indicates p<0.04 and  ** indicates p<0.009.)  (C)  Three 
independent tumors were harvested from mice given vehicle only or dasatinib at the 
conclusion of the experiment.  Protein extracts were immunoblotted for expression of total 
Ack1, phospho-Ack1, total AR and phospho-Y267 AR.  
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Figure 2.11.  Model of AR phosphorylation by non-androgen ligands.  Heregulin and 
Gas6 activate Ack1 kinase, which leads to AR Tyr-267 phosphorylation.  EGF, bombesin, 
and IL-6 activate Src kinase, leading to AR Tyr-534 phosphorylation.  Additionally, EGF 
activates an unidentified dasatinib-resistant tyrosine kinase that phosphorylates AR at Tyr-
267.  
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CHAPTER III 
 
REGULATION OF ANDROGEN RECEPTOR FUNCTION BY 
TYROSINE PHOSPHORYLATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been adapted from:  Mehmet Karaca, Yuanbo Liu, Zhentao Zhang, Dinuka 
De Silva, H. Shelton Earp, and Young E. Whang.  Regulation of androgen receptor by 
tyrosine phosphorylation. 2010.  Manuscript in progress. 
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3.1 Abstract 
 The androgen receptor (AR) is a ligand activated steroid hormone receptor that plays 
a critical role in normal prostate development and prostate cancer.  AR re-activation under 
low androgen environment is the hallmark of castration resistant or hormone refractory 
prostate cancer (HRPC).  Non-receptor tyrosine kinases phosphorylate AR in an androgen 
independent manner, and are thereby involved in HRPC.  Herein, we investigated the role of 
Ack1 target phosphorylation sites (Tyr-267 and Tyr-363) on growth factor-regulated AR 
phosphorylation as well as AR transcriptional and functional activity.  Both Tyr-267 and Tyr-
363 have a critical role for ligand-dependent and –independent control of activity of AR.  
Treatment of LNCaP cells overexpressing full length or truncated AR (missing the ligand 
binding domain (LBD) with epidermal growth factor (EGF), heregulin, or Gas6 (ligand 
binding to Mer receptor tyrosine kinase and activating Ack1 downstream) induced AR 
phosphorylation at Tyr-267 and that phosphorylation was lost in the AR-Y267F mutant 
protein.  The full length wild type overexpressing cells (FL-WT-AR) proliferated strongly 
without androgen treatment and they reached optimal growth at a lower dose of DHT 
treatment (0.1 nM DHT).  However, cells expressing full- or -truncated AR-Y267F mutant 
did not show androgen-independent proliferation and did not respond to androgen treatment.  
Overexpression of the Y267F mutant within full length- or truncated-AR showed significant 
reduction in soft agar colony formation, compared to the WT-AR.  The extent of reduction in 
colony formation of Y363F AR expressing cells was moderate, but not as much as Y267F.  
The analysis of AR subcellular localization by both immunoblotting and immunofluoresence 
assays suggested that mutating the Tyr-267 site impaired both androgen-dependent and –
independent nuclear translocation, compared to the AR-WT.  Global gene expression 
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profiling analysis demonstrated that there were no common genes regulated by both full 
length AR and AR-Y267F, suggesting that mutating Tyr-267 has a significant impact on not 
only AR dependent target gene expression but also global gene expression of LNCaP cells.  
Taken together, the results of our study demonstrate that tyrosine kinase target 
phosphorylation sites are important for both ligand-dependent and ligand-independent 
activity of AR protein.  Targeting upstream tyrosine kinases and the N terminal domain of 
AR in truncated AR missing LBD may expand the repertoire of therapeutics for combating 
prostate cancer. 
3.2 Introduction 
 Prostate cancer is the most commonly diagnosed cancer (192,280 new cases each 
year) and the second leading cause of death (27,360 deaths annually) among US men (Jemal 
et al., 2009).  Hormone refractory prostate cancer (HRPC) develops after the systemic 
hormone deprivation therapy of initially hormone dependent prostate cancer (Armstrong and 
Carducci, 2006; Isaacs and Isaacs, 2004).  The exact mechanisms by which hormone 
dependent prostate cancers evolves into hormone refractory disease remain to be solved, yet 
there is emerging consensus indicating that re-activation of androgen receptor is a common 
phenomenon in HRPC (Agoulnik and Weigel, 2006; Chen et al., 2004; Scher and Sawyers, 
2005).   Recent reports showed that there is a number of ways that AR become activated in 
the low androgen environment (Feldman and Feldman, 2001; Scher and Sawyers, 2005).  For 
example, ligand independent AR reactivation by growth factors such as epidermal growth 
factor or heregulin is one of the mechanism by which prostate cancer cells sustain AR 
activity.  Likewise, AR gene amplification or mutations in the ligand binding domain due to 
hormone deprivation therapy makes prostate cancer cells sensitized to low androgen levels 
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and broaden ligand specificity of AR, respectively (Ford et al., 2003; Linja et al., 2001; 
Visakorpi et al., 1995; Wallen et al., 1999; Waltering et al., 2009).    AR protein 
overexpression is commonly detected in clinical HRPC (Latil et al., 2001; Linja et al., 2001).   
Comparative gene expression analysis of hormone dependent and refractory human prostate 
cancer xenograft tumors identified AR as the only gene overexpressed in hormone refractory 
xenografts (Chen et al., 2004).  Furthermore, co-activators such as TIF-2 or SRC1 were 
upregulated in hormone refractory prostate cancer (Gregory et al., 2001).  Growth factors 
such as EGF or heregulin activate the AR under androgen deprivation therapy (ADT) in 
prostate cancer (Gregory et al., 2004).  The increase in AR stability along with AR 
overexpression and nuclear localization render prostate cancer cells to become very sensitive 
to low levels of androgen present in androgen deprived conditions (Gregory et al., 2001).   
 The modulation of AR signaling pathway though tyrosine phosphorylation of AR  by 
non-receptor tyrosine kinases is becoming a common theme among the mechanisms of AR 
activation and prostate cancer progression (Guo et al., 2006; Kraus et al., 2006; Mahajan et 
al., 2007).  Non-androgen ligand induced non-receptor tyrosine kinases such as Src or Ack1 
can directly phosphorylate and activate the AR in prostate cancer (Guo et al., 2006; Mahajan 
et al., 2007).  Guo et al. (2006) showed that Src can activate AR and induce its nuclear 
translocation by phosphorylating AR at Tyr534.  Likewise, Mahajan et al. (2007) showed 
that Ack1 phosphorylates AR at Tyr-267 and 363 sites and activates AR without androgen 
and transforms poorly tumorigenic androgen dependent LNCaP prostate cancer cell into 
castration recurrent highly tumorigenic cells in nude mice xenograft.  Characterization of 
upstream signaling of these two kinases showed that Ack1 were activated by epidermal 
growth factor (EGF), heregulin, and Gas6 (ligand binding to Mer receptor tyrosine kinase 
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and activating Ack1 downstream).  Src was activated by EGF, interleukin (IL)-6 or 
bombesin, respectively (Liu et al., 2010).  The Ack1 activation led to AR phosphorylation at 
Tyr-267, however, Src activation induced phosphorylation of AR at Tyr-534.  Dasatinib, a 
Src inhibitor, inhibited EGF induced AR phosphorylation at Tyr-534.  Likewise, dasatinib 
treatment prevented heregulin mediated AR phosphorylation at Tyr-267.   
In addition to these mechanisms, there are several recent reports that indicated that 
aberrant pre-mRNA splicing producing truncated constitutively active AR species that are 
resistant to anti-androgen or hormone deprivation therapy may be the underlying mechanism 
of how prostate cancer cells survive under ADT (Dehm et al., 2008; Dehm and Tindall, 2006; 
Hu et al., 2009; Libertini et al., 2007; Liu et al., 2009; Pelley et al., 2006).  Libertini et al. 
(2007) showed that calpain mediated AR cleavage created an AR protein variant that is 
missing CTD and constitutively active in 22Rv1 cells that expresses both truncated AR 
isoforms and full length wild type AR (Libertini et al., 2007).  They also reported elevated 
expression of the truncated AR isoforms in prostate tumor tissues.  Likewise, Dehm et al. 
(2008) reported that the 22Rv1 cell line, derived from the relapsed CWR22 xenograft during 
ADT, expressed three isoforms of AR: a full length version with duplicated exon 3 
(ARex3dup), and two truncated versions lacking the COOH terminal domain (CTD) 
(ARex1/2/2b or ARex1/2/3/2b) (Dehm et al., 2008).  Unlike the reports of  Tepper et al. 
(2002) and Libertini et al. (2007), Dehm et al. (2008) showed that truncated isoforms 
(ARex1/2/2b or ARex1/2/3/2b) of AR were not due to proteolytic cleavage off AR with exon 
3 duplication (ARex3dup) but derived from distinct mRNA species (Libertini et al., 2007; 
Tepper et al., 2002).  AR NTD isoforms expressed in 22Rv1 cells are the result of the 
splicing of a novel exon 2b after AR exon 2 (ARex1/2/2b) or exon 3 (ARex1/2/3/2b).  Exon 
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2 encodes the first zinc finger that harbors the recognition helix that directly engages with 
one hexameric half site within an androgen response element (ARE) (Shaffer et al. 2004). Hu 
et al. (2009) identified number of splice variants of AR and developed variant specific 
antibody to screen prostate cancer samples (Hu et al., 2009).  The variant encoding NTD of 
AR was highly expressed in HRPC and expression of AR-V7 at protein levels was found to 
be increased in hormone naïve PCa recurring after surgical therapy.  Mutation induced 
truncated AR missing LBD has been reported as constitutively active (Ceraline et al., 2004).  
Ceraline et al. (2004) using a yeast based functional assay showed that AR-Q640Stop/T877A 
mutation isolated from bone marrow metastasis of HRPC was constitutively active in the 
absence of androgens.  Quayle et al. (2007) showed that the decoy molecule derived from 
AR NTD inhibited growth of prostate cancer xenograft indicating that AR NTD species are 
driving force behind hormone refractory growth (Quayle et al., 2007).  A comprehensive 
study done by Guo et al. (2009) reported that constitutively active AR splice variant AR3 is 
highly expressed in androgen independent cell lines (C-81, CWR-R1, and 22Rv1) and AR3 
expression is inversely correlated with androgen dependence of the cell lines (Guo et al., 
2009).  The AR3 expression was not affected by androgen or anti-androgen therapy and 
seemed to be playing an indispensable role for androgen independent growth of prostate 
cancer cells.  The AR3 protein level was higher in the hormone refractory prostate tumor 
samples compared to hormone naïve tumors or benign prostate hyperplasia.  These reports 
suggest that prostate cancer evades the androgen deprivation therapy (ADT) and becomes 
HRPC due to the emergence of splice variants that are missing ligand binding domain and 
resistant to the anti-androgen and androgen deprivation therapy.  It has been reported that 
prostate cancer cells in hormone refractory stages induced testosterone synthesis from 
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adrenalin androgens or cholesterol that is sufficient to activate the AR signaling pathway 
because of the presence of highly sensitized AR protein (i.e. overexpressed AR) (Titus et al., 
2005).        
 The purpose of this study was to understand the role of Ack1 target tyrosine 
phosphorylation sites, Tyr-267 or Tyr-363, in AR activation and function under low 
androgen environment by generating full length or truncated AR, constitutively active and 
missing ligand binding domain, and stably overexpressing these expression constructs in 
LNCaP cell lines and analyzing their phenotype.  We showed that mutating Tyr-267 site 
abrogated the transcriptional activity of AR, cell proliferation, and anchorage independent 
growth of LNCaP cells.  The result of AR nuclear localization assays suggested that mutation 
of Tyr-267 impedes AR nuclear localization.     
3.3 Materials and Methods 
 Cell Lines and Reagents.  LNCaP, COS-7, HEK293 cells were obtained from the 
University of North Carolina Tissue Culture Facility.  LNCaP cells were grown in phenol red 
free RPMI 1640 supplemented with 10% FBS and 100 unit/ml penicillin/streptomycin (P/S).   
Both COS-7 and HEK293 were grown in DMEM supplemented with 10% FBS and P/C.  
EGF, IL-6 and Gas6 were purchased from R&D Systems, Minneapolis, MN.  Heregulin was 
a gift from Genentech (South San Francisco, CA)(Liu et al., 2010).  Phospho-specific 
polyclonal antibody against Tyr-267 of AR was raised and purified by a commercial vendor 
(21st Century Biochemicals, Marlboro, MA).  A mouse monoclonal antibody against AR 
(F39.4.1, Biogenex, San Ramon, CA) was used for the immunoblotting and 
immunofluorescence.  The polyclonal antibody against AR (C-19, Santa Cruz) was used to 
immunoprecipitate AR from the protein lysate.  A mouse monoclonal antibody against Flag-
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tag (M2)  (Sigma  Life Sciences, St. Louis, MO) and Flag conjugated agarose beads (Sigma  
Life Sciences, St. Louis, MO) were used for immnuoblotting and immunoprecipitation, 
respectively.  Rabbit polyclonal antibodies against Laminin A/C (H-110) and 14-3-3 β (c-20) 
(Santa Cruz Biotehnology Inc., Santa Cruz, CA) were used in immunoblotting of subcellular 
fractions.   Donkey anti-mouse FITC labeled secondary antibody (Jackson ImmunoResearch 
Laboratories, Inc. West Grove, PA) and mounting media with DAPI were used for staining 
AR and nucleus, respectively.       
 Western Blotting.   Cells were lysed in complete RIPA buffer supplemented with 1X 
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), and 1X phosphatase 
inhibitor cocktail 1 (Sigma-Aldrich, St. Louis, MO) and incubated on ice and centrifuged to 
clear the cell debris.  The supernatant was collected and stored in -80 until western blotting.  
The small aliquots of proteins were quantified with the Bradford assay reagent (Bio-Rad 
Laboratories, Hercules, CA) and 20 µg of protein sample was resolved in 10% SDS PAGE 
gel for 2 hrs.  Protein samples were transferred to the PVD membrane and subsequently 
blocked in 5 % non-fat dry milk in 1X TBS-T for one hour.  The membrane was incubated 
with AR antibody (Biogenix Inc) in 5% non-fat dry milk in TBS-T overnight.  Membranes 
were subsequently washed 10 minutes each three times with 1X TBS-T and incubated with 
anti-mouse secondary antibody for AR for 2 hours.  After incubation, membranes were 
washed three times for 10 minutes each with 1X TBS-T and developed with ECL solutions 
(Amersham Inc.). 
 Transfections.  COS7 and LNCaP cells were transiently transfected with either full 
length or truncated AR expression vectors using Effectene (Qiagen, Valencia, CA) or 
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FuGENE 6 (Roche Applied Science, Indianapolis, IN), following manufacturer’s protocol.  
Three experimental replicates were done for each assay. 
 Reporter Assays.  LNCaP cells were plated (1.5 X 105 cells per well) in 12 well 
plates using their respective growth medium the day before transfection.  Next day, 150 ng of 
the AR construct (wild type or mutant) and 150 ng of the reporter construct (ARR2-PB or 
MMTV-luciferase reporter) were co-transfected using Effectene.  Next day, medium was 
replaced with phenol-red free, serum free media and incubated for 8 hours.  Following serum 
starvation, the cells were treated with DHT (10 nM) or vehicle (1%  Ethanol) in serum free 
media for overnight.  The cells were harvested in passive lysis buffer and luciferase activity 
was measured on an Lmax Microplate Luminometer (Molecular Devices), as described 
(Mahajan et al., 2007).  
 Colony Formation in Soft Agar.  LNCaP cells stably expressing vector, WT-AR, or 
mutant AR constructs (104 cells per well) were suspended in 0.45% Noble agar and placed 
above a layer of solidified 0.9% Noble agar in 6 well plates in triplicates.  After 3 weeks, 
colonies were visualized by staining with MTT as described in (Liu et al., 2010).   
 Subcellular Fractionation of Protein.  Subcellular fractionation of cells was 
performed by using NE-PER Nuclear and Cytoplasmic Extraction Reagent (Pierce 
Biotechnology  Rockford, IL) supplemented with protease inhibitors to cytoplasmic 
extraction reagent I (CER I) and nuclear extraction reagent (NER) as described in their 
protocol.  Both cytoplasmic and nuclear extracts were quantified with the Bradford assay 
reagent (Bio-Rad Laboratories, Hercules, CA) and an equal amount of protein was used in 
western blotting.   
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 Immunofluorescence.  Cells were counted and 3x104 cells were plated in each well 
of two well chamber slides (LabTek II System, Nalge Nunc Int. Corp., Naperville, IL).  Next 
day, cells were transiently co-transfected with AR (100 ng) or vector (100 ng) along with 
caAck (100 ng) or vector (100 ng) expression constructs using FuGENE 6 (Roche Applied 
Science, Indianapolis, IN) and incubated for overnight.  Medium was changed to serum free 
medium and cells were serum starved for 8 hrs.  After serum starvation, cells were either 
treated with DHT (10 nM) or vehicle (1% ethanol) for 2 hours.  Next, media was removed 
from the cells and cells were rinsed with cold PBS once for 5 minutes.  The fixative (4% 
paraformaldehyde) was added on cells and incubated at room temperature for 15 minutes.  At 
the end of the fixation, cells were washed with cold PBS twice, and blocking solution (0.3% 
Triton X and 5% donkey serum) was added and incubated for 30 minutes at room 
temperature.  At the end of the incubation, blocking solutions were removed from the wells 
except the blank samples.  Primary antibody, mouse anti-androgen receptor (F39.4.1, 
Biogenex, San Ramon, CA) made in 1:100 dilution in blocking solution, was added on the 
cells and incubated in room temperature for two hour.  At the end of incubation, primary 
antibody was removed from cells and cells were washed three times with cold PBS (5 
minutes each wash).  Secondary antibody, fluorescein isothiocyanate conjugated (FITC) 
donkey anti mouse, was prepared in 1:250 dilution in blocking solution and added to cells.  
The cells were incubated in dark in 37ºC for an hour.  The secondary antibody was removed 
and cells were washed with cold PBS three times.  At the end of the wash, cover slips were 
placed with mounting media which includes 4',6-diamidino-2-phenylindole (DAPI) for 
nuclear staining (Vector Laboratories Inc. Burlingame, CA).  After cover slips were 
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mounted, the edges of the slides were sealed off with nail polisher and slides were kept in 
dark cold room until images were captured.    
 Microarray Gene Expression Analysis.  Total RNA from LNCaP cells expressing 
vector, FL-WT-AR, FL-AR-Y267F, TR-WT-AR and TR-AR-Y267F were isolated by using 
RNeasy Mini kit (Qiagen Inc. Valencia, CA) by following manufacturer’s instructions.  Two 
independent replicas were used per cell lines.  Each sample was assayed versus LNCaP cells 
expressing vector (Reference sample).  RNA integrity was evaluated using the RNA 6000 
Nano LabChip kit and a Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA) at 
the Genomic Core Facility in UNC.  The samples were hybridized onto Whole Human 
Genome Oligonucleotide Microarray (Human 4X44 genes) by following manufacturer’s 
protocol at the UNC Genomic Core Facility.  The microarrays were scanned on an Agilent 
scanner and the raw data extracted and deposited into the UNC Microarray Database (UMD). 
Background corrected normalized (lowess protocol) individual channel values were used as a 
data value for comparing gene expressions from LNCaP-vector cells to LNCaP cells 
expressing one of the four AR constructs.  Following filtering was done to retrieve the data 
from UMD: signal intensity at least units in both channels (Cy5 and Cy3) and genes at least 
one standard deviation apart in at least one of the 8 arrays.  A total of 18729 genes passed the 
filtering criterion and used an input for the significant analysis of microarray (SAM) program 
(Tusher et al., 2001).  We next performed two class unpaired comparison between vector and 
AR constructs to select the genes significantly up or down regulated.  In our SAM analysis to 
identify the gene sets, we used constant delta value of 10 to get a false discovery rate of 5 %.  
The SAM gene list from vector versus FL-WT-AR and vector versus FL-AR-Y267F were 
compared and the number of genes regulated by FL-WT-AR and FL-AR-Y267F as well as 
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genes that were only regulated by FL-WT-AR or FL-Y267F were identified by using JMP 
Program version 7 software (SAS Institute Inc. Cary, NC) and presented as a Venn diagram.     
Statistical Methods.  SAS software version 9 (SAS Institute Inc. Cary, NC) was used for 
statistical analysis of data.  ANOVA procedure of SAS was used to evaluate differences 
between group means.  P values less than 0.05 were considered to be statistically significant. 
3.4 Results 
 Phosphorylation Site Mutants of AR Exhibit Impaired Transcriptional Function 
in Reporter Assays.  The transcriptional activity of full length AR with mutations in the 
Ack1 phosphorylation sites Tyr-267 and Tyr-363 was tested in LNCaP cells using the AR 
reporter MMTV-luciferase construct.  The AR Y267F mutant demonstrated significant 
impairment of transcriptional activity while the Y363F mutant exhibited moderately 
decreased activity (Fig. 3.1).  To assess the role of phosphorylation sites in ligand-
independent AR activation, the Y267F and Y363F mutants of truncated AR missing the 
ligand binding domain and constitutively active without ligand were tested by reporter assays 
using ARR2-PB and MMTV promoter constructs.  The Y267F mutant of truncated AR 
exhibited marked reduction in its ability to activate the ARR2-PB and MMTV reporters.  The 
Y363F mutant showed only minimally decreased transcriptional activity, relative to the wild 
type truncated AR (Fig. 3.2).  Immunoblotting confirmed that protein levels of Y267F and 
Y363F mutants of full length and truncated AR were similar to wild type AR (Fig. 3.2).  
Taken together, these results suggest that both Tyr-267 and Tyr-363 sites are essential for 
both ligand-dependent and -independent transcriptional activity of AR, and that loss of Tyr-
267 exhibits more severe impairment of transcriptional function, compared to Tyr-363. 
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 Stable Overexpression of Full Length AR and Constitutively Active Truncated 
AR and Phosphorylation Site Mutants.  The functional requirement for Tyr-267 and Tyr-
363 sites of AR in driving cell proliferation at suboptimal androgen concentrations was 
investigated by stable overexpression of wild type and mutant AR constructs in the context of 
full length and truncated AR.  The total protein levels of full length AR in cells stably 
expressing exogenous AR by retroviral transduction was 2-3 fold higher than endogenous 
AR in vector control cells (Fig. 3.3A).  Levels of wild type, Y267F, and Y363F of truncated 
AR migrating at about 80 kDa were comparable to the endogenous AR (Fig. 3.3C).  
Detecting the exogenous AR by the epitope tag verified that wild type, Y267F, and Y363F 
AR were all expressed at comparable levels (Fig. 3.3A).  AR mRNA levels in stably 
overexpressing cells were 3-4 folds higher than vector control cells in full length AR-
expressing cells and 2-3 folds higher in truncated AR-expressing cells (Fig 3.3B and D).  
Immunoblotting with the phospho-Y267 specific antibody demonstrated that both full length 
and truncated exogenous AR proteins were phosphorylated at Tyr-267 after stimulation with 
EGF, heregulin, or Gas6 ligands, as previously shown for full length AR protein (Liu et al., 
2010) and that phosphorylation of Tyr-267 is lost in Y267F AR protein (Fig 3.4).  Mutation 
of Tyr-363 did not affect phosphorylation of Tyr-267. 
 Phosphorylation-site mutants of AR are defective in stimulating cell 
proliferation.  The effect of AR overexpression on cell proliferation at various androgen 
concentrations was characterized.  Proliferation of vector control cells was androgen-
dependent and required the full dose (10 nM) of DHT for optimal proliferation (Fig. 3.5A).  
Full length AR wt overexpressing cells proliferated well without androgen treatment and 
exhibited optimal proliferation to treatment with 0.1 nM DHT, which does not stimulate 
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proliferation of vector control cells (Fig. 3.5A).  However, Y267F mutant AR-expressing 
cells did not proliferate in the absence of androgen or responded to increasing concentrations 
of androgen.  Proliferation of Y363F mutant AR-expressing cells was intermediate between 
vector control and AR wt cells in the absence of androgen and at 0.1 nM DHT and did not 
respond to increasing androgen concentrations (Fig 3.5A).  Cells expressing constitutively 
active truncated AR proliferated optimally without androgen (Fig. 3.5B).  However, cells 
expressing the truncated AR with the Y267F mutation did not show androgen-independent 
proliferation and did not respond to androgen treatment.  Cells expressing the truncated AR 
with the Y363F mutation showed modest reduction in androgen-independent proliferation, 
compared to AR wt and androgen treatment did not affect its growth (Fig. 3.5B).  
Collectively, these data suggest that the Tyr-267 and Tyr-363 sites are both critical for the 
function of overexpressed AR protein in stimulating cell proliferation at low androgen 
concentrations. 
 Phosphorylation-site mutants of AR are defective in stimulating anchorage-
independent soft agar colony growth.  The effect of AR overexpression and the effect of 
phosphorylation site mutation on anchorage-independent growth in soft agar were 
determined for both full length and truncated AR.  Overexpression of full length or truncated 
AR wt significantly increased soft agar colony formation, compared to vector control cells 
(Fig 3.6A and B).  Overexpression of the Y267F mutant of full length AR or truncated AR 
demonstrated marked reduction in soft agar colony formation, compared to AR wt (Fig 3.6A 
and B).  The Y363F AR-expressing showed moderately decreased soft agar colonies, but not 
as much as the Y267F mutant.  These results suggest that the ability of AR to enhance cell 
proliferation at low androgen concentrations and to stimulate anchorage-independent growth 
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in LNCaP cells requires intact phosphorylation sites Tyr-267 and Tyr-363.  Mutation of Tyr-
267 exhibits more severe impairment than Tyr-363 in these assays. 
 Ack1 induced AR translocation into the nucleus in the absence of DHT.  AR is a 
ligand induced transcription factor that translocates into the nucleus and bind to the promoter 
or enhancer regions of AR dependent genes.  Guo et al. reported that AR nuclear 
translocation was induced by phosphorylation of AR at Tyr-534 site by Src (Guo et al., 
2006).  We investigated the effect of Ack1 kinase on subcellular localization of AR in COS-7 
cells by using transient transfection and immunofluoresence.  COS-7 cells were transiently 
co-transfected with vector or Ack1 and AR constructs with or without DHT treatments for 2 
hrs.  Cytoplasmic and nuclear protein isolates were probed with monoclonal AR antibody.  
Without DHT treatment, AR localized mostly in the cytoplasm for vector co-transfected 
cells.  However, caAck1 induced AR nuclear localization (Fig. 3.7A).  In both vector and 
caAck1 co-transfected with full length wild type AR, there was nuclear localization in 
response to DHT treatment (Fig. 3.7A).  For the FL-AR-Y267F and caAck1 co-transfected 
cells, AR mostly localized in the cytoplasm and DHT treatment induced nuclear localization 
was not as robust as that of FL-WT-AR.  The nuclear localization pattern of FL-AR-Y363F 
was very similar to wild type in that AR was localized to the nucleus in response to caAck1 
induction without androgen treatment and the amount of nuclear localization increased 
additively with androgen treatment of caAck1 co-transfected with FL-AR-Y363F (Fig. 
3.7A).  The result suggested that caAck1 induced androgen independent nuclear localization 
of AR protein, and mutating Tyr-267 inhibited caAck1 induced nuclear translocation.  The 
immunofluoresence assay result also showed that Ack1-induced nuclear localization of AR 
was impaired by mutating Tyr-267 of AR, suggesting that Tyr-267 is essential for Ack1 
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induced AR nuclear translocation (Fig. 3.8).  The effect of Ack1 target tyrosine 
phosphorylation sites on androgen- independent AR nuclear localization was evaluated in 
COS-7 cells transiently transfected with truncated AR expression constructs.  The androgen-
independent nuclear localization of constitutively active truncated AR was inhibited by 
mutating the Tyr-267 site.   The effect of mutating Tyr-363 was not dramatic compared to 
TR-AR-Y267F (Fig. 3.7B).  It has been previously reported that Src phosphorylates AR at 
Tyr-534 and induces its nuclear localization and its transcriptional activity. The result of our 
study suggested that Ack1 also phosphorylates AR at Tyr-267, similar to AR activation by 
Src, and induces the nuclear translocation and subsequent transcriptional activity of AR.  The 
AR is a ligand induced transcription factor that gets into the nucleus and scans for the 
promoter and enhancer regions of the AR target genes and regulates their transcriptional 
activity.  The defect in nuclear localization will impede the ability of AR to regulate target 
gene expression that might be involved in tumor progression. 
 Androgen receptor overexpression leads to androgen-independent AR nuclear 
translocation.  In order to determine the role of AR overexpression on AR nuclear 
localization, we investigated subcellular localization of exogenous AR protein in LNCaP 
cells by immunoprecipitation with FLAG antibody and subsequently immunoblotting with 
AR antibody.  Overexpression of both full length and truncated AR wt induced 
predominantly nuclear localization of AR without DHT treatment, yet overexpression of the 
Y267F mutant of full length and truncated AR predominantly localized in the cytoplasm and 
did not respond to the DHT induced nuclear localization observed with WT AR (Fig. 3.9A).  
The nuclear localization pattern of TR-AR-Y363F was very similar to wild type in that the 
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extent of impaired nuclear localization was not as dramatic as that of TR-AR-Y267F (Fig 
3.9B).    
 Y267F mutation has an impact on global gene expression.  The complex 
mechanism of hormone refractory prostate cancer progression cannot be fully explained by 
changes in a few genes.  Therefore, it is essential to employ approaches that interrogate 
whole genome such as microarray analysis of gene expression.  We studied the effect of 
mutating Tyr267 on global gene expression changes to characterize the defects we observed 
in transcriptional activity, proliferation and anchorage independent growth of LNCaP cells 
overexpressing Y267F mutant AR.  The comparative analysis of samples with their 
respective vector references showed that the genes modulated by FL-AR-Y267F were very 
different from that of FL-WT-AR (Fig. 3.10A). In fact, there were no common genes that 
were regulated by both groups.  However, comparison of TR-WT-AR and TR-AR-Y267F 
resulted in 50 genes that were regulated by both groups suggested that the defect in global 
gene expression  modulation observed with mutating Tyr-267 was not as remarkable in the 
truncated, constitutively active AR context as the full length AR context (Fig. 3.10B).  The 
comparison of gene expression changes in FL-WT-AR overexpressing cells with TR-WT-AR 
expressing cells suggested that 58 genes were commonly regulated by both AR constructs 
(Fig. 3.10C). It has been known that AR overexpression by itself has been sufficient to 
induce hormone refractory progression of androgen dependent prostate cancer cell (Chen et 
al., 2004).  Likewise, recent reports suggested that AR splice variants constitutively active 
and missing the ligand binding domain were commonly observed in hormone refractory 
metastatic tumors (Guo et al., 2009).  Our comparison of gene expression modulations in 
LNCaP cells overexpressing FL-WT-AR and TR-WT-AR will help to understand the some 
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of the underlying genetic changes occurring during these two different modes of AR 
regulated hormone refractory progression.  The unsupervised clustering of samples based on 
gene expressions of 18,729 showed that experimental replica samples tightly clustered with 
each other suggested that repeatability of each of these two pairs of samples was high  (Fig. 
3.10D). In fact, we used intraclass correlation (ICC) procedure implemented in UMD to 
assess the array quality of each replica (Table A1.8).  Interestingly, FL-WT-AR and TR-WT-
AR were distantly clustered from each other reflecting the biological nature of the difference 
in full and truncated constitutively active AR (Fig. 3.10D).  
 Y267F mutation inhibits recruitment and DNA binding of truncated AR to the 
androgen responsive enhancers of target genes.  To characterize the effect of Y267F and 
Y363F mutations of truncated AR in the chromatin context, recruitment and DNA binding of 
ectopically expressed FLAG-tagged truncated AR mutants to the PSA and HK2 androgen 
responsive enhancers were determined by chromatin immunoprecipitation using FLAG 
antibody (Fig 3.11A and B).  Constitutively active TR-WT-AR protein was bound to the PSA 
and HK2 enhancers in the absence of androgen.  The Y267F mutant did not bind to the PSA 
and HK2 enhancers (Fig. 3.11A and B).  The Y363F mutant also showed diminished binding 
although its effect is not as dramatic as that of Y267F.  Together, these results suggested that 
the Tyr-267 site has a critical role in the recruitment and DNA binding of constitutively 
active truncated AR missing LBD.   
3.5 Discussion 
 Androgen receptor function is essential for both prostate cancer development and 
progression to hormone refractory disease.  In addition to the mechanisms of AR activation 
studied so far, recent publications underlines the novel mechanisms of AR activation under 
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ADT including non-receptor tyrosine kinases and alternative splice variants of AR.  Guo et 
al. (2006) and Mahajan et al. (2007) independently showed that two distinct tyrosine kinases 
Src and Ack1 targeted two distinct tyrosine phosphorylation sites with a similar outcome of 
AR activation and progression to hormone independent cell growth, proliferation and 
tumorigenesis.  Recent work from our group suggested that growth factors such as EGF, 
heregulin, and Gas6 activated Ack1 and induced AR tyrosine phosphorylation at Tyr267.  
However, EGF, bombesin, and IL-6 induced Src activation and Tyr-534 phosphorylation of 
AR (Liu et al., 2010).  The Src inhibitor, dasatinib, inhibited heregulin and Gas6 mediated 
Ack1 activation and Try-267 phosphorylation of AR at a clinically relevant dose.  Here, we 
show that growth factor induced phosphorylation and activation of truncated AR were 
impaired by mutating AR-Y267F suggesting a novel mechanism of regulation of 
constitutively active AR species.  The analysis of subcellular localization of both full and 
truncated AR expression vector in transient and stable expression settings suggested that 
mutating Tyr-267 had a defect in nuclear localization compared to WT-AR.       
  Another group of researchers elucidated the existence of constitutively active AR 
missing LBD (Dehm et al., 2008; Guo et al., 2009; Hu et al., 2009) which allowed prostate 
cancer cells to proliferate and grow aberrantly compared to the cells that did not express 
splice variants of AR.  These two emerging mechanisms of activation of AR in HRPC led us 
to study the role of Ack1 target phosphorylation sites (Tyr-267 and Tyr-363) in the context of 
full length and truncated AR.  We generated two groups of LNCaP cells lines overexpressing 
wild type and mutant AR expression vectors in the full and truncated context.  In this report, 
we demonstrated that mutating Tyr-267 abrogated transcriptional activity, cell proliferation 
and anchorage independent growth observed with LNCaP cells overexpressing AR wt.  
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 Our results showed that LNCaP cells over expressing FL- or TR-WT-AR mostly 
localized in the nucleus (Fig. 3.7 and 3.8) and intensity of nuclear localization increased in 
the FL-WT-AR expressing cells with androgen treatment (Fig 3.7A).  The nuclear 
localization of truncated WT-AR did not seem to be affected by androgen treatment 
suggesting that under androgen depleted environment truncated AR variants can drive PCa 
growth and development.  The defective nuclear localization of both FL- and TR-AR-Y267F 
mutant may be due to the impairment in interacting with nuclear importer signals, and 
therefore they cannot be transferred into the nucleus.  This hypothesis should be further 
tested.  Since the mutations we introduced (Tyr-267 and Tyr-363) are not in the region that 
encode nuclear localization signal (NLS) (Zhou et al., 1994), we did not expect the defect 
observed is due to the intrinsic NLS of AR that moves AR from the cytoplasm into the 
nucleus, but may be interacting with proteins that shuttles the AR into the nucleus.    
 Our results are consistent with the previous reports that suggested AR overexpression 
or kinase signaling pathways may make AR sensitized to the lower levels of androgen 
present in HRPC (Bakin et al., 2003; Culig and Bartsch, 2006; Hobisch et al., 2006).  We 
showed that FL-WT-AR induced cell proliferation without androgen and maximum cell 
proliferation was observed at 0.1 nM DHT treatment compared to LNCaP cells over 
expressing vector that reached maximum growth at 10 nM DHT treatment (Fig. 3.4).    
 Both Ack1 induced AR activation and AR overexpression in LNCaP cells led to AR 
nuclear localization without androgen treatment (Fig 3.7A, 3.8 and Fig. 3.9).  It has been 
known that nuclear receptors including AR shuttle between the cytoplasm and nucleus (Bunn 
et al., 2001; Dauvois et al., 1993; Guiochon-Mantel et al., 1996; Madan and DeFranco, 
1993).  There may be a defect in nuclear shuttling of mutant AR-Y267F that made AR-
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Y267F mutant to localize predominantly in cytoplasm and to become insensitive to ligand-
induced nuclear localization.  If there is a defect in shuttling of AR, one way to address this 
problem is to use an approach such as heterokaryon shuttling assay (Black et al., 1999; 
Kesler et al., 2007) to elucidate whether the defect is in nuclear import of AR-Y267F. 
 Our results showed that overexpressing FL-WT-AR or TR-WT-AR was sufficient to 
induce cell proliferation and anchorage independent growth, suggesting that AR 
overexpression in different modes is enough to induce progression of hormone refractory 
disease, yet mutating AR phosphorylation sites abrogated the affect of over expression of AR 
suggesting that tyrosine phosphorylation of AR has a role in AR induced cell proliferation 
and anchorage independent growth. 
 Our results are consistent with the recent reports that identified novel splice variants 
missing LBD and highly expressed in hormone refractory prostate cancer (Guo et al., 2009; 
Hu et al., 2009), yet mutating Tyr-267 and Tyr-363 sites inhibits the strong transcriptional 
activity of AR NTD in both full length and truncated contexts.  The Y267F mutant acted like 
a dominant negative that can even override the function of endogenous AR present in LNCaP 
cells.  Since the phenotype observed with mutating Tyr-267 is stronger then that of mutating 
Tyr-363, we performed microarray gene expression profiling to characterize the global gene 
expression changes occurring when we mutated Tyr-267 compared to the AR wt within the 
full and truncated context.  Microarray gene expression results suggested that FL-WT-AR 
and FL-AR-Y267F were two separate entities.  There was not a overlapping gene list 
regulated by both expression constructs, yet TR-WT-AR and TR-AR-Y267F comparison led 
to a gene list that were modulated by both expression vector suggesting that defect in AR 
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activity due to loss of the Tyr-267 phosphorylation site was much dramatic in the full length 
context than truncated context.   
 Collectively, our results suggested that both full length and truncated AR 
overexpression in LNCaP cells is still modulated by AR tyrosine phosphorylation and 
subcellular localization.  It has been know that Src can phosphorylate AR at Tyr-534 and 
induce nuclear translocation of AR under the androgen depleted condition (Guo et al., 2006).  
Likewise, growth factor induced AR phosphorylation at Tyr-267 may promote nuclear 
translocation and downstream transcriptional activity under the androgen deprived condition.         
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Figure 3.1.  Phosphorylation site mutants of full length AR exhibit impaired 
transcriptional function in reporter assays.  Top panel. LNCaP cells were transiently 
transfected with the expression vector encoding full length wild type AR (FL-WT-AR), 
Y267F or Y363F mutant along with the AR-dependent reporter MMTV-luciferase.  Cells 
were treated with DHT (10 nM) for overnight (16 hrs).  Luciferase activity was measured 
from cell lysates.  The data shown with the mean and standard deviations of triplicate.  
Samples are representative of three independent experiments with similar results.   Bottom 
panel. Cell lysates of COS-7 cells transiently transfected with respective AR constructs and 
treated with or without DHT overnight were immunoblotted with the monoclonal antibody 
against AR.  Asterisk indicates statistical difference relative to FL-WT-AR (P < 0.05). 
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Figure 3.2.  Phosphorylation site mutants of truncated-AR exhibit impaired 
transcriptional function in reporter assays.  Top panel.  LNCaP cells were transiently 
transfected with the expression vector encoding truncated constitutively active wild type AR 
(Tr-WT-AR), Y267F or Y363F mutant along with the AR-dependent report ARR2-PB-
luciferase or MMTV-luciferase.  After 48 hours, luciferase activity was measured from cell 
lysates.  The data shows the mean and standard deviations of triplicates.   Samples are 
representative of three independent experiments with similar results.   Bottom panel. Cell 
lysates of COS-7 cells transiently transfected with respective AR constructs were 
immunoblotted with the monoclonal antibody against AR. Asterisk indicates statistical 
difference relative to TR-WT-AR (P < 0.05).   
 
 
 99 
 
Figure 3.3.  LNCaP cells stably overexpress full length or truncated wildtype AR or 
phosphorylation site mutants.  LNCaP cells stably overexpressing AR constructs or vector 
control were derived by retrovirus-mediated transduction and antibiotic selection.  A. Lysates 
from LNCaP cells overexpressing full-length AR were subjected to immunoprecipitation 
with AR antibody, followed by immunoblotted with AR or HA antibody, as indicated.  Total 
cell lysates were also immunoblotted with AR monoclonal antibody and beta-actin antibody.   
B.  The mRNA levels of AR was determined by quantitative reverse transcription PCR of 
total RNA isolated from LNCaP cells stably overexpressing full-length AR.  C. Lysates from 
LNCaP cells stably overexpressing truncated AR were subjected to immunoprecipitation, 
followed by immunoblotting, as indicated.   Total cell lysates were also immunoblotted with 
AR monoclonal antibody and beta-actin antibody.  D.  The mRNA levels of AR was 
determined by quantitative reverse transcription PCR of total RNA isolated from LNCaP 
cells stably overexpressing truncated AR.   
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Figure 3.4.  The AR Y267F mutant protein stably expressed in LNCaP cells is not 
recognized by the phospho-specific antibody.  A, B.  LNCaP cells stably overexpressing 
full length AR was treated with EGF (100 ng/ml) or heregulin (10 ng/ml) or Gas6 (100 
ng/ml) for 1 hr, as indicated.  Cell lysates were subjected to immunoprecipitation, followed 
by immunoblotting.  C, D.  LNCaP cells stably overexpressing truncated AR was treated 
with EGF (100 ng/ml) or heregulin (10 ng/ml) or Gas6 (100 ng/ml) for 1 hr, as indicated.  
Cell lysates were subjected to immunoprecipitation, followed by immunoblotting. 
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Figure 3.5.  The AR-Y267F mutant is defective in promoting cell proliferation A, B.  
LNCaP cells stably overexpressing full length AR (A) or truncated AR (B) were grown in a 
96-well plate for 72 hours in media with charcoal-stripped serum and indicated 
concentrations of DHT.  The colorimetric dye WST-8 reagent was added and incubated for 4 
hrs.  Absorbance at 450nm was measured to determine relative cell proliferation.  Asterisk 
and bar indicate statistical difference in corresponding doses relative to FL-WT-AR (P < 
0.05) in (A), and TR-WT-AR (P < 0.05) in (B), respectively. 
 
 
* 
* 
* 
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Figure 3.6.  The AR-Y267F mutant is defective in anchorage independent colony 
formation.  A, B.  LNCaP cells stably overexpressing full length AR (A) or truncated AR 
(B) Cells were plated in soft agar and incubated for 3 weeks.  Colonies were stained with 
crystal violet and counted.  The data shown with the mean and standard deviation of triplicate 
wells are representative of three independent experiments with similar results.  A 
representative view of the colonies is shown below the graph.  Asterisk indicates statistical 
difference relative to FL-WT-AR (P < 0.05) in (A), and TR-WT-AR (P < 0.05) in (B), 
respectively. 
 
* 
* 
* 
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Figure 3.7.  The AR-Y267F mutant is defective in androgen- and Ack1-induced nuclear 
translocation.  .  (A) and (B) COS-7 cells were co-transfected with the full length- or 
truncated-AR expression vector or truncated  and the constitutively active Ack1 expression 
vector and incubated for 48 hrs. Then, the cells were serum-starved overnight and treated 
with or without 10 nM DHT for 2 hr.  The cell fractionation was performed.  Fifteen 
micrograms of protein from cytoplasmic (C) and nuclear (N) fraction were immunoblotted 
with AR antibody.  Laminin A/C and 14-3-3 β were used as markers of nuclear and 
cytoplasmic fractions, respectively.   
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Figure 3.8.  The Tyr-267 is required Ack1-induced nuclear translocation of AR.  COS-7 
cells were co-transfected with the AR expression vector and the constitutively active Ack1 
expression vector and incubated for 48 hrs. Then, the cells were serum-starved overnight and 
treated with or without 10 nM DHT for 2 hr. 
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Figure 3.9.  The AR-Y267F mutant is defective in nuclear translocation in LNCaP cells 
stably overexpressing AR.   LNCaP cells stably overexpressing vector or AR constructs 
were grown in phenol red free media and serum starved for overnight and treated with or 
without 10 nM DHT for 2 hrs.  The cell fractionation was performed.   (A) The cytoplasmic 
and nuclear lysates from LNCaP cells overexpressing vector, FL-WT-AR, FL-AR-Y267F 
and FL-AR-Y363F were subjected to immunoprecipitation with Flag antibody, followed by 
immunoblotting with AR antibody as indicated.  The total lysates were also immunoblotted 
with Laminin A/C and 14-3-3 β antibodies as markers of nuclear and cytoplasmic fractions, 
respectively.  (B) The cytoplasmic and nuclear lysates from LNCaP cells overexpressing 
vector, TR-WT-AR, TR-AR-Y267F and TR-AR-Y363F were subjected to 
immunoprecipitation with Flag antibody, followed by immunoblotting with AR antibody as 
indicated.  The total lysates were also immunoblotted with Laminin A/C and 14-3-3 β 
antibodies as markers of nuclear and cytoplasmic fractions, respectively.   
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Figure 3.10.  Mutating the AR Tyr-267 site has an impact on global gene expression.  
Background corrected, lowess normalized data values from each of the four pairs (FL-WT-
AR, FL-AR-Y267F, TR-WT-AR, and TR-AR-Y267F) were retrieved from the UMD with 
the filtering procedure described in Materials and Methods.  The data were consisted of 
18729 genes.  Two class unpaired comparison between vector and AR constructs were 
performed in SAM with constant delta (δ=10) to have a false discover rate less than 5 % to 
identify genes differentially expressed between two groups.  The SAM gene lists from AR 
constructs were compared to identify the gene modulated by individual constructs as well as 
both of the construct compared.  The gene list comparisons were performed with JMP 7.1 
and results were depicted as Venn diagrams.  (A)  The number of genes that were either 
modulated by FL-WT-AR or FL-AR-Y267F or both.  (B)  The number of genes that were 
either modulated by TR-WT-AR or TR-AR-Y267F or both.  (C)  The number of genes that 
were either modulated by FL-WT-AR or TR-WT-AR or both. (D)  Experimental replicates 
clustered closely with each other.  Unsupervised cluster analysis of eight samples was 
performed with 18,729 genes that passed the filtering criteria described in Material and 
Methods.  Both genes and samples were clustered by using Cluster software (Eisen et al., 
1998) with lowess normalized, median centered genes with average linkage method.  The 
result of clustering was visualized with Java Treeview (Saldanha, 2004) and sample clusters 
were presented. 
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Figure 3.11.  The AR Tyr-267 site has a critical role in truncated AR recruitment to 
androgen target gene enhancers.  LNCaP cells over expressing TR-WT-AR, TR-AR-
Y267F, and TR-AR-Y363F were grown in phenol red free media supplemented with 
charcoal dextran stripped FBS and serum starved for over night.  ChIP analysis for binding of 
ectopically expressed FLAG-tagged truncated AR protein to the androgen responsive 
enhancer region of (A) PSA and (B) HK2 were performed using quantitative PCR.  Asterisk 
indicates statistical difference relative to FL-WT-AR (P < 0.05) in (A), and TR-WT-AR (P < 
0.05) in (B), respectively. 
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4.1 Conclusions and future directions 
 We explored the role of Ack1 target phosphorylation sites (Tyr-267 and Tyr-363) on 
AR transcriptional activity, cell proliferation, anchorage independent growth and nuclear 
localization.  We showed that mutating Ack1 target phosphorylation sites from tyrosine to 
phenylalanine (Y267F) inhibited AR transcriptional activity, cell proliferation, anchorage 
independent growth, and nuclear localization of AR.  By studying the affect of these 
phosphorylation sites in both full- and truncated-AR contexts allowed us to elucidate the role 
of these phosphorylation sites for both androgen-dependent and -independent activity of AR.   
 There is emerging evidence from the recent reports that ligand-independent activation 
of AR by growth factors and phosphorylation mediated AR activity is instrumental for 
hormone refractory prostate cancer cells to adapt to the selection pressure from ADT.  Our 
work showed that these phosphorylation sites (Tyr-267 and Tyr-363) where Ack1 signals 
through AR in response to growth factors has a critical role in the transcriptional activity, cell 
proliferation and anchorage independent growth of LNCaP cells overexpressing truncated 
AR missing LBD and constitutively active.  Recent work by (Guo et al., 2009) showed that 
the expression of splice variant form of AR missing LBD was elevated in HRPC tumors and 
they are resistant to therapies targeting LBD of AR.  Therefore, future therapeutic modalities 
targeting NTD of AR as well as these kinases (Ack1 or Src) that signal through these 
phosphorylation sites in NTD may prevent AR driven HRPC progression and development.   
 Our study implicated a role for Tyr-267 phosphorylation in transcriptional activity of 
TR-WT-AR.  Furthermore, TR-AR-Y267F overexpressing cells showed reduced cell 
proliferation, anchorage independent growth compared to that of TR-WT-AR suggesting that 
AR phosphorylation had a role in activity of truncated AR missing LBD.   
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 The effective prostate cancer treatment in the hormone refractory stage was limited 
by the shortcomings of current therapeutic modalities that can be improved significantly by 
understanding the underlying mechanisms of evasion of ADT induced selective pressure.  
Our report showed that tyrosine phosphorylation sites are essential for both growth factor 
induced and alternatively spliced truncated AR activity when these constructs were stably 
overexpressed in LNCaP cells.  The exact mechanism of how and when the alternative 
spliced AR occurs in prostate cancer cells under ADT remains unclear, yet its role in driving 
the resistance of prostate cancer to therapies and subsequent worsening of patient survival is 
well known.  Therefore, future therapies should include agents that target Ack1 and NTD of 
AR that is the predominantly transcriptionally active domain of AR that has a critical role in 
splice variant AR.  In fact recent work by Mahajan et al. (2010) showed that Ack1 kinase 
inhibitor AIM-100 inhibited both Ack1 Tyr-284 and AR Tyr-267 phosphorylation.  The 
inhibition of Tyr-267 phosphorylation declined drastically the ability of AR recruitments to 
AR target genes (PSA, TMPRSS2, and NKX3.1).  Furthermore, AIM-100 induced cell cycle 
arrest in G0/G1 phase in prostate cancer cells.  This initial work implicated that targeting 
Ack1 in HRPC may become a therapeutic choice in the future.        
 One of the possible mechanisms whereby AR-Y267F mutant showed defective 
phenotype might be an aberrant interaction of Tyr-267 mutant AR with chaperone proteins.  
It has been known that chaperone proteins are involved in critical processes that affect 
protein folding, activation, mobility, and transcriptional activity of many proteins including 
AR.  Without ligand, AR is located predominantly in the cytoplasm, kept in an inactive 
conformation by a large complex of chaperone proteins including heat shock proteins (HSPs) 
HSP-90, -70, and -56 (Elbi et al., 2004; Smith and Toft, 2008).  HSPs are responsible for 
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holding AR at a conformation to bind androgens and its interaction with proteins that 
mediates nucleocytoplasmic shuttling (Pratt and Toft, 1997; Smith and Toft, 2008).  Upon 
ligand binding, there is a conformational change in the AR that leads to dissociation of the 
AR-chaperone complex.  Next, the AR translocates into the nucleus, interacts with 
coregulators (coactivator or corepressor), dimerizes, and binds to the AREs present in the 
promoter or enhancer regions of AR target genes to regulate their transcriptional activity 
(Edwards and Bartlett, 2005).  The ligand induced disassociation of AR from chaperone 
complex (HSP-100, -90, -70, -60, and -27) is considered as one of regulatory mechanisms of 
AR signaling (Edwards and Bartlett, 2005).  For example, HSP-90 inhibitor, geldanamycin, 
inhibited the transcriptional activity of AR regulated genes by decreasing the stability and 
increasing the proteasomal degradation of AR (Vanaja et al., 2002).  There are recent reports 
indicated that elevated co-chaperone activities were detected in hormone refractory prostate 
cancer (Shatkina et al., 2003; Yamanaka et al., 2005).  The elevated expression of Bag-1L 
was detected in HRPC (Yamanaka et al., 2005) and further study suggested that both NH2 
and COOH terminal domain interaction of Bag-1L with the respective domains of AR is an 
essential requirement for inducing the transcriptional activity of AR (Shatkina et al., 2003).  
Zoubeidi et al. reported that HSP-27, ATP independent co-chaperone, was phosphorylated 
(Ser-78 and Ser-82) by ligand induced AR through p38-kinase dependent manner (Zoubeidi 
et al., 2007).  Subsequently, there is an increased AR protein stability, shuttling, and 
transcriptional activity which led to enhanced prostate cancer cell survival.  Interestingly, 
ligand activation of AR enhanced the presence of HSP-27 in the expense of HSP-90 in the 
chaperone complex.  Both AR and HSP27 were co-localized into the nucleus.  The inhibition 
of the phosphorylation of HSP27 or knocking down HSP-27 with antisense drug OGX-427 
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enhanced the interaction of AR and HSP-90, increased proteasomal degradation of AR, and 
concurrently diminished the transcriptional activity of AR.  Based on what we know about 
the chaperone proteins, it would be helpful to investigate the interaction of AR-WT and AR 
mutants with HSP-90 and HSP-27 co-chaperones to elucidate whether these chaperone 
proteins have any role in the defective phenotype observed with AR-Y267F mutant AR.  
Furthermore, future experiments may determine whether AR phosphorylation enhances the 
stability of AR protein.     
 The sustained AR activity from the onset of prostate cancer to HRPC led researchers 
to investigate co-regulatory proteins that interact with AR and affect its transcriptional 
activity in a cellular context-dependent manner (Heinlein and Chang, 2002).  Currently, there 
are more than 200 co-regulators which have diverse functions depending on the target gene 
and cellular context (Agoulnik and Weigel, 2009; Heemers and Tindall, 2007).  They may 
enhance (as co-activators) or reduce (as co-repressors) the target gene activity.  There are 
several reports that studied the changes in the expression of AR co-regulators in prostate 
cancer.  Gregory et al. (2001) studied the expression of three nuclear receptor co-activators, 
transcriptional intermediatory factor 2 (TIF2), steroid receptor co-activator 1 (SRC1), and 
amplified in breast cancer 1 (AIB1) in samples from benign prostate hyperplasia (BPH), 
androgen dependent prostate cancer, and androgen independent prostate cancer.  They 
showed that elevated expression of TIF2 and SRC1 correlated with increased AR expression 
in androgen independent prostate cancer.  Co-transfection of AR wild type or mutant AR 
with TIF2 made AR responsive to non-androgen ligands such as androstenedione, estradiol, 
and progesterone.  This study suggested that overexpression of co-activators may broaden the 
ligand specificity of AR like AR mutations and may sensitize AR to low levels of androgens.  
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We have not investigated the expression of co-activators in LNCaP cells over expressing 
full- or truncated- WT AR or mutant AR.  One future experiment may be to determine the 
expression levels of selected co-activators and co-repressors in the full- or truncated- WT AR 
overexpressing cells and how mutating Tyr-267 and Tyr-363 sites affect the expression of the 
co-activators and co-repressors.  There are co-activators (such as p160 co-activators) and co-
repressor that interact with NTD of AR (Alen et al., 1999; Ueda et al., 2002)  Understanding 
the mechanism of interaction of co-regulators with these phosphorylation sites may help to 
identify co-regulators involved in survival and proliferation of PCa.    
 AR phosphorylation by Ack1 and Src in hormone refractory prostate cancer 
suggested that AR phosphorylation may have a critical role in driving prostate cancer to 
recurrence that becomes an incurable disease.  The result of our studies suggested that 
growth factor induced AR phosphorylation through Ack1 or Src tyrosine kinases was 
inhibited by dasatinib, a Src family kinase inhibitor except AR Tyr-267 phosphorylation 
induced by EGF.  Therefore, there may be additional kinases that phosphorylate AR at Tyr-
267 in response to EGF treatment of cells.  It is possible to determine whether additional 
kinases become activated by EGF and phosphorylate AR by using proteomic analysis 
approaches.  Identification of other kinases that signal downstream of EGF will increase the 
number of drug targets that may enhance the efficacy of current prostate cancer therapies.   
 Our studies concentrated on Ack1 target phosphorylation sites, yet AR is 
phosphorylated at many sites serine-16, 81, 256, 308, 424, and 650 (Gioeli et al., 2002; Zhou 
et al., 1995).  One future experiment may be to determine the changes in the pattern of 
phosphorylation of AR at serine/threonine sites in comparison of AR-WT with AR-Y267F or 
AR-Y363F.    
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  Herein, we specifically studied the effect of AR tyrosine phosphorylation on 
androgen-independent activation of AR to understand the mechanism of AR activation in 
HRPC that arose under ADT.  However, there are other post-translational modifications such 
as ubiquitination, SUMOylation can also modulate AR activity (Cardozo and Pagano, 2004; 
Cheng et al., 2006; Ravid and Hochstrasser, 2008; Wu and Mo, 2007).  One future 
experiment may be to study how AR tyrosine phosphorylation (Tyr-267 or Tyr-363) affects 
AR ubiquitination and SUMOylation.  Characterizing these diverse post-translational 
modifications of AR may help us understand how AR functions are affected by these 
modifications.  These modifications are tightly regulated and components of dynamic 
regulation of AR transcriptional machinery.  Deregulation of these modifications may play a 
role in the pathogenesis and progression of PCa.  Therefore, understanding the mechanism of 
action of these modifications such as tyrosine phosphorylation of AR may help develop 
novel therapeutic approaches to enhance the efficacy of standard therapies.   
 Three independent groups reported the presence of splice variant AR species missing 
LBD and constitutively active in castration recurrent cell line models and PCa tissues (Dehm 
et al., 2008; Guo et al., 2009; Lin et al., 2009).  Two groups developed antibodies that 
specifically recognize truncated AR, but not full length AR to detect truncated AR species in 
PCa tissues. (Guo et al., 2009; Lin et al., 2009).  Their studies showed that although the 
expression level of truncated AR was lower than that of full length AR, they were able to 
detect splice variant truncated AR proteins in human PCa tissues.  Furthermore, microarray 
gene expression analysis showed that different groups of genes regulated by full length AR 
compared to the truncated AR variants suggested that these variants may modulate different 
biological processes with a selected group of genes.  Again, the difference in the mode of 
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transcription might be due to the set of co-regulators recruited to the AREs by these two 
different biological entities (full- and truncated-AR).  One experiment that might help us 
understand the difference in the mechanism of action of these two AR forms would be 
chromatin immunoprecipitation followed by sequencing (Chip-Seq) by using antibodies 
specifically recognizing full length or truncated AR.   
 One of the possible clinical implication of having splice variant specific antibody is to 
determine the expression level of TR-WT-AR during progression of PCa from hormone 
dependent PCa to HRPC using truncated AR as a biomarker for hormone recurrence.  The 
selective pressure of ADT induces constitutively active splice variants in HRPC cells that 
evade the therapy.  Understanding the mechanism of splice variant AR may help us develop 
therapeutic approaches that target NTD of AR where predominant AF-1 transcriptional unit 
resides.      
  In summary, our work underscores the significance of AR phosphorylation in AR 
transcriptional activity, cell proliferation, anchorage independent growth, nuclear localization 
and DNA binding under androgen depleted conditions.  Having phospho-Tyr-267 and Tyr-
534 AR antibodies as well as Ack1 phopho-Tyr-284 may allow us to measure the 
effectiveness of therapeutic targeting of Src and Ack1 in HRPC.  In the future, identification 
of additional kinases signaling through Tyr-267 will enhance our understanding of the role of 
these AR phosphorylation sites in HRPC and may help in developing therapeutic approaches 
that target these kinases.          
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Table 5.1 The list of the genes that are significantly up regulated in FL-WT-AR compared to vector control 
Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P145694 ASNS ^ Asparagine synthetase ^  1.78 
AGI_HUM1_OLIGO_A_23_P117782 FLJ11196 ^ Acheron ^  3.51 
AGI_HUM1_OLIGO_A_24_P941359 C6orf32 ^ Chromosome 6 open reading frame 32 ^  14.39 
AGI_HUM1_OLIGO_A_23_P120845 XBP1 ^ X-box binding protein 1 ^  1.71 
AGI_HUM1_OLIGO_A_23_P314584 
MAPKAPK3 ^ Mitogen-activated protein kinase-activated 
protein kinase 3 ^  1.44 
AGI_HUM1_OLIGO_A_24_P250333 
SNRPA ^ Small nuclear ribonucleoprotein polypeptide A 
^  1.23 
AGI_HUM1_OLIGO_A_32_P46594 LOC145837 ^ Hypothetical protein LOC145837 ^  1.62 
AGI_HUM1_OLIGO_A_23_P17855 HRIHFB2122 ^ Tara-like protein ^  2.35 
AGI_HUM1_OLIGO_A_32_P51518 ^ CDNA FLJ40901 fis, clone UTERU2003704 ^  2.40 
AGI_HUM1_OLIGO_A_24_P107695 ACTN1 ^ Actinin, alpha 1 ^  1.55 
AGI_HUM1_OLIGO_A_23_P305981 LOC388152 ^ LOC388161 ^  2.05 
AGI_HUM1_OLIGO_A_23_P1615 
FIBP ^ Fibroblast growth factor (acidic) intracellular 
binding protein ^  1.30 
AGI_HUM1_OLIGO_A_23_P394014 M-RIP ^ Myosin phosphatase-Rho interacting protein ^  1.59 
AGI_HUM1_OLIGO_A_23_P1682 LOC120224 ^ Hypothetical protein BC016153 ^  11.60 
AGI_HUM1_OLIGO_A_24_P45005 NPEPL1 ^ Aminopeptidase-like 1 ^  1.42 
AGI_HUM1_OLIGO_A_23_P312646 LOC286257 ^ Hypothetical protein LOC286257 ^  1.44 
AGI_HUM1_OLIGO_A_24_P256552 CSTF3 ^ Hypothetical protein LOC283267 ^  1.46 
AGI_HUM1_OLIGO_A_24_P204144 Uncharacterized gene 1.69 
AGI_HUM1_OLIGO_A_24_P109661 Uncharacterized gene 1.26 
AGI_HUM1_OLIGO_A_23_P132285 Uncharacterized gene 1.48 
AGI_HUM1_OLIGO_A_32_P2730 Uncharacterized gene 3.43 
AGI_HUM1_OLIGO_A_23_P63897 CTBP2 ^ C-terminal binding protein 2 ^  1.23 
AGI_HUM1_OLIGO_A_24_P350124 KIAA1618 ^ KIAA1618 ^  1.66 
   
  
125
Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P254944 GSTT1 ^ Glutathione S-transferase theta 1 ^  1.73 
AGI_HUM1_OLIGO_A_24_P595460 NUCB2 ^ Nucleobindin 2 ^  2.32 
AGI_HUM1_OLIGO_A_23_P379550 YARS ^ Tyrosyl-tRNA synthetase ^  2.07 
AGI_HUM1_OLIGO_A_23_P155009 C22orf3 ^ Chromosome 22 open reading frame 3 ^  1.49 
AGI_HUM1_OLIGO_A_23_P117992 KIAA0703 ^ KIAA0703 gene product ^  2.61 
AGI_HUM1_OLIGO_A_24_P814246 Uncharacterized gene 1.79 
AGI_HUM1_OLIGO_A_32_P217709 
RAC1 ^ Ras-related C3 botulinum toxin substrate 1 (rho 
family, small GTP binding protein Rac1) ^  1.38 
AGI_HUM1_OLIGO_A_24_P95439 Uncharacterized gene 2.17 
AGI_HUM1_OLIGO_A_24_P827738 Uncharacterized gene 2.17 
AGI_HUM1_OLIGO_A_23_P119943 
IGFBP2 ^ Insulin-like growth factor binding protein 2, 
36kDa ^  1.38 
AGI_HUM1_OLIGO_A_23_P54758 MIR16 ^ Membrane interacting protein of RGS16 ^  1.55 
AGI_HUM1_OLIGO_A_24_P306558 KIAA1049 ^ KIAA1049 protein ^  2.06 
AGI_HUM1_OLIGO_A_32_P135348 Uncharacterized gene 1.94 
AGI_HUM1_OLIGO_A_24_P936767 TRIM25 ^ Tripartite motif-containing 25 ^  1.79 
AGI_HUM1_OLIGO_A_32_P184796 RPLP0 ^ Ribosomal protein, large, P0 ^  1.67 
AGI_HUM1_OLIGO_A_23_P9472 VPS13A ^ Vacuolar protein sorting 13A (yeast) ^  1.84 
AGI_HUM1_OLIGO_A_23_P9688 
DNCLI2 ^ Dynein, cytoplasmic, light intermediate 
polypeptide 2 ^  1.90 
AGI_HUM1_OLIGO_A_23_P208030 SYT4 ^ Synaptotagmin IV ^  2.25 
AGI_HUM1_OLIGO_A_32_P21255 
SLC30A4 ^ Solute carrier family 30 (zinc transporter), 
member 4 ^  3.05 
AGI_HUM1_OLIGO_A_32_P194072 DKFZP434B0335 ^ DKFZP434B0335 protein ^  2.05 
AGI_HUM1_OLIGO_A_23_P155027 
ZCWCC1 ^ Zinc finger, CW type with coiled-coil domain 
1 ^  1.13 
AGI_HUM1_OLIGO_A_24_P212152 FLJ14346 ^ Hypothetical protein FLJ14346 ^  1.27 
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Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P53541 CHD4 ^ Chromodomain helicase DNA binding protein 4 ^  2.02 
AGI_HUM1_OLIGO_A_24_P398432 CENTD2 ^ Centaurin, delta 2 ^  1.61 
AGI_HUM1_OLIGO_A_23_P253029 BOK ^ BCL2-related ovarian killer ^  1.94 
AGI_HUM1_OLIGO_A_23_P390528 DUSP8 ^ Dual specificity phosphatase 8 ^  1.88 
AGI_HUM1_OLIGO_A_23_P204472 RPLP0 ^ Ribosomal protein, large, P0 ^  2.07 
AGI_HUM1_OLIGO_A_23_P101707 
M6PRBP1 ^ Mannose-6-phosphate receptor binding 
protein 1 ^  1.46 
AGI_HUM1_OLIGO_A_24_P412238 MUS81 ^ MUS81 endonuclease homolog (yeast) ^  1.33 
AGI_HUM1_OLIGO_A_24_P152635 TMX2 ^ Thioredoxin-related transmembrane protein 2 ^  1.33 
AGI_HUM1_OLIGO_A_23_P52569 
NUDT8 ^ Nudix (nucleoside diphosphate linked moiety 
X)-type motif 8 ^  1.81 
AGI_HUM1_OLIGO_A_23_P60683 
STK24 ^ Serine/threonine kinase 24 (STE20 homolog, 
yeast) ^  1.44 
AGI_HUM1_OLIGO_A_23_P216689 BRD3 ^ Bromodomain containing 3 ^  2.32 
AGI_HUM1_OLIGO_A_24_P938135 Uncharacterized gene 1.87 
AGI_HUM1_OLIGO_A_23_P320478 
FLJ22795 ^ Similar to golgi autoantigen golgin subfamily 
a2-like ^  2.04 
AGI_HUM1_OLIGO_A_24_P50554 Uncharacterized gene 1.08 
AGI_HUM1_OLIGO_A_24_P100234 
ZCWCC1 ^ Zinc finger, CW type with coiled-coil domain 
1 ^  1.51 
AGI_HUM1_OLIGO_A_24_P490857 ^ CDNA clone IMAGE:5263531, partial cds ^  1.54 
AGI_HUM1_OLIGO_A_24_P592570 Uncharacterized gene 1.47 
AGI_HUM1_OLIGO_A_23_P213102 KIAA0992 ^ Palladin ^  1.48 
AGI_HUM1_OLIGO_A_24_P144936 PKD1-like ^ Polycystic kidney disease 1-like ^  2.11 
AGI_HUM1_OLIGO_A_23_P113405 CNNM3 ^ Cyclin M3 ^  1.65 
AGI_HUM1_OLIGO_A_23_P118353 SRP68 ^ Signal recognition particle 68kDa ^  1.59 
AGI_HUM1_OLIGO_A_24_P247233 Uncharacterized gene 1.27 
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AGI_HUM1_OLIGO_A_24_P87763 EEF2 ^ Eukaryotic translation elongation factor 2 ^  2.11 
AGI_HUM1_OLIGO_A_23_P128246 HYPE ^ Huntingtin interacting protein E ^  1.92 
AGI_HUM1_OLIGO_A_32_P206899 Uncharacterized gene 2.39 
AGI_HUM1_OLIGO_A_23_P401106 PDE2A ^ Phosphodiesterase 2A, cGMP-stimulated ^  2.85 
AGI_HUM1_OLIGO_A_23_P52939 SLC43A1 ^ Solute carrier family 43, member 1 ^  2.37 
AGI_HUM1_OLIGO_A_23_P129221 
FAH ^ Fumarylacetoacetate hydrolase 
(fumarylacetoacetase) ^  1.59 
AGI_HUM1_OLIGO_A_24_P6083 C22orf16 ^ Chromosome 22 open reading frame 16 ^  1.86 
AGI_HUM1_OLIGO_A_23_P48747 
DHRS1 ^ Dehydrogenase/reductase (SDR family) 
member 1 ^  1.61 
AGI_HUM1_OLIGO_A_23_P341065 SELO ^ Selenoprotein O ^  1.77 
AGI_HUM1_OLIGO_A_23_P334021 IGF2R ^ Insulin-like growth factor 2 receptor ^  1.78 
AGI_HUM1_OLIGO_A_23_P120488 NPEPL1 ^ Aminopeptidase-like 1 ^  1.43 
AGI_HUM1_OLIGO_A_23_P101013 EVER1 ^ Epidermodysplasia verruciformis 1 ^  2.00 
AGI_HUM1_OLIGO_A_23_P217015 SET ^ SET translocation (myeloid leukemia-associated) ^  1.82 
AGI_HUM1_OLIGO_A_24_P216087 PD2 ^ Hypothetical protein F23149_1 ^  1.32 
AGI_HUM1_OLIGO_A_24_P188460 Uncharacterized gene 1.58 
AGI_HUM1_OLIGO_A_32_P49334 LOC284889 ^ Hypothetical protein LOC284889 ^  1.55 
AGI_HUM1_OLIGO_A_24_P803885 LOC149134 ^ Hypothetical protein LOC149134 ^  1.69 
AGI_HUM1_OLIGO_A_32_P159820 Uncharacterized gene 1.25 
AGI_HUM1_OLIGO_A_23_P80377 
PACSIN2 ^ Protein kinase C and casein kinase substrate 
in neurons 2 ^  2.11 
AGI_HUM1_OLIGO_A_23_P407628 
MYST3 ^ MYST histone acetyltransferase (monocytic 
leukemia) 3 ^  1.39 
AGI_HUM1_OLIGO_A_23_P368028 TP53I11 ^ Tumor protein p53 inducible protein 11 ^  1.58 
AGI_HUM1_OLIGO_A_23_P24723 HSPC196 ^ Hypothetical protein HSPC196 ^  1.55 
AGI_HUM1_OLIGO_A_23_P40108 COL9A3 ^ Collagen, type IX, alpha 3 ^  1.32 
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AGI_HUM1_OLIGO_A_23_P76690 
UCHL3 ^ Ubiquitin carboxyl-terminal esterase L3 
(ubiquitin thiolesterase) ^  1.42 
AGI_HUM1_OLIGO_A_32_P36136 Uncharacterized gene 1.50 
AGI_HUM1_OLIGO_A_24_P281374 Uncharacterized gene 1.18 
AGI_HUM1_OLIGO_A_24_P136484 MGC15875 ^ Hypothetical protein MGC15875 ^  1.65 
AGI_HUM1_OLIGO_A_23_P109606 SBF1 ^ SET binding factor 1 ^  2.27 
AGI_HUM1_OLIGO_A_23_P58622 
UBE2D2 ^ Ubiquitin-conjugating enzyme E2D 2 (UBC4/5 
homolog, yeast) ^  1.35 
AGI_HUM1_OLIGO_A_24_P127828 VCP ^ Valosin-containing protein ^  1.64 
AGI_HUM1_OLIGO_A_23_P35848 NADSYN1 ^ NAD synthetase 1 ^  1.38 
AGI_HUM1_OLIGO_A_23_P388780 
DMAP1 ^ DNA methyltransferase 1 associated protein 1 
^  1.26 
AGI_HUM1_OLIGO_A_24_P99071 RANBP5 ^ RAN binding protein 5 ^  1.75 
AGI_HUM1_OLIGO_A_23_P162486 
PTPN6 ^ Protein tyrosine phosphatase, non-receptor 
type 6 ^  1.75 
AGI_HUM1_OLIGO_A_23_P159539 ASMTL ^ Acetylserotonin O-methyltransferase-like ^  1.66 
AGI_HUM1_OLIGO_A_23_P103120 GTPBP1 ^ GTP binding protein 1 ^  1.48 
AGI_HUM1_OLIGO_A_23_P169629 
SHMT2 ^ Serine hydroxymethyltransferase 2 
(mitochondrial) ^  1.52 
AGI_HUM1_OLIGO_A_24_P205364 SHMT1 ^ Serine hydroxymethyltransferase 1 (soluble) ^  1.19 
AGI_HUM1_OLIGO_A_23_P16538 ELL ^ Elongation factor RNA polymerase II ^  1.24 
AGI_HUM1_OLIGO_A_23_P132675 
UQCRC1 ^ Ubiquinol-cytochrome c reductase core 
protein I ^  1.40 
AGI_HUM1_OLIGO_A_24_P944751 Uncharacterized gene 2.41 
AGI_HUM1_OLIGO_A_23_P205929 DPP8 ^ Dipeptidylpeptidase 8 ^  1.39 
AGI_HUM1_OLIGO_A_24_P100228 XBP1 ^ X-box binding protein 1 ^  2.33 
AGI_HUM1_OLIGO_A_23_P167559 FLJ31951 ^ Hypothetical protein FLJ31951 ^  1.53 
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AGI_HUM1_OLIGO_A_24_P196400 PHIP ^ Pleckstrin homology domain interacting protein ^  1.36 
AGI_HUM1_OLIGO_A_23_P140170 SEC23A ^ Sec23 homolog A (S. cerevisiae) ^  1.33 
AGI_HUM1_OLIGO_A_23_P355385 PPP6C ^ Protein phosphatase 6, catalytic subunit ^  1.26 
AGI_HUM1_OLIGO_A_24_P344510 KLK3 ^ Kallikrein 3, (prostate specific antigen) ^  4.63 
AGI_HUM1_OLIGO_A_32_P146898 Uncharacterized gene 1.78 
AGI_HUM1_OLIGO_A_24_P213161 
NALP2 ^ NACHT, leucine rich repeat and PYD containing 
2 ^  1.66 
AGI_HUM1_OLIGO_A_24_P267293 SARM1 ^ Sterile alpha and TIR motif containing 1 ^  1.62 
AGI_HUM1_OLIGO_A_24_P97785 PURA ^ Purine-rich element binding protein A ^  1.53 
AGI_HUM1_OLIGO_A_24_P98249 
TACC1 ^ Transforming, acidic coiled-coil containing 
protein 1 ^  2.04 
AGI_HUM1_OLIGO_A_23_P88046 FLJ10769 ^ Hypothetical protein FLJ10769 ^  1.72 
AGI_HUM1_OLIGO_A_23_P375147 Uncharacterized gene 1.55 
AGI_HUM1_OLIGO_A_23_P322845 HTPAP ^ HTPAP protein ^  1.44 
AGI_HUM1_OLIGO_A_23_P128073 
SMARCC2 ^ SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, member 2 
^  1.74 
AGI_HUM1_OLIGO_A_32_P114246 USP47 ^ Ubiquitin specific protease 47 ^  1.54 
AGI_HUM1_OLIGO_A_23_P141032 COX4I1 ^ Cytochrome c oxidase subunit IV isoform 1 ^  1.39 
AGI_HUM1_OLIGO_A_24_P115971 RIC-8 ^ Likely ortholog of mouse synembryn ^  1.42 
AGI_HUM1_OLIGO_A_23_P121795 ARGBP2 ^ Arg/Abl-interacting protein ArgBP2 ^  1.89 
AGI_HUM1_OLIGO_A_24_P940576 KIAA1340 ^ KIAA1340 protein ^  1.86 
AGI_HUM1_OLIGO_A_23_P129738 LLGL2 ^ Lethal giant larvae homolog 2 (Drosophila) ^  1.44 
AGI_HUM1_OLIGO_A_24_P305467 p66alpha ^ P66 alpha ^  1.42 
AGI_HUM1_OLIGO_A_23_P26713 RPL23 ^ Ribosomal protein L23 ^  1.18 
AGI_HUM1_OLIGO_A_23_P115167 TA-LRRP ^ T-cell activation leucine repeat-rich protein ^  1.46 
AGI_HUM1_OLIGO_A_23_P395703 HBXAP ^ Hepatitis B virus x associated protein ^  1.48 
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AGI_HUM1_OLIGO_A_24_P149766 MGC10765 ^ Hypothetical protein MGC10765 ^  1.59 
AGI_HUM1_OLIGO_A_23_P253177 
STK24 ^ Serine/threonine kinase 24 (STE20 homolog, 
yeast) ^  1.71 
AGI_HUM1_OLIGO_A_23_P124912 NPEPPS ^ Aminopeptidase puromycin sensitive ^  1.17 
AGI_HUM1_OLIGO_A_24_P324405 ANKRD11 ^ Ankyrin repeat domain 11 ^  2.30 
AGI_HUM1_OLIGO_A_23_P115534 PKD1-like ^ Polycystic kidney disease 1-like ^  1.79 
AGI_HUM1_OLIGO_A_23_P372771 C15orf17 ^ Chromosome 15 open reading frame 17 ^  1.88 
AGI_HUM1_OLIGO_A_23_P12849 FBXO18 ^ F-box protein, helicase, 18 ^  1.38 
AGI_HUM1_OLIGO_A_23_P64938 C3F ^ Putative protein similar to nessy (Drosophila) ^  1.93 
AGI_HUM1_OLIGO_A_23_P130886 FLJ14981 ^ Hypothetical protein FLJ14981 ^  1.37 
AGI_HUM1_OLIGO_A_32_P104063 ^ Hypothetical gene supported by AF275804 ^  1.58 
AGI_HUM1_OLIGO_A_23_P395172 ABHD2 ^ Abhydrolase domain containing 2 ^  2.19 
AGI_HUM1_OLIGO_A_23_P155335 PLD1 ^ Phospholipase D1, phophatidylcholine-specific ^  2.36 
AGI_HUM1_OLIGO_A_24_P231494 DNPEP ^ Aspartyl aminopeptidase ^  1.33 
AGI_HUM1_OLIGO_A_32_P89371 RANBP2L1 ^ RAN binding protein 2-like 1 ^  2.06 
AGI_HUM1_OLIGO_A_23_P162970 IPO4 ^ Importin 4 ^  1.50 
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Table 5.2 The list of the genes that are significantly down regulated in FL-WT-AR compared to vector control. 
Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P254271 TUBB6 ^ Tubulin, beta 6 ^  0.11 
AGI_HUM1_OLIGO_A_23_P252704 LOC51123 ^ HSPC038 protein ^  0.52 
AGI_HUM1_OLIGO_A_24_P83968 Uncharacterized gene 0.84 
AGI_HUM1_OLIGO_A_23_P51508 DUSP12 ^ Dual specificity phosphatase 12 ^  0.70 
AGI_HUM1_OLIGO_A_24_P88850 MRAS ^ Muscle RAS oncogene homolog ^  0.61 
AGI_HUM1_OLIGO_A_23_P309361 FLJ30525 ^ Hypothetical protein FLJ30525 ^  0.03 
AGI_HUM1_OLIGO_A_23_P74981 MGC12466 ^ Hypothetical protein MGC12466 ^  0.42 
AGI_HUM1_OLIGO_A_23_P201996 WAC ^ WW domain containing adaptor with coiled-coil ^  0.79 
AGI_HUM1_OLIGO_A_24_P327886 TCEA3 ^ Transcription elongation factor A (SII), 3 ^  0.13 
AGI_HUM1_OLIGO_A_24_P143189 TMSL3 ^ Thymosin-like 3 ^  0.21 
AGI_HUM1_OLIGO_A_23_P141044 
LOC146542 ^ Similar to hypothetical protein MGC13138 
^  0.47 
AGI_HUM1_OLIGO_A_23_P200901 ENSA ^ Endosulfine alpha ^  0.72 
AGI_HUM1_OLIGO_A_24_P384990 ^ Homo sapiens, clone IMAGE:4157625, mRNA ^  0.46 
AGI_HUM1_OLIGO_A_24_P374516 TMSB4X ^ Thymosin, beta 4, X-linked ^  0.26 
AGI_HUM1_OLIGO_A_23_P252711 LACTB2 ^ Lactamase, beta 2 ^  0.57 
AGI_HUM1_OLIGO_A_23_P201731 TRAF5 ^ TNF receptor-associated factor 5 ^  0.14 
AGI_HUM1_OLIGO_A_23_P200216 
MAGOH ^ Mago-nashi homolog, proliferation-associated 
(Drosophila) ^  0.43 
AGI_HUM1_OLIGO_A_23_P412577 ANKRD29 ^ Ankyrin repeat domain 29 ^  0.17 
AGI_HUM1_OLIGO_A_23_P385034 E2F3 ^ E2F transcription factor 3 ^  0.57 
AGI_HUM1_OLIGO_A_23_P256735 PGCP ^ Plasma glutamate carboxypeptidase ^  0.29 
AGI_HUM1_OLIGO_A_24_P201064 
PPP1R3B ^ Protein phosphatase 1, regulatory (inhibitor) 
subunit 3B ^  0.49 
AGI_HUM1_OLIGO_A_23_P414771 Uncharacterized gene 0.64 
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AGI_HUM1_OLIGO_A_23_P85726 MGC9084 ^ Hypothetical protein MGC9084 ^  0.58 
AGI_HUM1_OLIGO_A_23_P49546 
GRIN2C ^ Glutamate receptor, ionotropic, N-methyl D-
aspartate 2C ^  0.23 
AGI_HUM1_OLIGO_A_23_P208090 MBD1 ^ Methyl-CpG binding domain protein 1 ^  0.66 
AGI_HUM1_OLIGO_A_23_P103905 Ufc1 ^ Ufm1-conjugating enzyme 1 ^  0.56 
AGI_HUM1_OLIGO_A_24_P719948 ^ Full length insert cDNA YQ80D07 ^  0.50 
AGI_HUM1_OLIGO_A_23_P251002 Uncharacterized gene 0.60 
AGI_HUM1_OLIGO_A_23_P123672 TDRD7 ^ Tudor domain containing 7 ^  0.56 
AGI_HUM1_OLIGO_A_32_P44274 
CHTF18 ^ CTF18, chromosome transmission fidelity 
factor 18 homolog (S. cerevisiae) ^  0.74 
AGI_HUM1_OLIGO_A_24_P230416 Uncharacterized gene 0.66 
AGI_HUM1_OLIGO_A_23_P419239 ETNK1 ^ Ethanolamine kinase 1 ^  0.64 
AGI_HUM1_OLIGO_A_23_P52101 
NQO3A2 ^ NAD(P)H:quinone oxidoreductase type 3, 
polypeptide A2 ^  0.73 
AGI_HUM1_OLIGO_A_23_P161190 VIM ^ Vimentin ^  0.33 
AGI_HUM1_OLIGO_A_24_P209204 C6orf62 ^ Chromosome 6 open reading frame 62 ^  0.55 
AGI_HUM1_OLIGO_A_23_P122545 RDBP ^ RD RNA binding protein ^  0.93 
AGI_HUM1_OLIGO_A_23_P86570 ANXA7 ^ Annexin A7 ^  0.73 
AGI_HUM1_OLIGO_A_32_P41574 PXN ^ Paxillin ^  0.70 
AGI_HUM1_OLIGO_A_23_P155857 
NUDT6 ^ Nudix (nucleoside diphosphate linked moiety 
X)-type motif 6 ^  0.41 
AGI_HUM1_OLIGO_A_24_P382119 MTMR4 ^ Myotubularin related protein 4 ^  0.84 
AGI_HUM1_OLIGO_A_23_P160546 FLJ11280 ^ Hypothetical protein FLJ11280 ^  0.30 
AGI_HUM1_OLIGO_A_24_P374513 Uncharacterized gene 0.26 
AGI_HUM1_OLIGO_A_23_P114662 CRYZ ^ Crystallin, zeta (quinone reductase) ^  0.78 
AGI_HUM1_OLIGO_A_23_P127579 PTS ^ 6-pyruvoyltetrahydropterin synthase ^  0.72 
AGI_HUM1_OLIGO_A_23_P407583 PEG3 ^ Paternally expressed 3 ^  0.11 
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AGI_HUM1_OLIGO_A_23_P92765 Uncharacterized gene 0.77 
AGI_HUM1_OLIGO_A_23_P501624 
UGT2B17 ^ UDP glycosyltransferase 2 family, 
polypeptide B17 ^  0.82 
AGI_HUM1_OLIGO_A_23_P85952 FLJ22457 ^ Hypothetical protein FLJ22457 ^  0.13 
AGI_HUM1_OLIGO_A_23_P42435 DTNBP1 ^ Dystrobrevin binding protein 1 ^  0.69 
AGI_HUM1_OLIGO_A_23_P371824 TUFT1 ^ Tuftelin 1 ^  0.60 
AGI_HUM1_OLIGO_A_24_P178663 Uncharacterized gene 0.56 
AGI_HUM1_OLIGO_A_23_P116235 Uncharacterized gene 0.20 
AGI_HUM1_OLIGO_A_23_P48676 
PYGL ^ Phosphorylase, glycogen; liver (Hers disease, 
glycogen storage disease type VI) ^  0.23 
AGI_HUM1_OLIGO_A_24_P230009 Uncharacterized gene 0.63 
AGI_HUM1_OLIGO_A_23_P34375 TCEA3 ^ Transcription elongation factor A (SII), 3 ^  0.23 
AGI_HUM1_OLIGO_A_23_P110362 
MAP2K1IP1 ^ Mitogen-activated protein kinase kinase 1 
interacting protein 1 ^  0.58 
AGI_HUM1_OLIGO_A_23_P57137 C20orf29 ^ Chromosome 20 open reading frame 29 ^  0.77 
AGI_HUM1_OLIGO_A_32_P54018 KIAA1143 ^ KIAA1143 protein ^  0.69 
AGI_HUM1_OLIGO_A_23_P160518 TRIM45 ^ Tripartite motif-containing 45 ^  0.61 
AGI_HUM1_OLIGO_A_23_P70307 SMOC2 ^ SPARC related modular calcium binding 2 ^  0.29 
AGI_HUM1_OLIGO_A_24_P261083 C8orf1 ^ Chromosome 8 open reading frame 1 ^  0.69 
AGI_HUM1_OLIGO_A_23_P65000 HSU79274 ^ Protein predicted by clone 23733 ^  0.76 
AGI_HUM1_OLIGO_A_23_P141362 FZD2 ^ Frizzled homolog 2 (Drosophila) ^  0.35 
AGI_HUM1_OLIGO_A_23_P91350 Uncharacterized gene 0.55 
AGI_HUM1_OLIGO_A_23_P160567 ZMYND12 ^ Zinc finger, MYND domain containing 12 ^  0.56 
AGI_HUM1_OLIGO_A_24_P49539 MRPL55 ^ Mitochondrial ribosomal protein L55 ^  0.75 
AGI_HUM1_OLIGO_A_23_P257296 TFF3 ^ Trefoil factor 3 (intestinal) ^  0.51 
AGI_HUM1_OLIGO_A_24_P339611 PDCD5 ^ Programmed cell death 5 ^  0.78 
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AGI_HUM1_OLIGO_A_23_P48771 C14orf159 ^ Chromosome 14 open reading frame 159 ^  0.59 
AGI_HUM1_OLIGO_A_23_P92490 
DHRS6 ^ Dehydrogenase/reductase (SDR family) 
member 6 ^  0.42 
AGI_HUM1_OLIGO_A_24_P400355 C7orf20 ^ Chromosome 7 open reading frame 20 ^  0.72 
AGI_HUM1_OLIGO_A_32_P183356 Uncharacterized gene 0.48 
AGI_HUM1_OLIGO_A_23_P393425 PAPD4 ^ PAP associated domain containing 4 ^  0.74 
AGI_HUM1_OLIGO_A_24_P104174 TAOK3 ^ TAO kinase 3 ^  0.56 
AGI_HUM1_OLIGO_A_23_P20814 DDX58 ^ DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 ^  0.43 
AGI_HUM1_OLIGO_A_23_P102364 NGEF ^ Neuronal guanine nucleotide exchange factor ^  0.54 
AGI_HUM1_OLIGO_A_24_P302172 PTGFR ^ Prostaglandin F receptor (FP) ^  0.20 
AGI_HUM1_OLIGO_A_23_P46507 CGI-143 ^ CGI-143 protein ^  0.48 
AGI_HUM1_OLIGO_A_32_P233314 EXOC8 ^ Exocyst complex component 8 ^  0.61 
AGI_HUM1_OLIGO_A_23_P410017 MGC10233 ^ Hypothetical protein MGC10233 ^  0.53 
AGI_HUM1_OLIGO_A_32_P351277 ^ LOC440330 ^  0.34 
AGI_HUM1_OLIGO_A_32_P232035 Uncharacterized gene 0.85 
AGI_HUM1_OLIGO_A_24_P382253 P15RS ^ Hypothetical protein FLJ10656 ^  0.64 
AGI_HUM1_OLIGO_A_24_P8220 HS6ST1 ^ Heparan sulfate 6-O-sulfotransferase 1 ^  0.70 
AGI_HUM1_OLIGO_A_24_P149124 C5orf13 ^ Chromosome 5 open reading frame 13 ^  0.71 
AGI_HUM1_OLIGO_A_23_P81770 
PTP4A1 ^ Protein tyrosine phosphatase type IVA, 
member 1 ^  0.48 
AGI_HUM1_OLIGO_A_23_P148345 RNF128 ^ Ring finger protein 128 ^  0.35 
AGI_HUM1_OLIGO_A_23_P112481 AQP3 ^ Aquaporin 3 ^  0.39 
AGI_HUM1_OLIGO_A_23_P141484 FLJ10700 ^ Hypothetical protein FLJ10700 ^  0.64 
AGI_HUM1_OLIGO_A_23_P145408 FUCA2 ^ Fucosidase, alpha-L- 2, plasma ^  0.09 
AGI_HUM1_OLIGO_A_23_P77731 CRYM ^ Crystallin, mu ^  0.48 
AGI_HUM1_OLIGO_A_23_P391506 IVNS1ABP ^ Influenza virus NS1A binding protein ^  0.46 
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AGI_HUM1_OLIGO_A_23_P501435 CSRP2BP ^ CSRP2 binding protein ^  0.63 
AGI_HUM1_OLIGO_A_23_P19482 DDAH2 ^ Dimethylarginine dimethylaminohydrolase 2 ^  0.57 
AGI_HUM1_OLIGO_A_23_P142075 ACP5 ^ Acid phosphatase 5, tartrate resistant ^  0.18 
AGI_HUM1_OLIGO_A_24_P366495 Uncharacterized gene 0.69 
AGI_HUM1_OLIGO_A_24_P928765 Uncharacterized gene 0.49 
AGI_HUM1_OLIGO_A_23_P432448 MGC3771 ^ Hypothetical protein MGC3771 ^  0.47 
AGI_HUM1_OLIGO_A_23_P97328 C1orf35 ^ Chromosome 1 open reading frame 35 ^  0.51 
AGI_HUM1_OLIGO_A_23_P89249 
ERBB2 ^ V-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2, neuro/glioblastoma derived oncogene 
homolog (avian) ^  0.75 
AGI_HUM1_OLIGO_A_23_P146354 POMT1 ^ Protein-O-mannosyltransferase 1 ^  0.86 
AGI_HUM1_OLIGO_A_32_P171061 ASCL2 ^ Achaete-scute complex-like 2 (Drosophila) ^  0.25 
AGI_HUM1_OLIGO_A_23_P356554 BAG2 ^ BCL2-associated athanogene 2 ^  0.29 
AGI_HUM1_OLIGO_A_23_P87591 YEATS4 ^ YEATS domain containing 4 ^  0.73 
AGI_HUM1_OLIGO_A_32_P166921 TK2 ^ Thymidine kinase 2, mitochondrial ^  0.55 
AGI_HUM1_OLIGO_A_32_P119830 PEG3 ^ Paternally expressed 3 ^  0.16 
AGI_HUM1_OLIGO_A_23_P200930 
MTR ^ 5-methyltetrahydrofolate-homocysteine 
methyltransferase ^  0.61 
AGI_HUM1_OLIGO_A_23_P385217 ARL10C ^ ADP-ribosylation factor-like 10C ^  0.81 
AGI_HUM1_OLIGO_A_23_P416305 Uncharacterized gene 0.53 
AGI_HUM1_OLIGO_A_23_P82674 GBAS ^ Glioblastoma amplified sequence ^  0.83 
AGI_HUM1_OLIGO_A_23_P62764 MGC1203 ^ Hypothetical protein MGC1203 ^  0.54 
AGI_HUM1_OLIGO_A_24_P233995 FLJ22390 ^ Hypothetical protein FLJ22390 ^  0.82 
AGI_HUM1_OLIGO_A_23_P139575 DKFZp564J157 ^ DKFZp564J157 protein ^  0.74 
AGI_HUM1_OLIGO_A_23_P126129 C1orf25 ^ Chromosome 1 open reading frame 25 ^  0.61 
AGI_HUM1_OLIGO_A_23_P15937 
SMAD2 ^ SMAD, mothers against DPP homolog 2 
(Drosophila) ^  0.75 
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AGI_HUM1_OLIGO_A_32_P20221 
SMARCE1 ^ SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily e, member 1 
^  0.52 
AGI_HUM1_OLIGO_A_24_P867201 ^ Homo sapiens, clone IMAGE:5277945, mRNA ^  0.35 
AGI_HUM1_OLIGO_A_23_P56978 PTK6 ^ PTK6 protein tyrosine kinase 6 ^  0.31 
AGI_HUM1_OLIGO_A_23_P153958 Uncharacterized gene 0.59 
AGI_HUM1_OLIGO_A_23_P84475 Uncharacterized gene 0.64 
AGI_HUM1_OLIGO_A_24_P184230 
AASDHPPT ^ Aminoadipate-semialdehyde 
dehydrogenase-phosphopantetheinyl transferase ^  0.49 
AGI_HUM1_OLIGO_A_23_P350059 ^ Similar to KIAA0454 protein ^  0.87 
AGI_HUM1_OLIGO_A_23_P32861 CGI-07 ^ CGI-07 protein ^  0.49 
AGI_HUM1_OLIGO_A_23_P376449 Uncharacterized gene 0.68 
AGI_HUM1_OLIGO_A_24_P418250 Uncharacterized gene 0.62 
AGI_HUM1_OLIGO_A_23_P170058 
PSMB2 ^ Proteasome (prosome, macropain) subunit, 
beta type, 2 ^  0.73 
AGI_HUM1_OLIGO_A_23_P134854 CLDN23 ^ Claudin 23 ^  0.63 
AGI_HUM1_OLIGO_A_23_P89755 RNF138 ^ Ring finger protein 138 ^  0.73 
AGI_HUM1_OLIGO_A_23_P202532 DKFZP566K0524 ^ DKFZP566K0524 protein ^  0.08 
AGI_HUM1_OLIGO_A_23_P73208 MGC29891 ^ Hypothetical protein MGC29891 ^  0.44 
AGI_HUM1_OLIGO_A_23_P18304 
UBE1DC1 ^ Ubiquitin-activating enzyme E1-domain 
containing 1 ^  0.73 
AGI_HUM1_OLIGO_A_23_P361584 FLJ32028 ^ Hypothetical protein FLJ32028 ^  0.46 
AGI_HUM1_OLIGO_A_32_P211752 Uncharacterized gene 0.65 
AGI_HUM1_OLIGO_A_24_P28622 LOC90806 ^ Similar to RIKEN cDNA 2610307I21 ^  0.62 
AGI_HUM1_OLIGO_A_23_P217938 SPHAR ^ S-phase response (cyclin-related) ^  0.52 
AGI_HUM1_OLIGO_A_32_P3214 Uncharacterized gene 0.41 
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AGI_HUM1_OLIGO_A_23_P43484 
CDKN2A ^ Cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) ^  0.41 
AGI_HUM1_OLIGO_A_23_P12503 NUP133 ^ Nucleoporin 133kDa ^  0.58 
AGI_HUM1_OLIGO_A_23_P11674 PTGFR ^ Prostaglandin F receptor (FP) ^  0.18 
AGI_HUM1_OLIGO_A_23_P11295 MTCP1 ^ Mature T-cell proliferation 1 ^  0.70 
AGI_HUM1_OLIGO_A_32_P16451 SARA1 ^ SAR1a gene homolog 1 (S. cerevisiae) ^  0.49 
AGI_HUM1_OLIGO_A_23_P5742 FLJ13646 ^ Hypothetical protein FLJ13646 ^  0.86 
AGI_HUM1_OLIGO_A_23_P208880 
UHRF1 ^ Ubiquitin-like, containing PHD and RING finger 
domains, 1 ^  0.35 
AGI_HUM1_OLIGO_A_23_P158725 
SLC16A3 ^ Solute carrier family 16 (monocarboxylic acid 
transporters), member 3 ^  0.22 
AGI_HUM1_OLIGO_A_23_P23815 
SLC30A1 ^ Solute carrier family 30 (zinc transporter), 
member 1 ^  0.62 
AGI_HUM1_OLIGO_A_23_P133585 
CDK7 ^ Cyclin-dependent kinase 7 (MO15 homolog, 
Xenopus laevis, cdk-activating kinase) ^  0.71 
AGI_HUM1_OLIGO_A_23_P91487 C21orf6 ^ Chromosome 21 open reading frame 6 ^  0.59 
AGI_HUM1_OLIGO_A_23_P167212 QDPR ^ Quinoid dihydropteridine reductase ^  0.82 
AGI_HUM1_OLIGO_A_23_P59045 HIST1H2AE ^ Histone 1, H2ae ^  0.75 
AGI_HUM1_OLIGO_A_24_P355816 FLJ11259 ^ Hypothetical protein FLJ11259 ^  0.55 
AGI_HUM1_OLIGO_A_23_P23074 IFI44 ^ Interferon-induced protein 44 ^  0.28 
AGI_HUM1_OLIGO_A_23_P32165 LHX2 ^ LIM homeobox 2 ^  0.49 
AGI_HUM1_OLIGO_A_24_P59099 Uncharacterized gene 0.72 
AGI_HUM1_OLIGO_A_24_P364335 OCIL ^ Lectin-like NK cell receptor ^  0.78 
AGI_HUM1_OLIGO_A_23_P111171 
B3GALT4 ^ UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 4 ^  0.53 
AGI_HUM1_OLIGO_A_24_P230037 ^ CDNA clone IMAGE:3625232, partial cds ^  0.61 
AGI_HUM1_OLIGO_A_23_P123039 NUPL2 ^ Nucleoporin like 2 ^  0.65 
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AGI_HUM1_OLIGO_A_23_P500421 EYA2 ^ Eyes absent homolog 2 (Drosophila) ^  0.12 
AGI_HUM1_OLIGO_A_32_P199429 Uncharacterized gene 0.51 
AGI_HUM1_OLIGO_A_23_P119562 DF ^ D component of complement (adipsin) ^  0.29 
AGI_HUM1_OLIGO_A_32_P11786 SFRS6 ^ Splicing factor, arginine/serine-rich 6 ^  0.41 
AGI_HUM1_OLIGO_A_24_P175989 VPS29 ^ Vacuolar protein sorting 29 (yeast) ^  0.82 
AGI_HUM1_OLIGO_A_23_P102202 MSH6 ^ MutS homolog 6 (E. coli) ^  0.75 
AGI_HUM1_OLIGO_A_23_P399201 TMSL3 ^ Thymosin-like 3 ^  0.19 
AGI_HUM1_OLIGO_A_23_P103486 
CYP2J2 ^ Cytochrome P450, family 2, subfamily J, 
polypeptide 2 ^  0.62 
AGI_HUM1_OLIGO_A_23_P25030 RODH ^ 3-hydroxysteroid epimerase ^  0.34 
AGI_HUM1_OLIGO_A_32_P132827 Uncharacterized gene 0.71 
AGI_HUM1_OLIGO_A_23_P23266 Uncharacterized gene 0.66 
AGI_HUM1_OLIGO_A_23_P98092 OAT ^ Ornithine aminotransferase (gyrate atrophy) ^  0.55 
AGI_HUM1_OLIGO_A_24_P234094 RAB7L1 ^ RAB7, member RAS oncogene family-like 1 ^  0.48 
AGI_HUM1_OLIGO_A_24_P229756 Uncharacterized gene 0.76 
AGI_HUM1_OLIGO_A_23_P19455 MDC1 ^ Mediator of DNA damage checkpoint 1 ^  0.65 
AGI_HUM1_OLIGO_A_23_P35114 CKIP-1 ^ CK2 interacting protein 1; HQ0024c protein ^  0.73 
AGI_HUM1_OLIGO_A_23_P310068 Uncharacterized gene 0.47 
AGI_HUM1_OLIGO_A_23_P106481 LOC51234 ^ Hypothetical protein LOC51234 ^  0.75 
AGI_HUM1_OLIGO_A_24_P923142 
MGC14289 ^ Similar to RIKEN cDNA 1200014N16 gene 
^  0.35 
AGI_HUM1_OLIGO_A_32_P5205 Uncharacterized gene 0.54 
AGI_HUM1_OLIGO_A_23_P252371 RBBP8 ^ Retinoblastoma binding protein 8 ^  0.70 
AGI_HUM1_OLIGO_A_23_P121898 
PARP8 ^ Poly (ADP-ribose) polymerase family, member 
8 ^  0.56 
AGI_HUM1_OLIGO_A_24_P89509 Uncharacterized gene 0.73 
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AGI_HUM1_OLIGO_A_23_P15305 
PRPSAP1 ^ Phosphoribosyl pyrophosphate synthetase-
associated protein 1 ^  0.76 
AGI_HUM1_OLIGO_A_23_P60816 PDCD6IP ^ Programmed cell death 6 interacting protein ^  0.68 
AGI_HUM1_OLIGO_A_23_P200710 
PIK3C2B ^ Phosphoinositide-3-kinase, class 2, beta 
polypeptide ^  0.84 
AGI_HUM1_OLIGO_A_32_P228124 Uncharacterized gene 0.48 
AGI_HUM1_OLIGO_A_23_P383986 GALNAC4S-6ST ^ B cell RAG associated protein ^  0.41 
AGI_HUM1_OLIGO_A_23_P166280 Uncharacterized gene 0.50 
AGI_HUM1_OLIGO_A_23_P323685 HIST1H4H ^ Histone 1, H4h ^  0.66 
AGI_HUM1_OLIGO_A_23_P8452 Uncharacterized gene 0.28 
AGI_HUM1_OLIGO_A_24_P935986 BCAT1 ^ Branched chain aminotransferase 1, cytosolic ^  0.59 
AGI_HUM1_OLIGO_A_23_P216282 
ARHGEF10 ^ Rho guanine nucleotide exchange factor 
(GEF) 10 ^  0.69 
AGI_HUM1_OLIGO_A_24_P816844 Uncharacterized gene 0.49 
AGI_HUM1_OLIGO_A_24_P320221 FLJ12716 ^ FLJ12716 protein ^  0.64 
AGI_HUM1_OLIGO_A_24_P228796 GAGE2 ^ G antigen 7 ^  0.42 
AGI_HUM1_OLIGO_A_23_P29994 
RBPSUH ^ Recombining binding protein suppressor of 
hairless (Drosophila) ^  0.82 
AGI_HUM1_OLIGO_A_24_P165082 ZNF222 ^ Zinc finger protein 222 ^  0.69 
AGI_HUM1_OLIGO_A_23_P203030 
DLAT ^ Dihydrolipoamide S-acetyltransferase (E2 
component of pyruvate dehydrogenase complex) ^  0.54 
AGI_HUM1_OLIGO_A_32_P223256 Uncharacterized gene 0.72 
AGI_HUM1_OLIGO_A_23_P166248 DSCR1 ^ Down syndrome critical region gene 1 ^  0.51 
AGI_HUM1_OLIGO_A_23_P5912 YTHDF1 ^ YTH domain family, member 1 ^  0.73 
AGI_HUM1_OLIGO_A_23_P134113 C6orf192 ^ Chromosome 6 open reading frame 192 ^  0.48 
AGI_HUM1_OLIGO_A_23_P37244 
SNAPC1 ^ Small nuclear RNA activating complex, 
polypeptide 1, 43kDa ^  0.72 
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AGI_HUM1_OLIGO_A_23_P99253 LIN7A ^ Lin-7 homolog A (C. elegans) ^  0.50 
AGI_HUM1_OLIGO_A_23_P87049 
SORL1 ^ Sortilin-related receptor, L(DLR class) A 
repeats-containing ^  0.57 
AGI_HUM1_OLIGO_A_24_P229616 Uncharacterized gene 0.62 
AGI_HUM1_OLIGO_A_32_P182473 ZNF625 ^ Zinc finger protein 625 ^  0.66 
AGI_HUM1_OLIGO_A_24_P147263 USP31 ^ Ubiquitin specific protease 31 ^  0.60 
AGI_HUM1_OLIGO_A_24_P498854 LOC284998 ^ Hypothetical protein LOC284998 ^  0.62 
AGI_HUM1_OLIGO_A_24_P236799 RAB31 ^ RAB31, member RAS oncogene family ^  0.38 
AGI_HUM1_OLIGO_A_24_P924484 Uncharacterized gene 0.59 
AGI_HUM1_OLIGO_A_23_P319859 EYA2 ^ Eyes absent homolog 2 (Drosophila) ^  0.20 
AGI_HUM1_OLIGO_A_24_P90022 Uncharacterized gene 0.69 
AGI_HUM1_OLIGO_A_23_P27265 C18orf4 ^ Chromosome 18 open reading frame 4 ^  0.33 
AGI_HUM1_OLIGO_A_23_P52806 BACE1 ^ Beta-site APP-cleaving enzyme 1 ^  0.55 
AGI_HUM1_OLIGO_A_23_P357811 MBNL1 ^ Muscleblind-like (Drosophila) ^  0.65 
AGI_HUM1_OLIGO_A_32_P224911 TATDN1 ^ TatD DNase domain containing 1 ^  0.69 
AGI_HUM1_OLIGO_A_23_P11652 USP1 ^ Ubiquitin specific protease 1 ^  0.92 
AGI_HUM1_OLIGO_A_23_P131394 
SLC16A14 ^ Solute carrier family 16 (monocarboxylic 
acid transporters), member 14 ^  0.28 
AGI_HUM1_OLIGO_A_23_P717 FLJ10874 ^ Hypothetical protein FLJ10874 ^  0.58 
AGI_HUM1_OLIGO_A_23_P45934 SRP9 ^ Signal recognition particle 9kDa ^  0.62 
AGI_HUM1_OLIGO_A_23_P155316 NCBP2 ^ Nuclear cap binding protein subunit 2, 20kDa ^  0.85 
AGI_HUM1_OLIGO_A_23_P134147 ZBTB24 ^ Zinc finger and BTB domain containing 24 ^  0.70 
AGI_HUM1_OLIGO_A_24_P62530 RHOU ^ Ras homolog gene family, member U ^  0.69 
AGI_HUM1_OLIGO_A_24_P106591 TXNDC5 ^ Thioredoxin domain containing 5 ^  0.47 
AGI_HUM1_OLIGO_A_23_P166087 
RASSF2 ^ Ras association (RalGDS/AF-6) domain family 
2 ^  0.69 
  
141
Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_32_P99100 
PTPRK ^ Protein tyrosine phosphatase, receptor type, K 
^  0.50 
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Table 5.3.  The list of the genes that are significantly up regulated in FL-Y267F-AR compared to vector control. 
Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P111506 Uncharacterized gene 1.49 
AGI_HUM1_OLIGO_A_23_P304530 LCE5A ^ Late cornified envelope 5A ^  1.49 
AGI_HUM1_OLIGO_A_24_P508410 LOC388524 ^ Similar to Laminin receptor 1 ^  1.72 
AGI_HUM1_OLIGO_A_23_P125519 RPS4X ^ Ribosomal protein S4, X-linked ^  1.10 
AGI_HUM1_OLIGO_A_23_P115118 BMP8A ^ Bone morphogenetic protein 8a ^  1.39 
AGI_HUM1_OLIGO_A_32_P90455 Uncharacterized gene 1.34 
AGI_HUM1_OLIGO_A_32_P112100 Uncharacterized gene 1.48 
AGI_HUM1_OLIGO_A_23_P130194 PYCR1 ^ Pyrroline-5-carboxylate reductase 1 ^  1.30 
AGI_HUM1_OLIGO_A_23_P431853 Uncharacterized gene 2.23 
AGI_HUM1_OLIGO_A_24_P279060 
HCN4 ^ Hyperpolarization activated cyclic nucleotide-gated 
potassium channel 4 ^  1.34 
AGI_HUM1_OLIGO_A_24_P203909 RPL34 ^ Ribosomal protein L34 ^  1.10 
AGI_HUM1_OLIGO_A_32_P435367 
PSMD4 ^ Proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 4 ^  1.32 
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Table 5.4.  The list of the genes that are significantly up regulated in TR-WT-AR compared to vector control. 
Agilent Gene_ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_24_P221057 Uncharacterized gene 1.40 
AGI_HUM1_OLIGO_A_23_P76823 ADSSL1 ^ Adenylosuccinate synthase like 1 ^  1.73 
AGI_HUM1_OLIGO_A_23_P372234 CA12 ^ Carbonic anhydrase XII ^  3.01 
AGI_HUM1_OLIGO_A_23_P374389 PWWP2 ^ PWWP domain containing 2 ^  1.17 
AGI_HUM1_OLIGO_A_23_P159544 ASMTL ^ Acetylserotonin O-methyltransferase-like ^  1.92 
AGI_HUM1_OLIGO_A_24_P926820 Uncharacterized gene 1.62 
AGI_HUM1_OLIGO_A_23_P138899 COPB ^ Coatomer protein complex, subunit beta ^  1.46 
AGI_HUM1_OLIGO_A_24_P58477 Uncharacterized gene 1.42 
AGI_HUM1_OLIGO_A_23_P37983 MT1B ^ Metallothionein 1B (functional) ^  2.26 
AGI_HUM1_OLIGO_A_32_P150856 Uncharacterized gene 1.46 
AGI_HUM1_OLIGO_A_23_P373819 TUSC1 ^ Tumor suppressor candidate 1 ^  2.00 
AGI_HUM1_OLIGO_A_32_P21384 RPL17 ^ Ribosomal protein L17 ^  1.30 
AGI_HUM1_OLIGO_A_23_P56069 C19orf13 ^ Chromosome 19 open reading frame 13 ^  1.38 
AGI_HUM1_OLIGO_A_23_P138706 ADRA2A ^ Adrenergic, alpha-2A-, receptor ^  2.81 
AGI_HUM1_OLIGO_A_23_P11800 
CaMKIINalpha ^ Calcium/calmodulin-dependent protein 
kinase II ^  4.36 
AGI_HUM1_OLIGO_A_23_P104624 Uncharacterized gene 1.96 
AGI_HUM1_OLIGO_A_23_P255663 MANEA ^ Mannosidase, endo-alpha ^  2.74 
AGI_HUM1_OLIGO_A_24_P260101 
MME ^ Membrane metallo-endopeptidase (neutral 
endopeptidase, enkephalinase, CALLA, CD10) ^  3.16 
AGI_HUM1_OLIGO_A_24_P827738 Uncharacterized gene 1.63 
AGI_HUM1_OLIGO_A_24_P398319 C11orf15 ^ Chromosome 11 open reading frame 15 ^  1.39 
AGI_HUM1_OLIGO_A_23_P252306 
ID1 ^ Inhibitor of DNA binding 1, dominant negative helix-
loop-helix protein ^  2.85 
AGI_HUM1_OLIGO_A_24_P332953 Uncharacterized gene 3.53 
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AGI_HUM1_OLIGO_A_23_P143676 Uncharacterized gene 1.46 
AGI_HUM1_OLIGO_A_24_P263672 
LOC96610 ^ Hypothetical protein similar to KIAA0187 
gene product ^  1.57 
AGI_HUM1_OLIGO_A_23_P414343 MT1H ^ Metallothionein 1H ^  2.12 
AGI_HUM1_OLIGO_A_23_P252413 Uncharacterized gene 2.01 
AGI_HUM1_OLIGO_A_23_P121869 Uncharacterized gene 1.67 
AGI_HUM1_OLIGO_A_23_P81859 HIST1H2AH ^ Histone 1, H2ah ^  2.60 
AGI_HUM1_OLIGO_A_24_P361896 MT2A ^ Metallothionein 2A ^  2.13 
AGI_HUM1_OLIGO_A_32_P164215 Uncharacterized gene 1.80 
AGI_HUM1_OLIGO_A_24_P135322 NRP1 ^ Neuropilin 1 ^  1.63 
AGI_HUM1_OLIGO_A_23_P372516 
TCF8 ^ Transcription factor 8 (represses interleukin 2 
expression) ^  1.09 
AGI_HUM1_OLIGO_A_23_P33809 C15orf12 ^ Chromosome 15 open reading frame 12 ^  1.21 
AGI_HUM1_OLIGO_A_23_P39131 
GLTSCR2 ^ Glioma tumor suppressor candidate region 
gene 2 ^  1.29 
AGI_HUM1_OLIGO_A_24_P347624 SNRPN ^ SNRPN upstream reading frame ^  1.35 
AGI_HUM1_OLIGO_A_23_P42575 CALD1 ^ Caldesmon 1 ^  1.76 
AGI_HUM1_OLIGO_A_24_P573978 Uncharacterized gene 1.20 
AGI_HUM1_OLIGO_A_24_P201323 ZMYND11 ^ Zinc finger, MYND domain containing 11 ^  1.82 
AGI_HUM1_OLIGO_A_23_P354170 FLJ20522 ^ GPI-mannosyltransferase subunit ^  1.52 
AGI_HUM1_OLIGO_A_23_P163782 MT1H ^ Metallothionein 1H ^  2.12 
AGI_HUM1_OLIGO_A_23_P153256 MGC4728 ^ Similar to hypothetical protein FLJ23233 ^  1.79 
AGI_HUM1_OLIGO_A_23_P168014 HIST1H2AJ ^ Histone 1, H2aj ^  1.60 
AGI_HUM1_OLIGO_A_24_P230176 LOC339229 ^ Hypothetical protein LOC339229 ^  1.69 
AGI_HUM1_OLIGO_A_24_P133475 
DHRS1 ^ Dehydrogenase/reductase (SDR family) 
member 1 ^  1.24 
AGI_HUM1_OLIGO_A_24_P145787 Uncharacterized gene 1.12 
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AGI_HUM1_OLIGO_A_24_P391368 ATXN10 ^ Ataxin 10 ^  1.29 
AGI_HUM1_OLIGO_A_24_P261724 RNF10 ^ Ring finger protein 10 ^  1.10 
AGI_HUM1_OLIGO_A_23_P34800 
NASP ^ Nuclear autoantigenic sperm protein (histone-
binding) ^  1.30 
AGI_HUM1_OLIGO_A_23_P96853 FAF1 ^ Fas (TNFRSF6) associated factor 1 ^  1.33 
AGI_HUM1_OLIGO_A_23_P70045 H2AFY ^ H2A histone family, member Y ^  1.77 
AGI_HUM1_OLIGO_A_24_P508410 LOC388524 ^ Similar to Laminin receptor 1 ^  1.85 
AGI_HUM1_OLIGO_A_32_P152986 Uncharacterized gene 1.61 
AGI_HUM1_OLIGO_A_23_P47614 
PHLDA2 ^ Pleckstrin homology-like domain, family A, 
member 2 ^  1.67 
AGI_HUM1_OLIGO_A_23_P57521 
EIF3S6IP ^ Eukaryotic translation initiation factor 3, 
subunit 6 interacting protein ^  1.54 
AGI_HUM1_OLIGO_A_23_P310274 PRSS2 ^ Protease, serine, 2 (trypsin 2) ^  6.48 
AGI_HUM1_OLIGO_A_23_P135437 SEC8L1 ^ SEC8-like 1 (S. cerevisiae) ^  1.40 
AGI_HUM1_OLIGO_A_24_P161086 
NFKBIB ^ Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, beta ^  1.74 
AGI_HUM1_OLIGO_A_23_P27306 COLEC12 ^ Collectin sub-family member 12 ^  1.75 
AGI_HUM1_OLIGO_A_23_P17786 PITPNB ^ Phosphatidylinositol transfer protein, beta ^  1.55 
AGI_HUM1_OLIGO_A_24_P363615 MTPN ^ Myotrophin ^  1.96 
AGI_HUM1_OLIGO_A_24_P84408 Uncharacterized gene 1.24 
AGI_HUM1_OLIGO_A_23_P322845 HTPAP ^ HTPAP protein ^  1.57 
AGI_HUM1_OLIGO_A_24_P125096 MT1X ^ Metallothionein 1X ^  2.11 
AGI_HUM1_OLIGO_A_32_P181222 
KCNMA1 ^ Potassium large conductance calcium-
activated channel, subfamily M, alpha member 1 ^  2.96 
AGI_HUM1_OLIGO_A_24_P551302 RARA ^ Retinoic acid receptor, alpha ^  1.36 
AGI_HUM1_OLIGO_A_24_P341408 Uncharacterized gene 1.21 
AGI_HUM1_OLIGO_A_32_P135385 Uncharacterized gene 1.30 
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AGI_HUM1_OLIGO_A_24_P48057 IRX5 ^ Iroquois homeobox protein 5 ^  1.86 
AGI_HUM1_OLIGO_A_24_P86389 HIST1H2AM ^ Histone 1, H2am ^  1.85 
AGI_HUM1_OLIGO_A_24_P918808 OAZ1 ^ Ornithine decarboxylase antizyme 1 ^  1.98 
AGI_HUM1_OLIGO_A_32_P227845 
^ CDNA clone IMAGE:3346533, containing frame-shift 
errors ^  1.24 
AGI_HUM1_OLIGO_A_23_P54840 MT1A ^ Metallothionein 1A (functional) ^  1.91 
AGI_HUM1_OLIGO_A_32_P191290 ^ Transcribed locus ^  1.53 
AGI_HUM1_OLIGO_A_24_P345081 AE2 ^ Hypothetical protein AE2 ^  1.57 
AGI_HUM1_OLIGO_A_23_P60286 EIF4B ^ Eukaryotic translation initiation factor 4B ^  1.25 
AGI_HUM1_OLIGO_A_23_P115460 RPL22 ^ Ribosomal protein L22 ^  1.17 
AGI_HUM1_OLIGO_A_23_P23194 PINK1 ^ PTEN induced putative kinase 1 ^  1.75 
AGI_HUM1_OLIGO_A_24_P353289 C22orf13 ^ Chromosome 22 open reading frame 13 ^  1.32 
AGI_HUM1_OLIGO_A_23_P55716 
LU ^ Lutheran blood group (Auberger b antigen included) 
^  1.43 
AGI_HUM1_OLIGO_A_24_P285880 TLOC1 ^ Translocation protein 1 ^  1.39 
AGI_HUM1_OLIGO_A_23_P48570 
DHRS2 ^ Dehydrogenase/reductase (SDR family) 
member 2 ^  3.34 
AGI_HUM1_OLIGO_A_23_P15174 MT1F ^ Metallothionein 1F (functional) ^  2.15 
AGI_HUM1_OLIGO_A_23_P250035 
SDHA ^ Succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) ^  1.27 
AGI_HUM1_OLIGO_A_23_P56810 
SLC4A1AP ^ Solute carrier family 4 (anion exchanger), 
member 1, adaptor protein ^  1.32 
AGI_HUM1_OLIGO_A_32_P194072 DKFZP434B0335 ^ DKFZP434B0335 protein ^  1.74 
AGI_HUM1_OLIGO_A_24_P753476 Uncharacterized gene 1.55 
AGI_HUM1_OLIGO_A_23_P61881 ARIH2 ^ Ariadne homolog 2 (Drosophila) ^  1.45 
AGI_HUM1_OLIGO_A_23_P106016 PRKD1 ^ Protein kinase D1 ^  1.43 
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AGI_HUM1_OLIGO_A_32_P67259 
SDHA ^ Succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) ^  1.24 
AGI_HUM1_OLIGO_A_23_P16110 Uncharacterized gene 1.38 
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Table 5.5.  The list of the genes that are significantly down regulated in TR-WT-AR compared to vector control. 
Agilent Gene ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P103698 
MAPBPIP ^ Mitogen-activated protein-binding protein-
interacting protein ^  0.59 
AGI_HUM1_OLIGO_A_32_P146635 SESN3 ^ Sestrin 3 ^  0.39 
AGI_HUM1_OLIGO_A_32_P119830 PEG3 ^ Paternally expressed 3 ^  0.21 
AGI_HUM1_OLIGO_A_23_P200386 
KHDRBS1 ^ KH domain containing, RNA binding, signal 
transduction associated 1 ^  0.75 
AGI_HUM1_OLIGO_A_23_P4821 JUNB ^ Jun B proto-oncogene ^  0.76 
AGI_HUM1_OLIGO_A_24_P364335 OCIL ^ Lectin-like NK cell receptor ^  0.83 
AGI_HUM1_OLIGO_A_23_P337168 FLJ30596 ^ Hypothetical protein FLJ30596 ^  0.48 
AGI_HUM1_OLIGO_A_23_P114783 
PARP1 ^ Poly (ADP-ribose) polymerase family, member 
1 ^  0.51 
AGI_HUM1_OLIGO_A_23_P141362 FZD2 ^ Frizzled homolog 2 (Drosophila) ^  0.22 
AGI_HUM1_OLIGO_A_23_P214046 FBXW11 ^ F-box and WD-40 domain protein 11 ^  0.38 
AGI_HUM1_OLIGO_A_23_P73589 MSN ^ Moesin ^  0.53 
AGI_HUM1_OLIGO_A_32_P33576 OPRK1 ^ Opioid receptor, kappa 1 ^  0.22 
AGI_HUM1_OLIGO_A_23_P34375 TCEA3 ^ Transcription elongation factor A (SII), 3 ^  0.17 
AGI_HUM1_OLIGO_A_24_P302172 PTGFR ^ Prostaglandin F receptor (FP) ^  0.11 
AGI_HUM1_OLIGO_A_23_P66777 CDC27 ^ Cell division cycle 27 ^  0.46 
AGI_HUM1_OLIGO_A_23_P52189 GGPS1 ^ Geranylgeranyl diphosphate synthase 1 ^  0.61 
AGI_HUM1_OLIGO_A_23_P254271 TUBB6 ^ Tubulin, beta 6 ^  0.07 
AGI_HUM1_OLIGO_A_24_P186944 Uncharacterized gene 0.67 
AGI_HUM1_OLIGO_A_24_P521994 DRE1 ^ DRE1 protein ^  0.45 
AGI_HUM1_OLIGO_A_24_P255516 UNQ6077 ^ Similar to testis-specific protein NYD-TSP1 ^  0.56 
AGI_HUM1_OLIGO_A_23_P309361 FLJ30525 ^ Hypothetical protein FLJ30525 ^  0.02 
AGI_HUM1_OLIGO_A_24_P857404 LOC92312 ^ Hypothetical protein LOC92312 ^  0.47 
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AGI_HUM1_OLIGO_A_23_P42087 
BPHL ^ Biphenyl hydrolase-like (serine hydrolase; breast 
epithelial mucin-associated antigen) ^  0.57 
AGI_HUM1_OLIGO_A_32_P166921 TK2 ^ Thymidine kinase 2, mitochondrial ^  0.65 
AGI_HUM1_OLIGO_A_23_P143147 
TCFL5 ^ Transcription factor-like 5 (basic helix-loop-
helix) ^  0.61 
AGI_HUM1_OLIGO_A_24_P839239 Uncharacterized gene 0.43 
AGI_HUM1_OLIGO_A_23_P76538 TSC ^ Hypothetical protein FLJ20607 ^  0.36 
AGI_HUM1_OLIGO_A_23_P212968 
UGT2B11 ^ UDP glycosyltransferase 2 family, 
polypeptide B11 ^  0.64 
AGI_HUM1_OLIGO_A_24_P62530 RHOU ^ Ras homolog gene family, member U ^  0.74 
AGI_HUM1_OLIGO_A_23_P160406 
KCTD3 ^ Potassium channel tetramerisation domain 
containing 3 ^  0.65 
AGI_HUM1_OLIGO_A_23_P25684 RDH11 ^ DKFZP564M1462 protein ^  0.59 
AGI_HUM1_OLIGO_A_24_P365571 MRPS6 ^ Mitochondrial ribosomal protein S6 ^  0.50 
AGI_HUM1_OLIGO_A_23_P208706 BAX ^ BCL2-associated X protein ^  0.58 
AGI_HUM1_OLIGO_A_23_P116235 Uncharacterized gene 0.12 
AGI_HUM1_OLIGO_A_23_P160546 FLJ11280 ^ Hypothetical protein FLJ11280 ^  0.24 
AGI_HUM1_OLIGO_A_23_P412577 ANKRD29 ^ Ankyrin repeat domain 29 ^  0.19 
AGI_HUM1_OLIGO_A_23_P82206 
ECHDC1 ^ Enoyl Coenzyme A hydratase domain 
containing 1 ^  0.06 
AGI_HUM1_OLIGO_A_23_P85952 FLJ22457 ^ Hypothetical protein FLJ22457 ^  0.09 
AGI_HUM1_OLIGO_A_23_P68106 TMSB10 ^ Thymosin, beta 10 ^  0.37 
AGI_HUM1_OLIGO_A_24_P84428 CACYBP ^ Calcyclin binding protein ^  0.80 
AGI_HUM1_OLIGO_A_23_P11295 MTCP1 ^ Mature T-cell proliferation 1 ^  0.69 
AGI_HUM1_OLIGO_A_23_P137578 FBXO28 ^ F-box protein 28 ^  0.74 
AGI_HUM1_OLIGO_A_23_P46507 CGI-143 ^ CGI-143 protein ^  0.47 
AGI_HUM1_OLIGO_A_23_P44291 CRTAP ^ Cartilage associated protein ^  0.65 
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AGI_HUM1_OLIGO_A_24_P405205 
ATP2B4 ^ ATPase, Ca++ transporting, plasma 
membrane 4 ^  0.33 
AGI_HUM1_OLIGO_A_24_P413126 
TMEPAI ^ Transmembrane, prostate androgen induced 
RNA ^  0.72 
AGI_HUM1_OLIGO_A_23_P131394 
SLC16A14 ^ Solute carrier family 16 (monocarboxylic 
acid transporters), member 14 ^  0.29 
AGI_HUM1_OLIGO_A_23_P88484 DUT ^ DUTP pyrophosphatase ^  0.85 
AGI_HUM1_OLIGO_A_23_P43946 CIP29 ^ Cytokine induced protein 29 kDa ^  0.65 
AGI_HUM1_OLIGO_A_23_P18518 
TRAM1L1 ^ Translocation associated membrane protein 
1-like 1 ^  0.43 
AGI_HUM1_OLIGO_A_23_P374844 GAL ^ Galanin ^  0.44 
AGI_HUM1_OLIGO_A_23_P83438 FLJ13855 ^ Hypothetical protein FLJ13855 ^  0.59 
AGI_HUM1_OLIGO_A_24_P384990 ^ Homo sapiens, clone IMAGE:4157625, mRNA ^  0.45 
AGI_HUM1_OLIGO_A_23_P39445 RKHD1 ^ Ring finger and KH domain containing 1 ^  0.25 
AGI_HUM1_OLIGO_A_23_P399201 TMSL3 ^ Thymosin-like 3 ^  0.17 
AGI_HUM1_OLIGO_A_24_P382017 
RRN3 ^ RRN3 RNA polymerase I transcription factor 
homolog (yeast) ^  0.59 
AGI_HUM1_OLIGO_A_23_P200507 HSPC163 ^ HSPC163 protein ^  0.58 
AGI_HUM1_OLIGO_A_23_P119562 DF ^ D component of complement (adipsin) ^  0.25 
AGI_HUM1_OLIGO_A_24_P849245 Uncharacterized gene 0.47 
AGI_HUM1_OLIGO_A_24_P366495 Uncharacterized gene 0.67 
AGI_HUM1_OLIGO_A_23_P103414 YTHDF2 ^ YTH domain family, member 2 ^  0.66 
AGI_HUM1_OLIGO_A_23_P112481 AQP3 ^ Aquaporin 3 ^  0.30 
AGI_HUM1_OLIGO_A_24_P703614 Uncharacterized gene 0.61 
AGI_HUM1_OLIGO_A_23_P59791 LUC7L2 ^ LUC7-like 2 (S. cerevisiae) ^  0.56 
AGI_HUM1_OLIGO_A_32_P171061 ASCL2 ^ Achaete-scute complex-like 2 (Drosophila) ^  0.16 
AGI_HUM1_OLIGO_A_23_P52082 DKFZP434B168 ^ DKFZP434B168 protein ^  0.65 
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AGI_HUM1_OLIGO_A_23_P21033 GMPS ^ Guanine monphosphate synthetase ^  0.85 
AGI_HUM1_OLIGO_A_23_P145408 FUCA2 ^ Fucosidase, alpha-L- 2, plasma ^  0.05 
AGI_HUM1_OLIGO_A_24_P4212 PYCRL ^ Pyrroline-5-carboxylate reductase-like ^  0.73 
AGI_HUM1_OLIGO_A_24_P374513 Uncharacterized gene 0.23 
AGI_HUM1_OLIGO_A_24_P304051 GSTO1 ^ Glutathione S-transferase omega 1 ^  0.75 
AGI_HUM1_OLIGO_A_23_P256735 PGCP ^ Plasma glutamate carboxypeptidase ^  0.33 
AGI_HUM1_OLIGO_A_23_P128991 C14orf156 ^ Chromosome 14 open reading frame 156 ^  0.73 
AGI_HUM1_OLIGO_A_23_P161190 VIM ^ Vimentin ^  0.11 
AGI_HUM1_OLIGO_A_23_P49546 
GRIN2C ^ Glutamate receptor, ionotropic, N-methyl D-
aspartate 2C ^  0.17 
AGI_HUM1_OLIGO_A_23_P52278 KIF11 ^ Kinesin family member 11 ^  0.61 
AGI_HUM1_OLIGO_A_24_P230009 Uncharacterized gene 0.67 
AGI_HUM1_OLIGO_A_23_P19389 
HMGN4 ^ High mobility group nucleosomal binding 
domain 4 ^  0.70 
AGI_HUM1_OLIGO_A_23_P24633 THY28 ^ Thymocyte protein thy28 ^  0.62 
AGI_HUM1_OLIGO_A_23_P202696 
KBTBD4 ^ Kelch repeat and BTB (POZ) domain 
containing 4 ^  0.72 
AGI_HUM1_OLIGO_A_23_P255952 MYO6 ^ Myosin VI ^  0.40 
AGI_HUM1_OLIGO_A_23_P85742 CREG1 ^ Cellular repressor of E1A-stimulated genes 1 ^  0.74 
AGI_HUM1_OLIGO_A_23_P132718 
SEMA3B ^ Sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3B ^  0.74 
AGI_HUM1_OLIGO_A_23_P356554 BAG2 ^ BCL2-associated athanogene 2 ^  0.23 
AGI_HUM1_OLIGO_A_24_P327886 TCEA3 ^ Transcription elongation factor A (SII), 3 ^  0.08 
AGI_HUM1_OLIGO_A_32_P26443 Uncharacterized gene 0.38 
AGI_HUM1_OLIGO_A_24_P83262 TM4SF6 ^ Transmembrane 4 superfamily member 6 ^  0.29 
AGI_HUM1_OLIGO_A_32_P22263 
HMGN1 ^ High-mobility group nucleosome binding 
domain 1 ^  0.67 
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AGI_HUM1_OLIGO_A_24_P245246 
PIP5K2B ^ Phosphatidylinositol-4-phosphate 5-kinase, 
type II, beta ^  0.78 
AGI_HUM1_OLIGO_A_32_P137632 FBXL17 ^ F-box and leucine-rich repeat protein 17 ^  0.35 
AGI_HUM1_OLIGO_A_23_P403335 SLAC2-B ^ SLAC2-B ^  0.32 
AGI_HUM1_OLIGO_A_23_P1594 VEGFB ^ Vascular endothelial growth factor B ^  0.60 
AGI_HUM1_OLIGO_A_24_P65597 RPS19 ^ Ribosomal protein S19 ^  0.47 
AGI_HUM1_OLIGO_A_23_P201400 PPOX ^ Protoporphyrinogen oxidase ^  0.70 
AGI_HUM1_OLIGO_A_24_P521559 
UGT2B10 ^ UDP glycosyltransferase 2 family, 
polypeptide B10 ^  0.62 
AGI_HUM1_OLIGO_A_23_P48585 SALL2 ^ Sal-like 2 (Drosophila) ^  0.31 
AGI_HUM1_OLIGO_A_24_P115621 Uncharacterized gene 0.60 
AGI_HUM1_OLIGO_A_32_P231617 TM4SF1 ^ Transmembrane 4 superfamily member 1 ^  0.43 
AGI_HUM1_OLIGO_A_23_P158725 
SLC16A3 ^ Solute carrier family 16 (monocarboxylic acid 
transporters), member 3 ^  0.24 
AGI_HUM1_OLIGO_A_23_P202532 DKFZP566K0524 ^ DKFZP566K0524 protein ^  0.19 
AGI_HUM1_OLIGO_A_23_P251795 GPC2 ^ Glypican 2 (cerebroglycan) ^  0.56 
AGI_HUM1_OLIGO_A_23_P343382 Uncharacterized gene 0.21 
AGI_HUM1_OLIGO_A_23_P94118 
GTF2E2 ^ General transcription factor IIE, polypeptide 2, 
beta 34kDa ^  0.83 
AGI_HUM1_OLIGO_A_23_P377819 SFRS5 ^ Splicing factor, arginine/serine-rich 5 ^  0.84 
AGI_HUM1_OLIGO_A_24_P204971 HBP1 ^ HMG-box transcription factor 1 ^  0.64 
AGI_HUM1_OLIGO_A_23_P258048 
ZKSCAN1 ^ Zinc finger with KRAB and SCAN domains 1 
^  0.78 
AGI_HUM1_OLIGO_A_23_P211007 NRIP1 ^ Nuclear receptor interacting protein 1 ^  0.49 
AGI_HUM1_OLIGO_A_32_P138004 
FAM45A ^ Family with sequence similarity 45, member A 
^  0.45 
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AGI_HUM1_OLIGO_A_23_P200930 
MTR ^ 5-methyltetrahydrofolate-homocysteine 
methyltransferase ^  0.57 
AGI_HUM1_OLIGO_A_32_P208424 H3F3A ^ H3 histone, family 3A ^  0.52 
AGI_HUM1_OLIGO_A_23_P70371 PHF3 ^ PHD finger protein 3 ^  0.53 
AGI_HUM1_OLIGO_A_23_P6963 
UBE2E1 ^ Ubiquitin-conjugating enzyme E2E 1 (UBC4/5 
homolog, yeast) ^  0.24 
AGI_HUM1_OLIGO_A_23_P171143 TM4SF6 ^ Transmembrane 4 superfamily member 6 ^  0.30 
AGI_HUM1_OLIGO_A_23_P62764 MGC1203 ^ Hypothetical protein MGC1203 ^  0.52 
AGI_HUM1_OLIGO_A_23_P163858 ZNRF1 ^ Zinc and ring finger 1 ^  0.59 
AGI_HUM1_OLIGO_A_24_P358578 Uncharacterized gene 0.61 
AGI_HUM1_OLIGO_A_24_P54863 FLJ39370 ^ Hypothetical protein FLJ39370 ^  0.77 
AGI_HUM1_OLIGO_A_23_P67708 
TCF3 ^ Transcription factor 3 (E2A immunoglobulin 
enhancer binding factors E12/E47) ^  0.62 
AGI_HUM1_OLIGO_A_23_P97952 C10orf125 ^ Chromosome 10 open reading frame 125 ^  0.71 
AGI_HUM1_OLIGO_A_32_P5251 RARA ^ Retinoic acid receptor, alpha ^  0.62 
AGI_HUM1_OLIGO_A_23_P206359 CDH1 ^ Cadherin 1, type 1, E-cadherin (epithelial) ^  0.62 
AGI_HUM1_OLIGO_A_23_P211047 
BACH1 ^ BTB and CNC homology 1, basic leucine zipper 
transcription factor 1 ^  0.64 
AGI_HUM1_OLIGO_A_23_P137984 
S100A10 ^ S100 calcium binding protein A10 (annexin II 
ligand, calpactin I, light polypeptide (p11)) ^  0.05 
AGI_HUM1_OLIGO_A_24_P923142 
MGC14289 ^ Similar to RIKEN cDNA 1200014N16 gene 
^  0.28 
AGI_HUM1_OLIGO_A_32_P46840 IL17D ^ Interleukin 17D ^  0.77 
AGI_HUM1_OLIGO_A_24_P374516 TMSB4X ^ Thymosin, beta 4, X-linked ^  0.23 
AGI_HUM1_OLIGO_A_23_P2181 CYB5R2 ^ Cytochrome b5 reductase b5R.2 ^  0.56 
AGI_HUM1_OLIGO_A_23_P155765 HMGB2 ^ High-mobility group box 2 ^  0.63 
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AGI_HUM1_OLIGO_A_24_P228796 GAGE2 ^ G antigen 7 ^  0.47 
AGI_HUM1_OLIGO_A_24_P104174 TAOK3 ^ TAO kinase 3 ^  0.43 
AGI_HUM1_OLIGO_A_23_P162874 HSPCA ^ Heat shock 90kDa protein 1, alpha ^  0.58 
AGI_HUM1_OLIGO_A_23_P350886 KIAA0240 ^ KIAA0240 ^  0.46 
AGI_HUM1_OLIGO_A_23_P143981 FBLN2 ^ Fibulin 2 ^  0.33 
AGI_HUM1_OLIGO_A_23_P43490 
CDKN2A ^ Cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) ^  0.58 
AGI_HUM1_OLIGO_A_23_P254288 Uncharacterized gene 0.80 
AGI_HUM1_OLIGO_A_23_P215421 DKFZP434J154 ^ WIPI49-like protein 2 ^  0.56 
AGI_HUM1_OLIGO_A_24_P310756 Uncharacterized gene 0.85 
AGI_HUM1_OLIGO_A_23_P215956 
MYC ^ V-myc myelocytomatosis viral oncogene homolog 
(avian) ^  0.51 
AGI_HUM1_OLIGO_A_23_P63999 Uncharacterized gene 0.65 
AGI_HUM1_OLIGO_A_24_P861009 WDR9 ^ WD repeat domain 9 ^  0.49 
AGI_HUM1_OLIGO_A_23_P257278 
CDK5RAP1 ^ CDK5 regulatory subunit associated 
protein 1 ^  0.75 
AGI_HUM1_OLIGO_A_32_P482979 LOC389677 ^ Similar to RIKEN cDNA 3000004N20 ^  0.62 
AGI_HUM1_OLIGO_A_23_P121122 MAK3 ^ Mak3 homolog (S. cerevisiae) ^  0.67 
AGI_HUM1_OLIGO_A_23_P169470 
CDK9 ^ Cyclin-dependent kinase 9 (CDC2-related 
kinase) ^  0.70 
AGI_HUM1_OLIGO_A_24_P143189 TMSL3 ^ Thymosin-like 3 ^  0.20 
AGI_HUM1_OLIGO_A_23_P20022 HIG2 ^ Hypoxia-inducible protein 2 ^  0.64 
AGI_HUM1_OLIGO_A_24_P127442 Uncharacterized gene 0.60 
AGI_HUM1_OLIGO_A_23_P97328 C1orf35 ^ Chromosome 1 open reading frame 35 ^  0.62 
AGI_HUM1_OLIGO_A_23_P385771 PAOX ^ Polyamine oxidase (exo-N4-amino) ^  0.47 
AGI_HUM1_OLIGO_A_23_P6307 
U2AF1 ^ U2(RNU2) small nuclear RNA auxiliary factor 1 
^  0.75 
   
  
155
Agilent Gene_ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_24_P677634 Uncharacterized gene 0.73 
AGI_HUM1_OLIGO_A_24_P898915 FLJ45445 ^ FLJ45445 protein ^  0.81 
AGI_HUM1_OLIGO_A_23_P10559 AATK ^ Apoptosis-associated tyrosine kinase ^  0.59 
AGI_HUM1_OLIGO_A_23_P500734 POGZ ^ Pogo transposable element with ZNF domain ^  0.71 
AGI_HUM1_OLIGO_A_23_P77493 TUBB3 ^ Tubulin, beta 3 ^  0.50 
AGI_HUM1_OLIGO_A_23_P152115 NME3 ^ Non-metastatic cells 3, protein expressed in ^  0.79 
AGI_HUM1_OLIGO_A_23_P717 FLJ10874 ^ Hypothetical protein FLJ10874 ^  0.49 
AGI_HUM1_OLIGO_A_24_P182433 
MAPBPIP ^ Mitogen-activated protein-binding protein-
interacting protein ^  0.61 
AGI_HUM1_OLIGO_A_23_P201731 TRAF5 ^ TNF receptor-associated factor 5 ^  0.16 
AGI_HUM1_OLIGO_A_23_P60591 
DNAJC7 ^ DnaJ (Hsp40) homolog, subfamily C, member 
7 ^  0.43 
AGI_HUM1_OLIGO_A_23_P307940 
CAPZA2 ^ Capping protein (actin filament) muscle Z-line, 
alpha 2 ^  0.72 
AGI_HUM1_OLIGO_A_32_P167493 SAP18 ^ Sin3-associated polypeptide, 18kDa ^  0.86 
AGI_HUM1_OLIGO_A_23_P32175 LHX6 ^ LIM homeobox 6 ^  0.35 
AGI_HUM1_OLIGO_A_23_P29836 MGC29956 ^ Hypothetical protein MGC29956 ^  0.36 
AGI_HUM1_OLIGO_A_32_P158302 Uncharacterized gene 0.63 
AGI_HUM1_OLIGO_A_23_P161719 CWF19L2 ^ CWF19-like 2, cell cycle control (S. pombe) ^  0.58 
AGI_HUM1_OLIGO_A_23_P28969 C20orf178 ^ Chromosome 20 open reading frame 178 ^  0.29 
AGI_HUM1_OLIGO_A_23_P55376 LOC284058 ^ Hypothetical protein LOC284058 ^  0.56 
AGI_HUM1_OLIGO_A_23_P124855 ZCCHC7 ^ Zinc finger, CCHC domain containing 7 ^  0.52 
AGI_HUM1_OLIGO_A_23_P37088 
RDH12 ^ Retinol dehydrogenase 12 (all-trans and 9-cis) 
^  0.61 
AGI_HUM1_OLIGO_A_23_P102391 
SLC40A1 ^ Solute carrier family 40 (iron-regulated 
transporter), member 1 ^  0.26 
AGI_HUM1_OLIGO_A_24_P913431 TRIO ^ Triple functional domain (PTPRF interacting) ^  0.54 
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AGI_HUM1_OLIGO_A_23_P500421 EYA2 ^ Eyes absent homolog 2 (Drosophila) ^  0.09 
AGI_HUM1_OLIGO_A_24_P154214 
IRF2BP2 ^ Interferon regulatory factor 2 binding protein 2 
^  0.48 
AGI_HUM1_OLIGO_A_23_P40156 C20orf121 ^ Chromosome 20 open reading frame 121 ^  0.54 
AGI_HUM1_OLIGO_A_24_P209204 C6orf62 ^ Chromosome 6 open reading frame 62 ^  0.40 
AGI_HUM1_OLIGO_A_23_P51548 MGST3 ^ Microsomal glutathione S-transferase 3 ^  0.58 
AGI_HUM1_OLIGO_A_23_P22625 
SLC9A6 ^ Solute carrier family 9 (sodium/hydrogen 
exchanger), isoform 6 ^  0.67 
AGI_HUM1_OLIGO_A_24_P124672 DNCL1 ^ Dynein, cytoplasmic, light polypeptide 1 ^  0.86 
AGI_HUM1_OLIGO_A_24_P254346 DSCR3 ^ Down syndrome critical region gene 3 ^  0.66 
AGI_HUM1_OLIGO_A_23_P149847 LZTS2 ^ Leucine zipper, putative tumor suppressor 2 ^  0.78 
AGI_HUM1_OLIGO_A_24_P90097 ADD3 ^ Adducin 3 (gamma) ^  0.69 
AGI_HUM1_OLIGO_A_23_P123874 
SMU1 ^ Smu-1 suppressor of mec-8 and unc-52 
homolog (C. elegans) ^  0.58 
AGI_HUM1_OLIGO_A_23_P164826 RNASEH2A ^ Ribonuclease H2, large subunit ^  0.87 
AGI_HUM1_OLIGO_A_23_P99253 LIN7A ^ Lin-7 homolog A (C. elegans) ^  0.40 
AGI_HUM1_OLIGO_A_23_P418413 OXSR1 ^ Oxidative-stress responsive 1 ^  0.51 
AGI_HUM1_OLIGO_A_23_P52127 
ACBD6 ^ Acyl-Coenzyme A binding domain containing 6 
^  0.59 
AGI_HUM1_OLIGO_A_24_P111912 DKFZP564D172 ^ Hypothetical protein FLJ12078 ^  0.64 
AGI_HUM1_OLIGO_A_23_P48676 
PYGL ^ Phosphorylase, glycogen; liver (Hers disease, 
glycogen storage disease type VI) ^  0.53 
AGI_HUM1_OLIGO_A_24_P366457 Uncharacterized gene 0.86 
AGI_HUM1_OLIGO_A_23_P12503 NUP133 ^ Nucleoporin 133kDa ^  0.40 
AGI_HUM1_OLIGO_A_23_P11874 MPZL1 ^ Myelin protein zero-like 1 ^  0.66 
AGI_HUM1_OLIGO_A_23_P88522 NMB ^ Neuromedin B ^  0.29 
AGI_HUM1_OLIGO_A_23_P73801 TCEAL1 ^ Transcription elongation factor A (SII)-like 1 ^  0.68 
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AGI_HUM1_OLIGO_A_23_P372874 Uncharacterized gene 0.43 
AGI_HUM1_OLIGO_A_23_P15123 KIAA1970 ^ KIAA1970 protein ^  0.81 
AGI_HUM1_OLIGO_A_24_P917866 SET ^ SET translocation (myeloid leukemia-associated) ^  0.68 
AGI_HUM1_OLIGO_A_24_P230877 ^ CDNA FLJ33330 fis, clone BRACE2000441 ^  0.79 
AGI_HUM1_OLIGO_A_24_P137434 
DCBLD2 ^ Discoidin, CUB and LCCL domain containing 
2 ^  0.41 
AGI_HUM1_OLIGO_A_23_P97749 DHX9 ^ DEAH (Asp-Glu-Ala-His) box polypeptide 9 ^  0.62 
AGI_HUM1_OLIGO_A_23_P257296 TFF3 ^ Trefoil factor 3 (intestinal) ^  0.50 
AGI_HUM1_OLIGO_A_23_P38167 
GPRC5C ^ G protein-coupled receptor, family C, group 5, 
member C ^  0.40 
AGI_HUM1_OLIGO_A_23_P319859 EYA2 ^ Eyes absent homolog 2 (Drosophila) ^  0.19 
AGI_HUM1_OLIGO_A_24_P293192 
FXYD3 ^ FXYD domain containing ion transport regulator 
3 ^  0.54 
AGI_HUM1_OLIGO_A_24_P340286 LOC150356 ^ Hypothetical protein BC012882 ^  0.12 
AGI_HUM1_OLIGO_A_24_P200603 
DCOHM ^ Dimerization cofactor of hepatocyte nuclear 
factor 1 ( HNF1) from muscle ^  0.90 
AGI_HUM1_OLIGO_A_23_P72737 
IFITM1 ^ Interferon induced transmembrane protein 1 (9-
27) ^  0.42 
AGI_HUM1_OLIGO_A_23_P91487 C21orf6 ^ Chromosome 21 open reading frame 6 ^  0.48 
AGI_HUM1_OLIGO_A_23_P371824 TUFT1 ^ Tuftelin 1 ^  0.51 
AGI_HUM1_OLIGO_A_24_P141332 
CAMK2G ^ Calcium/calmodulin-dependent protein kinase 
(CaM kinase) II gamma ^  0.76 
AGI_HUM1_OLIGO_A_23_P349882 PDCL ^ Phosducin-like ^  0.64 
AGI_HUM1_OLIGO_A_23_P109345 
PTTG1IP ^ Pituitary tumor-transforming 1 interacting 
protein ^  0.75 
AGI_HUM1_OLIGO_A_23_P359111 PAI-RBP1 ^ PAI-1 mRNA-binding protein ^  0.79 
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AGI_HUM1_OLIGO_A_23_P428849 
CHCHD4 ^ Coiled-coil-helix-coiled-coil-helix domain 
containing 4 ^  0.86 
AGI_HUM1_OLIGO_A_24_P9671 
DNAJA1 ^ DnaJ (Hsp40) homolog, subfamily A, member 
1 ^  0.93 
AGI_HUM1_OLIGO_A_23_P59798 MKRN1 ^ Makorin, ring finger protein, 1 ^  0.86 
AGI_HUM1_OLIGO_A_32_P182473 ZNF625 ^ Zinc finger protein 625 ^  0.72 
AGI_HUM1_OLIGO_A_23_P109974 RAB6B ^ RAB6B, member RAS oncogene family ^  0.58 
AGI_HUM1_OLIGO_A_23_P138725 MARVELD1 ^ MARVEL domain containing 1 ^  0.48 
AGI_HUM1_OLIGO_A_32_P223859 
SMPDL3A ^ Sphingomyelin phosphodiesterase, acid-like 
3A ^  0.65 
AGI_HUM1_OLIGO_A_23_P433107 ZNF561 ^ Zinc finger protein 561 ^  0.45 
AGI_HUM1_OLIGO_A_24_P216765 
TOMM20 ^ Translocase of outer mitochondrial 
membrane 20 homolog (yeast) ^  0.62 
AGI_HUM1_OLIGO_A_23_P37560 PEX11A ^ Peroxisomal biogenesis factor 11A ^  0.78 
AGI_HUM1_OLIGO_A_23_P211899 Uncharacterized gene 0.39 
AGI_HUM1_OLIGO_A_23_P150255 RBM14 ^ RNA binding motif protein 14 ^  0.78 
AGI_HUM1_OLIGO_A_32_P12820 Uncharacterized gene 0.45 
AGI_HUM1_OLIGO_A_23_P170037 MID1 ^ Midline 1 (Opitz/BBB syndrome) ^  0.30 
AGI_HUM1_OLIGO_A_23_P62920 KIFAP3 ^ Kinesin-associated protein 3 ^  0.65 
AGI_HUM1_OLIGO_A_23_P257201 RNF146 ^ Ring finger protein 146 ^  0.79 
AGI_HUM1_OLIGO_A_24_P200652 C6orf62 ^ Chromosome 6 open reading frame 62 ^  0.29 
AGI_HUM1_OLIGO_A_23_P137514 IVNS1ABP ^ Influenza virus NS1A binding protein ^  0.47 
AGI_HUM1_OLIGO_A_24_P55250 C6orf74 ^ Chromosome 6 open reading frame 74 ^  0.86 
AGI_HUM1_OLIGO_A_23_P435407 GPC4 ^ Glypican 4 ^  0.56 
AGI_HUM1_OLIGO_A_23_P251248 TBCC ^ Tubulin-specific chaperone c ^  0.64 
AGI_HUM1_OLIGO_A_24_P48204 SECTM1 ^ Secreted and transmembrane 1 ^  0.62 
AGI_HUM1_OLIGO_A_23_P9416 ACO1 ^ Aconitase 1, soluble ^  0.72 
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AGI_HUM1_OLIGO_A_24_P867201 ^ Homo sapiens, clone IMAGE:5277945, mRNA ^  0.32 
AGI_HUM1_OLIGO_A_23_P31073 
MYB ^ V-myb myeloblastosis viral oncogene homolog 
(avian) ^  0.39 
AGI_HUM1_OLIGO_A_24_P530977 Uncharacterized gene 0.17 
AGI_HUM1_OLIGO_A_32_P3214 Uncharacterized gene 0.29 
AGI_HUM1_OLIGO_A_32_P19101 Uncharacterized gene 0.48 
AGI_HUM1_OLIGO_A_24_P605190 Uncharacterized gene 0.41 
AGI_HUM1_OLIGO_A_23_P27613 MAN2B1 ^ Mannosidase, alpha, class 2B, member 1 ^  0.77 
AGI_HUM1_OLIGO_A_24_P548415 Uncharacterized gene 0.56 
AGI_HUM1_OLIGO_A_23_P200216 
MAGOH ^ Mago-nashi homolog, proliferation-associated 
(Drosophila) ^  0.65 
AGI_HUM1_OLIGO_A_23_P59613 FZD9 ^ Frizzled homolog 9 (Drosophila) ^  0.53 
AGI_HUM1_OLIGO_A_23_P168306 WASF1 ^ WAS protein family, member 1 ^  0.36 
AGI_HUM1_OLIGO_A_23_P121234 Uncharacterized gene 0.59 
AGI_HUM1_OLIGO_A_32_P133670 
ANP32A ^ Acidic (leucine-rich) nuclear phosphoprotein 
32 family, member A ^  0.64 
AGI_HUM1_OLIGO_A_24_P240187 LRRN1 ^ Leucine rich repeat neuronal 1 ^  0.46 
AGI_HUM1_OLIGO_A_23_P256375 STX4A ^ Syntaxin 4A (placental) ^  0.79 
AGI_HUM1_OLIGO_A_23_P203120 IGSF4 ^ Immunoglobulin superfamily, member 4 ^  0.32 
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AGI_HUM1_OLIGO_A_24_P928052 NRP1 ^ Neuropilin 1 ^  3.81 
AGI_HUM1_OLIGO_A_24_P382591 Uncharacterized gene 1.42 
AGI_HUM1_OLIGO_A_23_P252413 Uncharacterized gene 1.90 
AGI_HUM1_OLIGO_A_23_P79911 
PSMF1 ^ Proteasome (prosome, macropain) inhibitor subunit 
1 (PI31) ^  1.24 
AGI_HUM1_OLIGO_A_23_P121657 
HS3ST1 ^ Heparan sulfate (glucosamine) 3-O-sulfotransferase 
1 ^  2.06 
AGI_HUM1_OLIGO_A_23_P54540 Uncharacterized gene 1.52 
AGI_HUM1_OLIGO_A_32_P51518 ^ CDNA FLJ40901 fis, clone UTERU2003704 ^  1.55 
AGI_HUM1_OLIGO_A_23_P90679 
ALS2CR2 ^ Amyotrophic lateral sclerosis 2 (juvenile) 
chromosome region, candidate 2 ^  1.54 
AGI_HUM1_OLIGO_A_23_P428260 
STEAP2 ^ Six transmembrane epithelial antigen of prostate 2 
^  2.28 
AGI_HUM1_OLIGO_A_24_P658427 NFIB ^ Nuclear factor I/B ^  1.90 
AGI_HUM1_OLIGO_A_23_P382043 NT5C2L1 ^ 5'-nucleotidase, cytosolic II-like 1 ^  1.64 
AGI_HUM1_OLIGO_A_23_P372234 CA12 ^ Carbonic anhydrase XII ^  2.93 
AGI_HUM1_OLIGO_A_23_P145644 
DDC ^ Dopa decarboxylase (aromatic L-amino acid 
decarboxylase) ^  6.70 
AGI_HUM1_OLIGO_A_23_P123330 RPL30 ^ Ribosomal protein L30 ^  1.33 
AGI_HUM1_OLIGO_A_24_P48898 APOL2 ^ Apolipoprotein L, 2 ^  1.35 
AGI_HUM1_OLIGO_A_24_P271285 BTBD14B ^ BTB (POZ) domain containing 14B ^  1.31 
AGI_HUM1_OLIGO_A_23_P310274 PRSS2 ^ Protease, serine, 2 (trypsin 2) ^  8.47 
AGI_HUM1_OLIGO_A_23_P15889 CBLN2 ^ Cerebellin 2 precursor ^  5.90 
AGI_HUM1_OLIGO_A_23_P2223 MLC1SA ^ Myosin light chain 1 slow a ^  1.10 
AGI_HUM1_OLIGO_A_23_P91699 
EIF3S7 ^ Eukaryotic translation initiation factor 3, subunit 7 
zeta, 66/67kDa ^  1.32 
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AGI_HUM1_OLIGO_A_24_P67976 ZNF403 ^ Zinc finger protein 403 ^  1.60 
AGI_HUM1_OLIGO_A_24_P918808 OAZ1 ^ Ornithine decarboxylase antizyme 1 ^  1.87 
AGI_HUM1_OLIGO_A_24_P221869 TSPY1 ^ Testis specific protein, Y-linked 1 ^  4.28 
AGI_HUM1_OLIGO_A_23_P141208 DKFZp566O084 ^ DKFZP566O084 protein ^  1.34 
AGI_HUM1_OLIGO_A_24_P298886 Uncharacterized gene 3.63 
AGI_HUM1_OLIGO_A_32_P165477 
SLC7A11 ^ Solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11 ^  1.87 
AGI_HUM1_OLIGO_A_23_P132910 FLJ20273 ^ RNA-binding protein ^  1.50 
AGI_HUM1_OLIGO_A_23_P138706 ADRA2A ^ Adrenergic, alpha-2A-, receptor ^  5.06 
AGI_HUM1_OLIGO_A_23_P218170 SMAP-1 ^ Smooth muscle cell associated protein-1 ^  1.36 
AGI_HUM1_OLIGO_A_23_P83953 Uncharacterized gene 1.32 
AGI_HUM1_OLIGO_A_23_P99967 BBS4 ^ Bardet-Biedl syndrome 4 ^  2.36 
AGI_HUM1_OLIGO_A_23_P91619 
MIF ^ Macrophage migration inhibitory factor (glycosylation-
inhibiting factor) ^  1.78 
AGI_HUM1_OLIGO_A_23_P140450 
SLC27A2 ^ Solute carrier family 27 (fatty acid transporter), 
member 2 ^  1.82 
AGI_HUM1_OLIGO_A_23_P3632 ANKRD11 ^ Ankyrin repeat domain 11 ^  2.08 
AGI_HUM1_OLIGO_A_24_P409891 Uncharacterized gene 1.24 
AGI_HUM1_OLIGO_A_23_P22800 TSPY1 ^ Testis specific protein, Y-linked 1 ^  2.89 
AGI_HUM1_OLIGO_A_23_P117928 BAHD1 ^ Bromo adjacent homology domain containing 1 ^  1.47 
AGI_HUM1_OLIGO_A_23_P110686 STC2 ^ Stanniocalcin 2 ^  1.50 
AGI_HUM1_OLIGO_A_23_P213102 KIAA0992 ^ Palladin ^  1.54 
AGI_HUM1_OLIGO_A_24_P101201 GRP58 ^ Glucose regulated protein, 58kDa ^  1.53 
AGI_HUM1_OLIGO_A_24_P881430 
^ Transcribed locus, moderately similar to NP_000991.1 
ribosomal protein L39 [Homo sapiens] ^  2.12 
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AGI_HUM1_OLIGO_A_24_P246552 
VTI1B ^ Vesicle transport through interaction with t-SNAREs 
homolog 1B (yeast) ^  1.63 
AGI_HUM1_OLIGO_A_23_P37983 MT1B ^ Metallothionein 1B (functional) ^  2.69 
AGI_HUM1_OLIGO_A_23_P375147 Uncharacterized gene 1.49 
AGI_HUM1_OLIGO_A_24_P203726 Uncharacterized gene 1.37 
AGI_HUM1_OLIGO_A_23_P56150 MGC15631 ^ Hypothetical protein MGC15631 ^  1.14 
AGI_HUM1_OLIGO_A_24_P84048 Uncharacterized gene 1.10 
AGI_HUM1_OLIGO_A_23_P381102 DKFZp434E2321 ^ Hypothetical protein DKFZp434E2321 ^  1.85 
AGI_HUM1_OLIGO_A_23_P321949 
PLA2G2A ^ Phospholipase A2, group IIA (platelets, synovial 
fluid) ^  4.47 
AGI_HUM1_OLIGO_A_32_P139414 FEM1A ^ Fem-1 homolog a (C.elegans) ^  2.15 
AGI_HUM1_OLIGO_A_23_P409945 OAZ1 ^ Ornithine decarboxylase antizyme 1 ^  1.45 
AGI_HUM1_OLIGO_A_23_P402287 LNX2 ^ Ligand of numb-protein X 2 ^  1.56 
AGI_HUM1_OLIGO_A_24_P44462 TPM1 ^ Tropomyosin 1 (alpha) ^  1.49 
AGI_HUM1_OLIGO_A_24_P363802 PSMD5 ^ Hypothetical protein LOC253039 ^  4.88 
AGI_HUM1_OLIGO_A_23_P214766 
HIVEP2 ^ Human immunodeficiency virus type I enhancer 
binding protein 2 ^  1.69 
AGI_HUM1_OLIGO_A_23_P88347 
PLEKHC1 ^ Pleckstrin homology domain containing, family C 
(with FERM domain) member 1 ^  2.30 
AGI_HUM1_OLIGO_A_23_P119943 IGFBP2 ^ Insulin-like growth factor binding protein 2, 36kDa ^  1.05 
AGI_HUM1_OLIGO_A_23_P108244 
COX6B1 ^ Cytochrome c oxidase subunit Vib polypeptide 1 
(ubiquitous) ^  1.34 
AGI_HUM1_OLIGO_A_23_P15542 HSD17B1 ^ Hydroxysteroid (17-beta) dehydrogenase 1 ^  1.46 
AGI_HUM1_OLIGO_A_24_P116242 KLHDC2 ^ Kelch domain containing 2 ^  1.19 
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AGI_HUM1_OLIGO_A_24_P263672 
LOC96610 ^ Hypothetical protein similar to KIAA0187 gene 
product ^  1.55 
AGI_HUM1_OLIGO_A_23_P121356 BBX ^ Bobby sox homolog (Drosophila) ^  2.47 
AGI_HUM1_OLIGO_A_23_P66719 MGC23280 ^ Hypothetical protein MGC23280 ^  1.46 
AGI_HUM1_OLIGO_A_32_P71736 PIGH ^ Phosphatidylinositol glycan, class H ^  1.42 
AGI_HUM1_OLIGO_A_23_P29855 VDP ^ Vesicle docking protein p115 ^  1.42 
AGI_HUM1_OLIGO_A_23_P125519 RPS4X ^ Ribosomal protein S4, X-linked ^  1.15 
AGI_HUM1_OLIGO_A_24_P363615 MTPN ^ Myotrophin ^  1.84 
AGI_HUM1_OLIGO_A_24_P67892 ZNF403 ^ Zinc finger protein 403 ^  1.55 
AGI_HUM1_OLIGO_A_23_P139958 CDK8 ^ Cyclin-dependent kinase 8 ^  1.97 
AGI_HUM1_OLIGO_A_23_P93613 
MKLN1 ^ Muskelin 1, intracellular mediator containing kelch 
motifs ^  1.57 
AGI_HUM1_OLIGO_A_23_P99883 GRP58 ^ Glucose regulated protein, 58kDa ^  1.60 
AGI_HUM1_OLIGO_A_23_P25204 
SLC25A3 ^ Solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 3 ^  1.17 
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Agilent Gene_ID Gene Name Fold Change 
AGI_HUM1_OLIGO_A_23_P114783 
PARP1 ^ Poly (ADP-ribose) polymerase family, member 
1 ^  0.43 
AGI_HUM1_OLIGO_A_23_P216257 TPD52 ^ Tumor protein D52 ^  0.67 
AGI_HUM1_OLIGO_A_23_P150255 RBM14 ^ RNA binding motif protein 14 ^  0.62 
AGI_HUM1_OLIGO_A_32_P119830 PEG3 ^ Paternally expressed 3 ^  0.16 
AGI_HUM1_OLIGO_A_24_P185394 GSK3A ^ Glycogen synthase kinase 3 alpha ^  0.81 
AGI_HUM1_OLIGO_A_23_P49517 
SFRS1 ^ Splicing factor, arginine/serine-rich 1 (splicing 
factor 2, alternate splicing factor) ^  0.70 
AGI_HUM1_OLIGO_A_23_P148519 TMEM29 ^ Transmembrane protein 29 ^  0.80 
AGI_HUM1_OLIGO_A_24_P307486 Uncharacterized gene 0.68 
AGI_HUM1_OLIGO_A_23_P171077 EBP ^ Emopamil binding protein (sterol isomerase) ^  0.62 
AGI_HUM1_OLIGO_A_24_P61864 GK001 ^ GK001 protein ^  0.55 
AGI_HUM1_OLIGO_A_32_P96036 LOC92312 ^ Hypothetical protein LOC92312 ^  0.34 
AGI_HUM1_OLIGO_A_23_P104651 CDCA5 ^ Cell division cycle associated 5 ^  0.50 
AGI_HUM1_OLIGO_A_23_P70060 PPAP2A ^ Phosphatidic acid phosphatase type 2A ^  0.64 
AGI_HUM1_OLIGO_A_24_P366495 Uncharacterized gene 0.58 
AGI_HUM1_OLIGO_A_24_P857404 LOC92312 ^ Hypothetical protein LOC92312 ^  0.40 
AGI_HUM1_OLIGO_A_23_P103414 YTHDF2 ^ YTH domain family, member 2 ^  0.60 
AGI_HUM1_OLIGO_A_23_P251795 GPC2 ^ Glypican 2 (cerebroglycan) ^  0.63 
AGI_HUM1_OLIGO_A_23_P200477 
ACBD3 ^ Acyl-Coenzyme A binding domain containing 3 
^  0.55 
AGI_HUM1_OLIGO_A_24_P382119 MTMR4 ^ Myotubularin related protein 4 ^  0.71 
AGI_HUM1_OLIGO_A_23_P17074 MGC12981 ^ Hypothetical protein MGC12981 ^  0.75 
AGI_HUM1_OLIGO_A_32_P11181 Uncharacterized gene 0.74 
AGI_HUM1_OLIGO_A_23_P122304 HDAC2 ^ Histone deacetylase 2 ^  0.70 
AGI_HUM1_OLIGO_A_23_P200710 
PIK3C2B ^ Phosphoinositide-3-kinase, class 2, beta 
polypeptide ^  0.84 
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AGI_HUM1_OLIGO_A_23_P76901 
PLEKHG3 ^ Pleckstrin homology domain containing, 
family G (with RhoGef domain) member 3 ^  0.70 
AGI_HUM1_OLIGO_A_23_P103398 PSEN2 ^ Presenilin 2 (Alzheimer disease 4) ^  0.69 
AGI_HUM1_OLIGO_A_23_P160406 
KCTD3 ^ Potassium channel tetramerisation domain 
containing 3 ^  0.67 
AGI_HUM1_OLIGO_A_24_P387839 
DEGS ^ Degenerative spermatocyte homolog, lipid 
desaturase (Drosophila) ^  0.76 
AGI_HUM1_OLIGO_A_23_P218456 ILF3 ^ Interleukin enhancer binding factor 3, 90kDa ^  0.80 
AGI_HUM1_OLIGO_A_23_P143981 FBLN2 ^ Fibulin 2 ^  0.39 
AGI_HUM1_OLIGO_A_23_P161190 VIM ^ Vimentin ^  0.15 
AGI_HUM1_OLIGO_A_23_P49546 
GRIN2C ^ Glutamate receptor, ionotropic, N-methyl D-
aspartate 2C ^  0.23 
AGI_HUM1_OLIGO_A_23_P107421 TK1 ^ Thymidine kinase 1, soluble ^  0.50 
AGI_HUM1_OLIGO_A_23_P200901 ENSA ^ Endosulfine alpha ^  0.56 
AGI_HUM1_OLIGO_A_23_P343382 Uncharacterized gene 0.24 
AGI_HUM1_OLIGO_A_24_P123601 DDR1 ^ Discoidin domain receptor family, member 1 ^  0.66 
AGI_HUM1_OLIGO_A_23_P411833 
LOC197336 ^ Similar to RIKEN cDNA 3230401M21 [Mus 
musculus] ^  0.49 
AGI_HUM1_OLIGO_A_24_P682601 Uncharacterized gene 0.47 
AGI_HUM1_OLIGO_A_23_P50775 
LRFN3 ^ Leucine rich repeat and fibronectin type III 
domain containing 3 ^  0.65 
AGI_HUM1_OLIGO_A_32_P191895 
^ Homo sapiens, Similar to syndecan binding protein 
(syntenin), clone IMAGE:4814292, mRNA ^  0.48 
AGI_HUM1_OLIGO_A_23_P45917 CKS1B ^ CDC28 protein kinase regulatory subunit 1B ^  0.52 
AGI_HUM1_OLIGO_A_24_P414419 
HADHSC ^ L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain ^  0.65 
AGI_HUM1_OLIGO_A_23_P39364 HOMER3 ^ Homer homolog 3 (Drosophila) ^  0.54 
AGI_HUM1_OLIGO_A_32_P12183 LOC349114 ^ Hypothetical protein LOC349114 ^  0.63 
AGI_HUM1_OLIGO_A_32_P456537 TCP1 ^ T-complex 1 ^  0.68 
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AGI_HUM1_OLIGO_A_32_P146635 SESN3 ^ Sestrin 3 ^  0.54 
AGI_HUM1_OLIGO_A_23_P428849 
CHCHD4 ^ Coiled-coil-helix-coiled-coil-helix domain 
containing 4 ^  0.83 
AGI_HUM1_OLIGO_A_23_P120153 RNF149 ^ Ring finger protein 149 ^  0.46 
AGI_HUM1_OLIGO_A_23_P214678 C6orf82 ^ Chromosome 6 open reading frame 82 ^  0.79 
AGI_HUM1_OLIGO_A_23_P421423 
TNFAIP2 ^ Tumor necrosis factor, alpha-induced protein 
2 ^  0.27 
AGI_HUM1_OLIGO_A_23_P130027 EPN3 ^ Epsin 3 ^  0.67 
AGI_HUM1_OLIGO_A_23_P110941 GSTA4 ^ Glutathione S-transferase A4 ^  0.66 
AGI_HUM1_OLIGO_A_23_P77360 CIAO1 ^ WD40 protein Ciao1 ^  0.80 
AGI_HUM1_OLIGO_A_23_P59791 LUC7L2 ^ LUC7-like 2 (S. cerevisiae) ^  0.53 
AGI_HUM1_OLIGO_A_23_P99249 
SUCLG2 ^ Succinate-CoA ligase, GDP-forming, beta 
subunit ^  0.60 
AGI_HUM1_OLIGO_A_23_P104372 
DNAJC9 ^ DnaJ (Hsp40) homolog, subfamily C, member 
9 ^  0.69 
AGI_HUM1_OLIGO_A_23_P70409 POLR1C ^ Polymerase (RNA) I polypeptide C, 30kDa ^  0.70 
AGI_HUM1_OLIGO_A_23_P46507 CGI-143 ^ CGI-143 protein ^  0.57 
AGI_HUM1_OLIGO_A_23_P12874 GTPBP4 ^ GTP binding protein 4 ^  0.76 
AGI_HUM1_OLIGO_A_24_P314337 GAGEB1 ^ G antigen, family B, 1 (prostate associated) ^  0.26 
AGI_HUM1_OLIGO_A_23_P94422 MELK ^ Maternal embryonic leucine zipper kinase ^  0.67 
AGI_HUM1_OLIGO_A_23_P110837 IRX4 ^ Iroquois homeobox protein 4 ^  0.45 
AGI_HUM1_OLIGO_A_23_P90612 
MCM6 ^ MCM6 minichromosome maintenance deficient 
6 (MIS5 homolog, S. pombe) (S. cerevisiae) ^  0.66 
AGI_HUM1_OLIGO_A_24_P229616 Uncharacterized gene 0.79 
AGI_HUM1_OLIGO_A_24_P339272 MGC40157 ^ Hypothetical protein MGC40157 ^  0.82 
AGI_HUM1_OLIGO_A_32_P114574 CACYBP ^ Calcyclin binding protein ^  0.55 
AGI_HUM1_OLIGO_A_23_P319859 EYA2 ^ Eyes absent homolog 2 (Drosophila) ^  0.17 
AGI_HUM1_OLIGO_A_23_P43946 CIP29 ^ Cytokine induced protein 29 kDa ^  0.49 
AGI_HUM1_OLIGO_A_32_P31633 SF3B1 ^ Splicing factor 3b, subunit 1, 155kDa ^  0.87 
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AGI_HUM1_OLIGO_A_24_P839239 Uncharacterized gene 0.42 
AGI_HUM1_OLIGO_A_24_P38895 H2AFX ^ H2A histone family, member X ^  0.64 
AGI_HUM1_OLIGO_A_23_P86330 IER5 ^ Immediate early response 5 ^  0.59 
AGI_HUM1_OLIGO_A_24_P195831 Uncharacterized gene 0.60 
AGI_HUM1_OLIGO_A_23_P374844 GAL ^ Galanin ^  0.42 
AGI_HUM1_OLIGO_A_23_P51660 MUTYH ^ MutY homolog (E. coli) ^  0.86 
AGI_HUM1_OLIGO_A_23_P118462 
DPH2L1 ^ Candidate tumor suppressor in ovarian cancer 
2 ^  0.79 
AGI_HUM1_OLIGO_A_24_P178415 Uncharacterized gene 0.71 
AGI_HUM1_OLIGO_A_24_P924484 Uncharacterized gene 0.47 
AGI_HUM1_OLIGO_A_23_P34375 TCEA3 ^ Transcription elongation factor A (SII), 3 ^  0.19 
AGI_HUM1_OLIGO_A_24_P343869 TEBP ^ Unactive progesterone receptor, 23 kD ^  0.65 
AGI_HUM1_OLIGO_A_23_P256413 CKLFSF7 ^ Chemokine-like factor super family 7 ^  0.70 
AGI_HUM1_OLIGO_A_23_P381979 
OGT ^ O-linked N-acetylglucosamine (GlcNAc) 
transferase (UDP-N-acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) ^  0.60 
AGI_HUM1_OLIGO_A_23_P20502 
SLC39A4 ^ Solute carrier family 39 (zinc transporter), 
member 4 ^  0.76 
AGI_HUM1_OLIGO_A_24_P464798 Uncharacterized gene 0.66 
AGI_HUM1_OLIGO_A_23_P200493 LBR ^ Lamin B receptor ^  0.58 
AGI_HUM1_OLIGO_A_24_P228796 GAGE2 ^ G antigen 7 ^  0.52 
AGI_HUM1_OLIGO_A_23_P12680 
PSAP ^ Prosaposin (variant Gaucher disease and variant 
metachromatic leukodystrophy) ^  0.59 
AGI_HUM1_OLIGO_A_23_P162559 SPPL3 ^ Signal peptide peptidase 3 ^  0.76 
AGI_HUM1_OLIGO_A_23_P53276 TIMELESS ^ Timeless homolog (Drosophila) ^  0.46 
AGI_HUM1_OLIGO_A_23_P58293 
UBE2D3 ^ Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 
homolog, yeast) ^  0.58 
AGI_HUM1_OLIGO_A_24_P401150 Uncharacterized gene 0.85 
AGI_HUM1_OLIGO_A_23_P141362 FZD2 ^ Frizzled homolog 2 (Drosophila) ^  0.33 
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AGI_HUM1_OLIGO_A_23_P208880 
 
UHRF1 ^ Ubiquitin-like, containing PHD and RING finger 
domains, 1 ^  
 
0.23 
AGI_HUM1_OLIGO_A_23_P116235 Uncharacterized gene 0.20 
AGI_HUM1_OLIGO_A_23_P82206 
ECHDC1 ^ Enoyl Coenzyme A hydratase domain 
containing 1 ^  0.06 
AGI_HUM1_OLIGO_A_23_P58353 
HNRPD ^ Heterogeneous nuclear ribonucleoprotein D 
(AU-rich element RNA binding protein 1, 37kDa) ^  0.62 
AGI_HUM1_OLIGO_A_23_P121095 TOP2B ^ Topoisomerase (DNA) II beta 180kDa ^  0.86 
AGI_HUM1_OLIGO_A_23_P56978 PTK6 ^ PTK6 protein tyrosine kinase 6 ^  0.24 
AGI_HUM1_OLIGO_A_24_P222684 
SSA2 ^ Sjogren syndrome antigen A2 (60kDa, 
ribonucleoprotein autoantigen SS-A/Ro) ^  0.55 
AGI_HUM1_OLIGO_A_23_P68106 TMSB10 ^ Thymosin, beta 10 ^  0.41 
AGI_HUM1_OLIGO_A_23_P119562 DF ^ D component of complement (adipsin) ^  0.30 
AGI_HUM1_OLIGO_A_23_P256735 PGCP ^ Plasma glutamate carboxypeptidase ^  0.28 
AGI_HUM1_OLIGO_A_32_P33576 OPRK1 ^ Opioid receptor, kappa 1 ^  0.39 
AGI_HUM1_OLIGO_A_23_P210581 
KCNG1 ^ Potassium voltage-gated channel, subfamily G, 
member 1 ^  0.64 
AGI_HUM1_OLIGO_A_23_P254271 TUBB6 ^ Tubulin, beta 6 ^  0.06 
AGI_HUM1_OLIGO_A_23_P30813 HIST1H4K ^ Histone 1, H4k ^  0.75 
AGI_HUM1_OLIGO_A_23_P97328 C1orf35 ^ Chromosome 1 open reading frame 35 ^  0.52 
AGI_HUM1_OLIGO_A_23_P112341 C9orf76 ^ Chromosome 9 open reading frame 76 ^  0.44 
AGI_HUM1_OLIGO_A_23_P319270 Uncharacterized gene 0.83 
AGI_HUM1_OLIGO_A_24_P287785 CGI-14 ^ CGI-14 protein ^  0.70 
AGI_HUM1_OLIGO_A_23_P155765 HMGB2 ^ High-mobility group box 2 ^  0.41 
AGI_HUM1_OLIGO_A_32_P192430 CKS1B ^ CDC28 protein kinase regulatory subunit 1B ^  0.47 
AGI_HUM1_OLIGO_A_32_P24165 Uncharacterized gene 0.38 
AGI_HUM1_OLIGO_A_23_P74115 RAD54L ^ RAD54-like (S. cerevisiae) ^  0.59 
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AGI_HUM1_OLIGO_A_23_P20722 
SNAPC4 ^ Small nuclear RNA activating complex, 
polypeptide 4, 190kDa ^  0.61 
AGI_HUM1_OLIGO_A_32_P52911 
MTCBP-1 ^ Membrane-type 1 matrix metalloproteinase 
cytoplasmic tail binding protein-1 ^  0.75 
AGI_HUM1_OLIGO_A_23_P428129 
CDKN1C ^ Cyclin-dependent kinase inhibitor 1C (p57, 
Kip2) ^  0.55 
AGI_HUM1_OLIGO_A_24_P791515 
SYNCRIP ^ Synaptotagmin binding, cytoplasmic RNA 
interacting protein ^  0.53 
AGI_HUM1_OLIGO_A_23_P50426 ANKRD25 ^ Ankyrin repeat domain 25 ^  0.83 
AGI_HUM1_OLIGO_A_24_P244356 NOD9 ^ NOD9 protein ^  0.80 
AGI_HUM1_OLIGO_A_23_P66608 
GCN5L2 ^ GCN5 general control of amino-acid synthesis 
5-like 2 (yeast) ^  0.55 
AGI_HUM1_OLIGO_A_23_P61487 LRRC20 ^ Leucine rich repeat containing 20 ^  0.66 
AGI_HUM1_OLIGO_A_24_P654066 Uncharacterized gene 0.43 
AGI_HUM1_OLIGO_A_23_P124522 FLJ22955 ^ Hypothetical protein FLJ22955 ^  0.84 
AGI_HUM1_OLIGO_A_23_P341223 KIAA0469 ^ KIAA0469 gene product ^  0.76 
AGI_HUM1_OLIGO_A_24_P222022 CSIG ^ Cellular senescence inhibited gene protein ^  0.73 
AGI_HUM1_OLIGO_A_23_P212639 
SFRS10 ^ Splicing factor, arginine/serine-rich 10 
(transformer 2 homolog, Drosophila) ^  0.88 
AGI_HUM1_OLIGO_A_24_P280873 Uncharacterized gene 0.61 
AGI_HUM1_OLIGO_A_23_P309361 FLJ30525 ^ Hypothetical protein FLJ30525 ^  0.02 
AGI_HUM1_OLIGO_A_23_P88522 NMB ^ Neuromedin B ^  0.35 
AGI_HUM1_OLIGO_A_23_P204484 RAB35 ^ RAB35, member RAS oncogene family ^  0.62 
AGI_HUM1_OLIGO_A_24_P15821 Uncharacterized gene 0.69 
AGI_HUM1_OLIGO_A_23_P142424 FLJ22573 ^ Hypothetical protein FLJ22573 ^  0.67 
AGI_HUM1_OLIGO_A_23_P259272 WSB2 ^ WD repeat and SOCS box-containing 2 ^  0.68 
AGI_HUM1_OLIGO_A_24_P724040 
SNRPB2 ^ Small nuclear ribonucleoprotein polypeptide 
B'' ^  0.65 
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AGI_HUM1_OLIGO_A_23_P65174 Uncharacterized gene 0.04 
AGI_HUM1_OLIGO_A_24_P229756 Uncharacterized gene 0.63 
AGI_HUM1_OLIGO_A_32_P173481 IK ^ IK cytokine, down-regulator of HLA II ^  0.82 
AGI_HUM1_OLIGO_A_23_P216068 ATAD2 ^ ATPase family, AAA domain containing 2 ^  0.55 
AGI_HUM1_OLIGO_A_23_P158725 
SLC16A3 ^ Solute carrier family 16 (monocarboxylic acid 
transporters), member 3 ^  0.18 
AGI_HUM1_OLIGO_A_23_P37144 C14orf126 ^ Chromosome 14 open reading frame 126 ^  0.85 
AGI_HUM1_OLIGO_A_23_P422026 ME1 ^ Malic enzyme 1, NADP(+)-dependent, cytosolic ^  0.90 
AGI_HUM1_OLIGO_A_23_P407583 PEG3 ^ Paternally expressed 3 ^  0.12 
AGI_HUM1_OLIGO_A_23_P11674 PTGFR ^ Prostaglandin F receptor (FP) ^  0.09 
AGI_HUM1_OLIGO_A_24_P263623 TEBP ^ Unactive progesterone receptor, 23 kD ^  0.75 
AGI_HUM1_OLIGO_A_23_P50455 
POLD1 ^ Polymerase (DNA directed), delta 1, catalytic 
subunit 125kDa ^  0.55 
AGI_HUM1_OLIGO_A_32_P27020 MGC8902 ^ Hypothetical protein MGC8902 ^  0.60 
AGI_HUM1_OLIGO_A_23_P115482 
HSPC150 ^ HSPC150 protein similar to ubiquitin-
conjugating enzyme ^  0.48 
AGI_HUM1_OLIGO_A_23_P110846 CNOT8 ^ CCR4-NOT transcription complex, subunit 8 ^  0.64 
AGI_HUM1_OLIGO_A_23_P10385 
RAMP ^ RA-regulated nuclear matrix-associated protein 
^  0.42 
AGI_HUM1_OLIGO_A_23_P34376 TCEA3 ^ Transcription elongation factor A (SII), 3 ^  0.08 
AGI_HUM1_OLIGO_A_23_P111171 
B3GALT4 ^ UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 4 ^  0.56 
AGI_HUM1_OLIGO_A_23_P202696 
KBTBD4 ^ Kelch repeat and BTB (POZ) domain 
containing 4 ^  0.72 
AGI_HUM1_OLIGO_A_32_P22263 
HMGN1 ^ High-mobility group nucleosome binding 
domain 1 ^  0.61 
AGI_HUM1_OLIGO_A_23_P50096 TYMS ^ Thymidylate synthetase ^  0.79 
AGI_HUM1_OLIGO_A_24_P349560 EIF4E ^ Eukaryotic translation initiation factor 4E ^  0.66 
AGI_HUM1_OLIGO_A_23_P160546 FLJ11280 ^ Hypothetical protein FLJ11280 ^  0.28 
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AGI_HUM1_OLIGO_A_24_P154214 
IRF2BP2 ^ Interferon regulatory factor 2 binding protein 2 
^  0.50 
AGI_HUM1_OLIGO_A_24_P4212 PYCRL ^ Pyrroline-5-carboxylate reductase-like ^  0.57 
AGI_HUM1_OLIGO_A_23_P400217 MUM1 ^ Melanoma associated antigen (mutated) 1 ^  0.74 
AGI_HUM1_OLIGO_A_23_P334751 
MGC39558 ^ Beta 1,3-N-
acetylgalactosaminyltransferase-II ^  0.64 
AGI_HUM1_OLIGO_A_23_P89249 
ERBB2 ^ V-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, neuro/glioblastoma derived 
oncogene homolog (avian) ^  0.49 
AGI_HUM1_OLIGO_A_23_P51627 FLJ11838 ^ Hypothetical protein FLJ11838 ^  0.81 
AGI_HUM1_OLIGO_A_32_P11786 SFRS6 ^ Splicing factor, arginine/serine-rich 6 ^  0.33 
AGI_HUM1_OLIGO_A_23_P91487 C21orf6 ^ Chromosome 21 open reading frame 6 ^  0.64 
AGI_HUM1_OLIGO_A_24_P274795 RAM2 ^ Transcription factor RAM2 ^  0.84 
AGI_HUM1_OLIGO_A_23_P24433 CTSF ^ Cathepsin F ^  0.57 
AGI_HUM1_OLIGO_A_23_P134650 PTCD1 ^ Pentatricopeptide repeat domain 1 ^  0.79 
AGI_HUM1_OLIGO_A_32_P155091 ATXN2L ^ Ataxin 2-like ^  0.70 
AGI_HUM1_OLIGO_A_23_P118815 Uncharacterized gene 0.67 
AGI_HUM1_OLIGO_A_23_P63789 ZWINT ^ ZW10 interactor ^  0.52 
AGI_HUM1_OLIGO_A_23_P215419 ICA1 ^ Islet cell autoantigen 1, 69kDa ^  0.83 
AGI_HUM1_OLIGO_A_32_P8251 KIAA1542 ^ CTD-binding SR-like protein rA9 ^  0.73 
AGI_HUM1_OLIGO_A_23_P11705 FLJ10276 ^ Hypothetical protein FLJ10276 ^  0.83 
AGI_HUM1_OLIGO_A_23_P257296 TFF3 ^ Trefoil factor 3 (intestinal) ^  0.62 
AGI_HUM1_OLIGO_A_23_P391506 IVNS1ABP ^ Influenza virus NS1A binding protein ^  0.36 
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Table 5.8.  Intra class correlation (ICC) matrix of microarray samples.  
 
FL-WT- 
AR-1 
FL-WT-
AR-2 
FL-AR-
Y267F-1 
FL-AR-
Y267F-2 
TR-WT-
AR-1 
TR-WT-
AR-2 
TR-AR-
Y267F-1 
TR-AR-
Y267F-2 
FL-WT-AR-1 1 0.92 0.57 0.63 0.89 0.83 0.79 0.56 
FL-WT-AR-2 
 1 0.60 0.68 0.83 0.84 0.84 0.62 
FL-AR-Y267F-1 
  1 0.78 0.49 0.45 0.55 0.31 
FL-AR-Y267F-2 
   1 0.57 0.68 0.70 0.32 
TR-WT-AR-1 
    1 0.88 0.82 0.66 
TR-WT-AR-2 
     1 0.89 0.57 
TR-AR-Y267F-1 
      1 0.74 
TR-AR-Y267F-2 
       1 
 
 
 
 
 
 
 
 
 
 
 
